{
"documentInfo": {
"documentType": "https://xbrl.org/2021/xbrl-json",
"features": {
"xbrl:canonicalValues": true
},
"namespaces": {
"HOF": "http://hofsethbiocare.no/2024-12-31",
"ifrs-full": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
"iso4217": "http://www.xbrl.org/2003/iso4217",
"scheme": "http://standards.iso.org/iso/17442",
"xbrl": "https://xbrl.org/2021",
"xbrli": "http://www.xbrl.org/2003/instance"
},
"taxonomy": [
"http://hofsethbiocare.no/2024-12-31/hofsethbiocareasa-2024-12-31.xsd"
]
},
"facts": {
"f1__s2__3__5": {
"value": "256825000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RevenueFromContractsWithCustomers",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__5": {
"value": "190815000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RevenueFromContractsWithCustomers",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__6": {
"value": "8122000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__6": {
"value": "23637000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__7": {
"value": "592000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__7": {
"value": "4059000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__8": {
"value": "265539000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RevenueAndOperatingIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__8": {
"value": "218511000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RevenueAndOperatingIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__9": {
"value": "169553000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CostOfSales",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__9": {
"value": "150686000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CostOfSales",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__10": {
"value": "70670000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:EmployeeBenefitsExpense",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__10": {
"value": "58275000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:EmployeeBenefitsExpense",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__11": {
"value": "90617000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherExpenseByNature",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__11": {
"value": "75665000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherExpenseByNature",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__12": {
"value": "39781000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__12": {
"value": "36413000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__13": {
"value": "-105081000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLossFromOperatingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__13": {
"value": "-102529000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLossFromOperatingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__14": {
"value": "-7484000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__14": {
"value": "2541000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__15": {
"value": "9015000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FinanceIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__15": {
"value": "6597000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FinanceIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__16": {
"value": "21749000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FinanceCosts",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__16": {
"value": "13293000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FinanceCosts",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__17": {
"value": "-20219000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FinanceIncomeCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__17": {
"value": "-4155000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FinanceIncomeCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__18": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLossBeforeTax",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__18": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLossBeforeTax",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__19": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__19": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncomeTaxExpenseContinuingOperations",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__20": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__20": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__23": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__23": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__24": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__24": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__25": {
"value": "-125298000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__25": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__26": {
"value": "-2000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__26": {
"value": "-1000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__27": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__4__27": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s2__3__30": {
"value": "-0.3",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:BasicEarningsLossPerShare",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK/xbrli:shares"
}
},
"f1__s2__4__30": {
"value": "-0.27",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:BasicEarningsLossPerShare",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK/xbrli:shares"
}
},
"f1__s2__3__31": {
"value": "-0.3",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DilutedEarningsLossPerShare",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK/xbrli:shares"
}
},
"f1__s2__4__31": {
"value": "-0.27",
"decimals": 2,
"dimensions": {
"concept": "ifrs-full:DilutedEarningsLossPerShare",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK/xbrli:shares"
}
},
"f1__s3__3__5": {
"value": "42430000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__5": {
"value": "55284000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__6": {
"value": "42430000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IntangibleAssetsAndGoodwill",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__6": {
"value": "55284000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IntangibleAssetsAndGoodwill",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__7": {
"value": "41802000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:MachineryAndEquipment",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__7": {
"value": "52775000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:MachineryAndEquipment",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__8": {
"value": "93724000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RightofuseAssetsThatDoNotMeetDefinitionOfInvestmentProperty",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__8": {
"value": "109638000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RightofuseAssetsThatDoNotMeetDefinitionOfInvestmentProperty",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__9": {
"value": "2458000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FixturesAndFittings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__9": {
"value": "3290000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:FixturesAndFittings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__10": {
"value": "137983000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:PropertyPlantAndEquipmentIncludingRightOfUseAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__10": {
"value": "165703000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:PropertyPlantAndEquipmentIncludingRightOfUseAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__11": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:InvestmentsInSubsidiaries",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__11": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:InvestmentsInSubsidiaries",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__12": {
"value": "45699000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__12": {
"value": "37691000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__13": {
"value": "1247000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherNoncurrentFinancialAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__13": {
"value": "439000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherNoncurrentFinancialAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__14": {
"value": "46946000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentFinancialAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__14": {
"value": "38130000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentFinancialAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__15": {
"value": "227359000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__15": {
"value": "259116000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__18": {
"value": "55917000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Inventories",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__18": {
"value": "82542000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Inventories",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__19": {
"value": "18853000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentTradeReceivables",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__19": {
"value": "14849000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentTradeReceivables",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__20": {
"value": "11716000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherCurrentReceivables",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__20": {
"value": "9721000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherCurrentReceivables",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__21": {
"value": "25577000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__21": {
"value": "23890000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__22": {
"value": "112063000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__22": {
"value": "131003000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__25": {
"value": "339422000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Assets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__25": {
"value": "390119000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Assets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__28": {
"value": "4111000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssuedCapital",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__28": {
"value": "3951000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssuedCapital",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__29": {
"value": "55934000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:SharePremium",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__29": {
"value": "37876000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:SharePremium",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__30": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdditionalPaidinCapital",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__30": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdditionalPaidinCapital",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__31": {
"value": "60044000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:PaidInCapital",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__31": {
"value": "41827000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:PaidInCapital",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__32": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:RetainedEarningsAndOtherReserves",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__32": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:RetainedEarningsAndOtherReserves",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__33": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:RetainedEarningsAndOtherReserves",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__33": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:RetainedEarningsAndOtherReserves",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__34": {
"value": "-689000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncontrollingInterests",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__34": {
"value": "-687000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncontrollingInterests",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__35": {
"value": "59356000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__35": {
"value": "41140000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__38": {
"value": "25100000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:LongtermBorrowings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__38": {
"value": "271000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:LongtermBorrowings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__39": {
"value": "86543000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentLeaseLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__39": {
"value": "96831000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentLeaseLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__40": {
"value": "111643000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__40": {
"value": "97102000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:NoncurrentLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__43": {
"value": "48020000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShorttermBorrowings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__43": {
"value": "28893000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShorttermBorrowings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__44": {
"value": "11217000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentLeaseLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__44": {
"value": "10794000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentLeaseLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__45": {
"value": "93629000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__45": {
"value": "55161000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__46": {
"value": "15557000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherCurrentLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__46": {
"value": "157029000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherCurrentLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__47": {
"value": "168424000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__47": {
"value": "251877000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CurrentLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__50": {
"value": "280067000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Liabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__50": {
"value": "348979000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Liabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__3__53": {
"value": "339422000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:EquityAndLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s3__4__53": {
"value": "390119000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:EquityAndLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__5": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLossBeforeTax",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__5": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLossBeforeTax",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__6": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__6": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__7": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:AdjustmentsForWriteDownOfShares",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__7": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:AdjustmentsForWriteDownOfShares",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__8": {
"value": "-8122000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__8": {
"value": "-23488000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__9": {
"value": "39781000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__9": {
"value": "36413000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__10": {
"value": "-7484000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__10": {
"value": "-2541000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__11": {
"value": "26626000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__11": {
"value": "33983000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__12": {
"value": "-4004000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__12": {
"value": "-777000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__13": {
"value": "38468000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__13": {
"value": "-90591000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__14": {
"value": "-144399000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:AdjustmentsForDecreaseIncreaseInPrepaymentsAndAccruedIncomeIncludingContractAssetsAndAdjustmentsForIncreaseDecreaseInAccrualsAndDeferredIncomeIncludingContractLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__14": {
"value": "141870000.0",
"decimals": -3,
"dimensions": {
"concept": "HOF:AdjustmentsForDecreaseIncreaseInPrepaymentsAndAccruedIncomeIncludingContractAssetsAndAdjustmentsForIncreaseDecreaseInAccrualsAndDeferredIncomeIncludingContractLiabilities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__15": {
"value": "144000000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherAdjustmentsForNoncashItems",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__15": {
"value": "0.0",
"dimensions": {
"concept": "ifrs-full:OtherAdjustmentsForNoncashItems",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__16": {
"value": "15685000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherAdjustmentsForWhichCashEffectsAreInvestingOrFinancingCashFlow",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__16": {
"value": "9493000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherAdjustmentsForWhichCashEffectsAreInvestingOrFinancingCashFlow",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__17": {
"value": "-9780000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__17": {
"value": "2761000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__20": {
"value": "2444000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__20": {
"value": "8194000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__21": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__21": {
"value": "685000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__22": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__22": {
"value": "1615000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__23": {
"value": "1629000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__23": {
"value": "5868000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__24": {
"value": "-4074000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__24": {
"value": "-14992000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__27": {
"value": "292000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PaymentsForShareIssueCosts",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__27": {
"value": "215000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PaymentsForShareIssueCosts",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__28": {
"value": "25100000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__28": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__29": {
"value": "15685000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:InterestPaidClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__29": {
"value": "9493000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:InterestPaidClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__30": {
"value": "19397000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__30": {
"value": "28353000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__31": {
"value": "541000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__31": {
"value": "541000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__32": {
"value": "12440000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__32": {
"value": "13639000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__33": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__33": {
"value": "771000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__34": {
"value": "15539000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__34": {
"value": "3694000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__37": {
"value": "23890000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__37": {
"value": "32427000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__38": {
"value": "1686000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__38": {
"value": "-8537000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__3__39": {
"value": "25577000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s4__4__39": {
"value": "23890000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:CashAndCashEquivalents",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__5": {
"value": "3951000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__5": {
"value": "144765000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__5": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__5": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__5": {
"value": "-686000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__5": {
"value": "148030000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__6": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__6": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__6": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__6": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__6": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__6": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__7": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__7": {
"value": "215000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__7": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__7": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__7": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__7": {
"value": "215000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__8": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__8": {
"value": "9000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__8": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__8": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__8": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__8": {
"value": "9000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__9": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__9": {
"value": "-106682000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__9": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__9": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__9": {
"value": "-1000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__9": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__10": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__10": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__10": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__10": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__10": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__10": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__11": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__11": {
"value": "-106682000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__11": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__11": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__11": {
"value": "-1000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__11": {
"value": "-106684000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2023-01-01T00:00:00/2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__12": {
"value": "3951000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__12": {
"value": "37876000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__12": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__12": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__12": {
"value": "-687000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__12": {
"value": "41140000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__19": {
"value": "3951000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__19": {
"value": "37876000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__19": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__19": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__19": {
"value": "-687000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__19": {
"value": "41140000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__20": {
"value": "160000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__20": {
"value": "143840000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__20": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__20": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__20": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__20": {
"value": "144000000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__21": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__21": {
"value": "292000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__21": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__21": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__21": {
"value": "-0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__21": {
"value": "292000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ShareIssueRelatedCost",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__22": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__22": {
"value": "-193000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__22": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__22": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__22": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__22": {
"value": "-193000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__23": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__23": {
"value": "-125298000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__23": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__23": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__23": {
"value": "-2000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__23": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ProfitLoss",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__24": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__24": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__24": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__24": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__24": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__24": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:OtherComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__25": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__25": {
"value": "-125298000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__25": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__25": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__25": {
"value": "-2000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__25": {
"value": "-125300000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:ComprehensiveIncome",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__4__26": {
"value": "4111000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__5__26": {
"value": "55934000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:SharePremiumMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__6__26": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__7__26": {
"value": "0.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "HOF:RetainedEarningsAndOtherReservesMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__8__26": {
"value": "-689000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"ifrs-full:ComponentsOfEquityAxis": "ifrs-full:NoncontrollingInterestsMember",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__26": {
"value": "59356000.0",
"decimals": -3,
"dimensions": {
"concept": "ifrs-full:Equity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2025-01-01T00:00:00",
"unit": "iso4217:NOK"
}
},
"f1__s5__9__29": {
"value": "144000000.0",
"decimals": -6,
"dimensions": {
"concept": "ifrs-full:IssueOfEquity",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00",
"ifrs-full:ClassesOfShareCapitalAxis": "ifrs-full:PreferenceSharesMember",
"unit": "iso4217:NOK"
}
},
"f1__s8__6__5": {
"value": "Note 1 Accounting policies General informationHofseth BioCare ASA ia a public limited liability company domicilied in \u00c5lesund, Norway. The company`s headquarter is in Keiser Wilhelmsgate 24 in \u00c5lesund, with one manufacturing facility in the municipality of Molde and one manufacturing facility in the municipality of Rennebu. The annual financial statements were approved for issuance by the board of directors 11 April 2025.The Group`s operation is the processing of fish offcuts into high quality protein and other food supplements.The company\u2019s consolidated financial statements for 2024 consist of the parent company and the subsidiaries HBC Berk\u00e5k AS, HBC Therapeutics AS, Hofseth BioCare R\u00f8rvik AS, HBC Switzerland GmbH, Hofseth Biocare UK Limited and Hofseth Biocare Americas Holdings Inc. (the Group).Basis of preparation The consolidated financial statements and the parent company financial statements of Hofseth BioCare ASA have been prepared in accordance with IFRS\u00ae Accounting Standards as adopted by the EU as of 31 December 2024, as well as the additional disclosure requirements following from the Norwegian accounting act as of 31 December 2024.The consolidated financial statements and the parent company financial statements are prepared on the historical cost basis, with the exception of financial instruments that are measured at fair value with changes in value through profit or loss.The consolidated financial statements and the parent company financial statements have been prepared applying consistent accounting policies for similar transactions and event.Basis for consolidation(i) SubsidiariesThe consolidated financial statements include Hofseth BioCare ASA and companies controlled by Hofseth BioCare ASA. Companies are determined to be controlled when the Group is exsposed to, or has rights to, variable returns as a result of the involvement from the Group, and the Group is able to influence the returns through its power over the company. All the following criteria must be fulfilled: \u203a power over the company \u203a exposed to, or have rights to, variable returns from its involvement in the company invested in, and \u203a possibility to exercise its power over the company to influence the amount of the returns(ii) Associated companiesAssociated companies are units in which the group has significant influence, but not control over the financial and operational management (normally with an ownership share between 20% and 50%). Significant influence is the power to participate in financial and operational decisions in principle in the company, but where Hofseth BioCare still has no control or joint control. In the case of an ownership interest of less than 20%, in order to be treated as an associated company, it must be clearly demonstrated that significant influence exists, for example through shareholder agreements. The consolidated financial statements include the group\u2019s share of profit from associated companies recognized according to the equity method from the time significant influence is achieved and until such influence ceases. When the group\u2019s share of negative profit exceeds the value of the investment, the carrying amount of the investment decreases to zero and recognition of additional negative profit ceases. The exception is those cases where the group has an obligation to cover negative results.(iii) Joint ventureA joint venture is a type of joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exests only when decisions about the relevant activities require the unanimous consent of the parties sharing control.(iv) Elimination of transactions in the consolidationGroup internal balances and any unrealised gains or losses or revenues and costs related to intra Group transactions, are eliminated in full in the consolidated financial statements.(v) The non-controlling interest in the consolidated financial statements is the non-controlled share of the Group\u2019s equity. In business combinations the non-controlling interest is measured including the non-controlling interest\u2019s share of the acquired entity\u2019s identifyable net assets. The subsidiary\u2019s annual result, together with the individual components recognized in other comprehensive income, is attributable to the parent company and the non-controlling interests. Total comprehensive income is attributed to the share holders of the parent company and to the non-controlling interests even if this results in negative non-controlling interests.Functional currency and presentation currencyThe Group\u2019s presentation currency is NOK, which is also the functional currency of all Norwegian companies in the Group. The Companies abroad uses local currency as their functional currency. All amounts are presented in NOK 1 000 unless specifically noted. Use of estimates when preparing the annual financial statementsManagement has to some extent used estimates and assumptions which have affected assets, liabilities, revenues, expenses, and information of potential commitments. Future events may cause changes in the estimates. Estimates and the underlying assumptions are assessed continuously. Changes in accounting estimates are recognized in the period the changes occur. To the extent the changes also affect future periods, the effect is allocated over the current and future periods. See note 2.Foreign currencyTransactions in foreign currency are translated at the exchange rates prevailing at the date of the transaction. Monetary items in foreign currency are translated at the exchange rate at the balance sheet date. Currency exchange gains and losses are recognized in the income statement and presented as financial income/financial expense.Revenue recognition policiesRevenues are primarily generated from manufactured own goods within the following product types: \u203a Salmon oil (OmeGo\u00ae) \u203a Water-soluble protein (ProGo\u00ae) \u203a Calcium (CalGo\u00ae) \u203a Non-soluble protein (PetGo\u2122)Revenue from contracts with customers is recognized when control of goods or services is transferred to the customers with an amount that reflects the consideration that the Group expects to be entitled to in exchange for delivered goods and services. Control is normally transferred to the customer when goods are sent from the warehouse to the customer. To the extent the customers enter into a contract for the purchase of goods, which the customers wish to continue to store at Hofseth BioCares\u2019 warehouse, the consideration is recognized as revenue when control has passed to the purchasing party. The customers have a desire to continue storing on the group\u2019s stock as a result of requirements for moisture, temperature, etc. when storing the goods, especially Calcium and Protein. In such sales, there is an agreement of control transfer to the customers for the actual delivery of the goods. The parent company and the group also earn revenues from the service of storing the goods, which are recognized at a fixed price per month in storage.The Group assesses whether there are obligations in the sales contracts that are separate performance obligations, and for which parts of the transaction price must be allocated or agreed variable payment terms in the contracts. The parent company and the group have offered rights of return when selling from the web-stores to customers in the human market and have factored in an estimated level of returns when calculating revenue. Furthermore, the Group also assesses whether there are significant financing components in the sales contracts (advance payment, extra long credit terms, etc.).Trade receivablesA receivable represents the Group\u2019s right to payment of an amount which is unconditional (i.e. the agreed credit time before payment of the consideration falls due). See accounting principles for financial assets\u2019 initial recognition and subsequent measurement. Payment terms in the group\u2019s customer contracts vary from 0 days to 90 days.SegmentsAn operating segment is a component of the Group that engages in business activities from which it earns revenues and incurs expenses.The Group\u2019s operating results are regularly reviewed by the managing director to monitor the Group\u2019s results and make decisions about resource allocations.As the Group has one common and not separable manufacturing process for its products, management focuses its financial review on revenues and quality generated from the manufacturing process. Management monitors the financial results at Group level and, hence, the Group only has one segment. Information about products is presented in note 3.Government grantsGovernment grants are recognised at the time it is reasonably assurance that the company complies with the requirements stated to be eligible for the grants and will receive payment. Grants relating to operating expenditures are recognised systematically over the grant period. Grants are recognised against the costs the grant is meant to cover. Grants for investments are recognised systematically over the asset\u2019s useful lives. Grants for investments are recognised as a reduction to the related assets\u2019 carrying amount. Employee benefitsDefined contribution pension planA defined contribution pension plan is an arrangement in which the employer pays fixed constributions to a fund or a pension fund, and in which the parent company and the group has no further legal or constructive obligations to pay additional contributions. The contributions are recognized in the income statement as salary related costs in the period in which the employee renders the service.AFP pension planThe group is affiliated with the AFP scheme, which is a collective pension scheme for the collectively agreed sector in Norway.Accounting-wise, the scheme is considered a defined benefit multi-employer scheme. However, the group is unable to identify its share of the scheme\u2019s underlying financial position and performance with sufficient reliability. Therefore, the scheme is accounted for as a defined contribution scheme. As a result, obligations from the AFP scheme are not recognized on the balance sheet. Premiums to the scheme are expensed as they accrue.Financial income and financial expensesFinancial income consists of interest income, dividends, foreign exchange gains and gains from sale of financial instruments. Interest income is recognised when earned, calculated using the effective interest rate method, while dividends are recognised on the date of the general meeting approving the dividends.Financial expenses consist of interest expenses, guarantee commissions, foreign exchange losses and losses from sale of financial instruments. Interest expenses and guarantee commissions are recognized when incurred, calculated using the effective interest rate method.Income taxesIncome tax expenses consist of current taxes payable and changes in deferred taxes. Current taxes payable are taxes payable or tax receivables related to taxable income or loss for the year, based on tax rates substantively enacted at the balance sheet date. Changes in calculated current taxes payable related to prior years are included in the amount.Deferred tax/deferred tax assets are calculated on all temporary differences between carrying amounts and tax bases for all assets and liabilities on the balance sheet date.Deferred taxes are calculated using the tax rate expected to be applicable at the time of reversal of the temporary differences. Deferred tax assets are recognised to the extent the company is expected to have sufficient taxable income in future periods to utilize the tax benefit.The companies recognize previously unrecognized deferred tax assets to the extent it has become likely that the company may utilize the deferred tax benefit. Likewise, the company will reduce deferred tax assets to the extent the company no longer expects that it will be able to utilise the deferred tax benefit. Deferred tax and deferred tax assets are measured at nominal values. Deferred tax liabilities are presented as provisions/long term liabilities in the balance sheet, while deferred tax assets are presented as intangible assets.Intangible assetsIntangible assets acquired separately are recognised at their cost price. The cost price for intangible assets acquired are recognised at fair value in the Group. Recognised intangible assets are accounted for at cost less any depreciation and impairment write-down.Internally generated intangibe assets, except for recognised development costs, are not recognised, but expensed as incurred.Intangible assets with finite useful life are depreciated over their useful lives and tested for impairment when impairment indicators are present. Depreciation methods and useful lives are assessed annually as a minimum. Changes to depreciation method and/or useful life are accounted for as estimate changes. Patents and licencesAcquisition costs for patents and licences are recognised and depreciated over their estimated useful lives. Development activitiesExpenditures on research are recognised in the income statement as incurred. Expenditures on development activities, including product development (new or improved products) are recognized when all the following criteria are fullfilled: \u203a It is technically possible to complete the asset / product in such a way that the Group may use or sell the asset /product in the future \u203a It is management\u2019s intention to complete the asset / product, as well as to use or sell the asset / product \u203a It is possible to use the asset / sell the product \u203a How the asset / product will generate future revenues can be proven \u203a The Group has sufficient technological and financial ressources available to complete the asset / development of the product \u203a The costs can be reliably measured Recognised costs include cost of material, consultant fees and direct salary costs. Other development costs are recognized in the income statement as incurred. Previously expensed development costs are not subsequently capitalized. Recognised development costs are depreciated on a straight-line basis over the assets / products estimated useful lives.Fixed assetsFixed assets are measured at cost, less accumulated depreciations and impairment write- downs. Fixed assets are derecognized when sold or disposed of and any gains or losses are recognized in the income statement.Acquisition cost for fixed assets is the cost price and costs directly associated wih getting the asset ready for its intended use.Expenditures incurred after recognition of the fixed asset, such as day-to-day maintenance, are recognized in the income statement as incurred, while expenditures expected to generate future economic benefits are recognized in the carrying amount. Depreciation period, depreciation method and residual values are assessed annually.Fixed assets are carried at cost until manufacturing or development has been completed. Fixed assets under construction are not depreciated until the assets are ready for their intended use.When significant components of a property, plant and equipment are determined to have different useful lives, they are accounted for as separate components. Each component of property, plant and equipment is depreciated on a straight-line basis over its estimated useful life, as this is considered to best represent the consumption of the future economic benefits of the assets. Land is not depreciated. Estimated useful life for the current period and depreciation periods are disclosed in note 11. Depreciation method, useful life and residual values are reassessed at the balance sheet date and adjusted if found necessary. When the carrying amount of a fixed asset or a cash-generating unit is higher than the recoverable amount, the asset is written-down to its recoverable amount. Recoverable amount is the higher of value in use and fair value less costs of disposal.Investment in subsidiaries, associated companies and joint venturesInvestments in subsidiaries, associated companies and joint ventures are assessed according to the cost method in the company financial statements. Investments are valued at acquisition cost, unless impairment has been necessary. Write-downs have been made at fair value when impairment is due to reasons that cannot be expected to be temporary. Impairment losses are reversed when the basis for impairment is no longer present.Dividends and other distributions are recognized as income when adopted at the general meeting of the subsidiaries. If dividends exceed the retained earnings after the acquisition, the excess part represents repayment of invested capital, and the dividends are deducted from the value of the investment in the balance sheet.LeasesFor contracts constituting or containing a lease, the company and the group separate lease components if the underlying asset may be used either on its own or together with other resources easily available to the company and the group, and the underlying asset is neither dependent nor interrelated on other underlying assets in the contract. The company and the group then account for each single lease component in the contract as one lease contract separately from the non-lease component in the contract. At the time of commencement of a lease contract the company and the group recognize a lease liability and a corresponding right of use asset for all leases, except for the following excemptions elected under the standard: \u203a Short-term leases (lease term of 12 months or less) \u203a Low value assetsFor such leases the company and the group recognize the lease payments as other operating expenses in the profit or loss when incurred.Lease liabilitiesThe company and the group measure the lease liabilities at the present value of the lease payments to be made over the lease term at the commencement date. The lease term is the non-cancellable period of the lease, in addition to periods covered by options to extend or terminate the lease if it is reasonably certain that the group will (will not) exercise the option.The lease payments included in the measurement of the lease liability consist of: \u203a Fixed lease payments (including in substance fixed payments), less any lease incentives receivable \u203a Variable lease payments which are dependant on an index or rate, measured for the first time using the index or rate applicable at the commencement date \u203a Amounts expected to be payable by the company and the group under residual value guarantees \u203a The exercise price for an option to purchase the asset, if it is reasonably certain that the company and the group will exercise this option \u203a Termination fee, if the lease term has been determined on the basis that the company and the group will exercise an option to terminate the leaseThe lease liability is subsequently remeasured by increasing the carrying amount by an accretion amount on the lease liability, and reduce the carrying amount for lease payments made, as well as potential reassessments or changes to the lease agreement, or to reflect adjustments to lease payments as a result of a change in an index or a rate. The company and the group do not include variable lease payments in the lease liability. Variable payments are recognized in the profit or loss as incurred. The company and the group presenter the lease liabilities in separate line items in the statement of financial position. Right of use assets The company and the group measures right of use assets at cost, less accumulated depreciations and impairment losses, adjusted for potential new measurements of the lease liability. Cost for the right of use assets comprise: \u203a The amount established at initial recognition of the lease liabiilty All lease payments made at or before the commencement date, less lease incentives received if any \u203a All direct expenditures incurred for the company and the group related to entering into the agreementThe group applies the depreciation provisions in IAS 16 Property, plant and equipment when depreciating the right of use asset, except for the fact that the right of use asset is depreciated from the date of commencement until the end of the lease period or the end of the asset\u2019s useful life, whichever is expected to take place first, unless there is an option to purchase the asset which has been determined to be exercised with reasonable certainty, in which case the right of use asset is depreciated over the expected economic life of the underlying asset.The group applies IAS 36 \u00abImpairment of assets\u00bb in order to determine whether the right of use asset has been impaired and, if this is the case, write it down for impairment.Impairment of non-financial assetsDepreciable fixed assets and intangible assets are assessed for impairment when impairment indicators are identified. Impairment write-downs for the difference between the carrying amount and the recoverable amount are recognised in the income statement. The recoverable amount for an asset or a cash generating unit is the higher of value in use and fair value less costs of disposal. When assessing value in use, estimated future cash flows are discounted to net present value using a pre-tax market-based discount rate. The discount rate includes the time value of money and asset specific risk. When testing for impairment, assets which are not tested individually are tested at a Group level representing the lowest level of identifiable cash flows which are independent of cash flows from other assets or Groups of assets (cash generating units or CGUs). Impairment write-downs are recognised to the extent the carrying amount of an asset or cash generating unit exceed the estimated recoverable amount. When recognizing impairment write-downs related to cash generating units, any goodwill impairment is recognized first. Any remaining impairment amount is split pro-rata on other assets in the cash generating unit (Group of cash generating units). Impairments are presented in the line item depreciations and impairments.For other assets an assessment as to whether there are indications that the impairment is no longer present or reduced is made on the balance sheet date (reporting date). Impairments are reversed if the estimates in the calculation have favourably changed the recoverable amount. Impairment reversals are limited to the carrying amounts being equal to what it would have been if no impairment had been recognised.Financial assetsFinancial assets are classified at initial recognition and are subsequently measured at amortized cost, at fair value through other comprehensive income (OCI) or at fair value through profit or loss.The classification of financial assets on initial recognition depends on both the characteristics of the financial assets\u2019 contractual cash flows and the Group\u2019s business model for managing these. The Group\u2019s business model for managing financial assets refers to how the Group manages its financial assets to generate cash flows. The business model determines whether cash flows will arise by receiving contractual cash flows, or by selling the financial assets or both.Accounts receivables that do not contain a significant financing component are measured at the transaction price determined in accordance with IFRS 15, see the accounting policies in section on revenue from contracts with customers, and then measured at amortized cost.Other long-term and short-term receivables, as well as cash and cash equivalents, are recognized at fair value on initial recognition and subsequently at amortized cost.Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated at fair value through profit or loss, or financial assets that are required to measure at fair value. Financial assets are classified as held for trading if they are purchased for the purpose of being sold or repurchased within a short period of time. Derivatives are also classified as held for trading.Financial assets at fair value through profit or loss are recognized in the balance sheet at fair value with net changes in fair value recognized in the income statement. The category includes derivative instruments (forward contracts in foreign currency) and long-term equity investments. Dividends on equity investments are recognized as financial income in the income statement when there is a right to payment of dividends. Financial assets are derecognised when the rights to receive cash flows from the assets have expired or the Group has transferred its rights to receive cash flows from the assets.Impairment of financial assetsFor accounts receivables and contract assets, the Group uses a simplified approach to calculating expected credit losses (ECL). The Group therefore does not track changes in credit risk, but instead recognizes a loss provision based on expected credit losses over the life of the trade receivable and the contract asset on each reporting date. The Group has established a provision matrix that is based on historical losses, adjusted for future-oriented factors that are specific to the debtors and the economic environment.The Group considers a financial asset to be in default when it is more than 60 days overdue. In some cases, however, the Group may also consider that a financial asset is in default when internal or external information indicates that the Group is unable to receive the outstanding contract amounts in its entirety before taking into account any credit insurance that the Group has. A financial asset is recognized as a loss when there is no reasonable expectation of receiving contractual cash flows.Further information on any impairment of financial assets is provided in notes 20, 21 and 22.InventoryInventories are measured at the lower of cost and net realisable value. Net realisable value has been estimated as selling price in the ordinary course of business less the estimated costs of completion and the estimated costs for marketing and distribution. Cost is allocated using the FIFO-method and includes expenditures incurred in purchasing the goods, raw material, costs to bring the goods and the raw material to their current condition and location. Owned goods are valued at manufacturing cost and include raw material costs, as well as other variable and fixed production costs that can be allocated based on normal capacity utilization. See note 2 and 19 for more information.Cash and short-term depositsCash and short-term desposits in the statement of financial position comprise cash at banks and on hand and short-term higly liquid deposits with a maturity of three months or less, that are held for the purpose of meeting short-term cash commitments and are readily convertible to a known amount of cash and subject to a insignificant risk of change in value.Financial liabilitiesFinancial liabilities are initially recognized as financial liabilities at fair value through profit or loss.Interest-bearing debt and other liabilities are recognized at fair value less transaction costs at the time of establishment. In subsequent periods, loans are recognized at amortized cost using the effective interest rate. For more information see note 16.Financial liabilities at fair value through profit or loss include financial liabilities held for trading purposes and financial liabilities designated at initial recognition at fair value through profit or loss. Financial liabilities are classified as held for trading purposes if they are contractual for the purpose of being sold or repurchased within a short period of time. This category also includes derivative instruments (currency forward contracts). Gains or losses on liabilities held for trading are recognized in the income statement, see note 7.DerivativesThe Group uses financial forward exchange contracts (derivatives) to hedge the Group\u2019s currency risk. The forward exchange contracts are recognized in the balance sheet at fair value at the time the contract is entered into with the credit institutions, and subsequently the portfolio of forward exchange contracts is adjusted continuously at fair value through profit or loss. The forward exchange contracts are capitalized as financial assets when fair value is positive and as financial liabilities when fair value is negative. See notes 7, 15 and 18.The Group does not have forward exchange contracts or other derivatives that are considered hedging instruments in hedging terms as defined in IFRS 9.ProvisionsA provision is recognised when the company has an obligation (legal or constructive) as a result of a past event, it is likely (more likely than not) that payment will be made as a result of the liability and the amount can be measured reliably. If the effect is significant, the provision is measured at the discounted value of future cash outflows using a pre-tax discount rate reflecting the market\u2019s pricing of the time value of money and, if relevant, the risks specifically related to the liability.A provision for a guarantee is recognised when the under lying products or services are sold. The provision is based on historical information about guarantees and a weighting of potential outcomes against their likelihood of occuring.Provisions for onerous contracts are recognised when the company\u2019s expected revenues from a contract is lower than the unavoidable costs of meeting the obligations under the contract.Contingent liabilities and contingent assetsContingent liabilities for which it is not likely that the liability will incur are not recognized in the financial statements. Signi ficant contingent liabilities are disclosed, except for contingent liabilities related to which it is remote that payment will have to be made.Contingent assets are not recognised in the financial statements unless they are virtually certain. Othercontingent assets are disclosed if it is likely that an economic benefit will be received by the Group.Going concern In accordance with the accounting act \u00a7 3-3a we confirm that the condition for continued operations is present and that the annual report have been prepared based on the going concern assumption.The company has a credit facility of 67 million, whereas 19.3 million is available as of the end of the year. Additionally, the board has been authorized by the general meeting held on 10 May 2024 to issue up to 79,016,200 new shares. These authorizations are intended to be utilized in case the parent company requires additional equity and liquidity. As of 31 December 2024, the Company is not in breach with any covenants or loan conditions. Refer to note 16 for more details on the group\u2019s and the parent company\u2019s interest-bearing debt conditions, as well as note 18 for information on liquidity risk and maturity structure of the group\u2019s liabilities. The operations of the Group are subject to uncertainty with respect to its ability to sell products at favourable margins and maintain adequate cash reserves. If additional resources are needed to ensure continuity of operations and support planned activities aimed at generating positive cash flow and profitability, the Board will consider appropriate measures such as obtaining loans or equity. The current outlook indicates a positive trend, and the Board will take necessary steps to sustain this momentum. If the group and the parent company do not achieve planned market measures adequately, new loan facilities or share issues will be established in 2025. Due to the factors described above, there is uncertainty for the Company to continue as a going concern over the next 12 months. Assuming a going concern, the group\u2019s and the parent company\u2019s assets and values are currently present. However, the value of some of the group\u2019s and the parent company\u2019s assets may be lower than their carrying amounts in a potential forced sale related to liquidation. This uncertainty is primarily related to the value of intangible assets, fixed assets, financial assets, and investments, as well as the value of inventories. Financial implications of climate changeWhile it is widely recognized that continued emission of greenhouse gases will cause further warming of the planet and this warming could lead to damaging economic and social consequences, the exact timing and severity of physical effects for HBC are difficult to quantify. The large-scale and long-term nature of the problem makes it uniquely challenging, especially in the context of economic decision making.While changes associated with a transition to a lower-carbon economy present risk, HBC also create significant opportunities in the nature of our business model. Turning waste streams into high-end human and pet nutrition is important for the environment and out teams at the facilities are focused on climate change mitigation and adaptation of new technology solutions.Circular economy initiatives which HBC is a part of, and the strive to reduce greenhouse gases is high on the agenda with the Board and management of HBC and the Group has invested significant amounts in both machinery and knowledge since we joined the Global Reporting Initiative (GRI) in 2019.In a carbon constraint world, climate change is confronting HBC with totally new challenges. One way the Group deal with the impacts of climate change is to comprehend them as risks and analyse possible effects as we do elsewhere in our organization by the combination of probability and its consequence. Therefore, HBC view climate risks as the possible impacts of climate change with the potential to influence positively or negatively the future development of the HBC Group, and together with the rest of the Hofseth Group.The risks and opportunities for HBC from climate change are classified as direct or indirect. Direct climate risks and opportunities are resulting out of changing natural conditions as rising temperatures, sea levels or an increasing number of extreme weather events. Indirect climate risks and opportunities seems to have much more implications than the direct ones. Examples of indirect risks are regulatory or litigation, credit risk, market risk and reputation risk. As previously mentioned, these risks are also great opportunities for HBC. However, risks and opportunities HBC as an organization face today related to climate change, are difficult to estimate, and mitigate or explore. HBC has a work group among the management team, led by the head of Sustainability, that analyse climate risks and utilize the opportunities that arise from climate change. As of the end of 2024, the financial implications of climate change are very limited. As of today, there are few requirements for sustainability in the finished product, no distinctly strict emission rules at the factories, no external influence (e.g. sea level rise). The management expect increased focus on impairment testing as the Group grow and increase its asset base in the future.New accounting standardsIn 2024 new standards and amendments to existing standards have become effective. This is related to the following standards:-Lease liability in a sale leaseback(amendments to IFRS 16)-Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants(amendments to IAS 1)-Supplier Finance Arrangements(Amendments to IAS 7 and IFRS 7)The amendments had no impact on the Group`s consolidated financial statements.The following revised IFRS`s have been issued, but are not yet effective, and in some cases have not been adopted by EU.-Lack of Exchangeability(amendment to IAS 21, The effects of Changes in Foreign Exchange Rates)-Amendments to the Classification and Measurement of Financial Instruments(amendments to IFRS 9, Financial Instruments and IFRS 7, Financial Instruments, Disclosures)-IFRS 18 Presentation and Disclosure in Financial StatementsThe Group is assesing the impact of IFRS 18 - Presentation and Disclosures in Financial Statements, which introduces new presentation and disclosure requriements. The assesment is ongoing, and any necessary adjustments will be made in line with the standard`s effective date and regulatory requriements.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__6": {
"value": "General informationHofseth BioCare ASA ia a public limited liability company domicilied in \u00c5lesund, Norway. The company`s headquarter is in Keiser Wilhelmsgate 24 in \u00c5lesund, with one manufacturing facility in the municipality of Molde and one manufacturing facility in the municipality of Rennebu. The annual financial statements were approved for issuance by the board of directors 11 April 2025.The Group`s operation is the processing of fish offcuts into high quality protein and other food supplements.The company\u2019s consolidated financial statements for 2024 consist of the parent company and the subsidiaries HBC Berk\u00e5k AS, HBC Therapeutics AS, Hofseth BioCare R\u00f8rvik AS, HBC Switzerland GmbH, Hofseth Biocare UK Limited and Hofseth Biocare Americas Holdings Inc. (the Group).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__16": {
"value": "Hofseth BioCare ASA",
"dimensions": {
"concept": "ifrs-full:NameOfUltimateParentOfGroup",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__15": {
"value": "Hofseth BioCare ASA",
"dimensions": {
"concept": "ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__8": {
"value": "Hofseth BioCare ASA",
"dimensions": {
"concept": "ifrs-full:NameOfParentEntity",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__14": {
"value": "public limited liability company",
"dimensions": {
"concept": "ifrs-full:LegalFormOfEntity",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__10": {
"value": "\u00c5lesund, Norway",
"dimensions": {
"concept": "ifrs-full:PrincipalPlaceOfBusiness",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__11": {
"value": "Norway",
"dimensions": {
"concept": "ifrs-full:CountryOfIncorporation",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__9": {
"value": "Norway",
"dimensions": {
"concept": "ifrs-full:DomicileOfEntity",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__12": {
"value": "Keiser Wilhelmsgate 24 in \u00c5lesund",
"dimensions": {
"concept": "ifrs-full:AddressOfRegisteredOfficeOfEntity",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__7": {
"value": "The annual financial statements were approved for issuance by the board of directors 11 April 2025.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__13": {
"value": "The Group`s operation is the processing of fish offcuts into high quality protein and other food supplements.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__18": {
"value": "Basis of preparation The consolidated financial statements and the parent company financial statements of Hofseth BioCare ASA have been prepared in accordance with IFRS\u00ae Accounting Standards as adopted by the EU as of 31 December 2024, as well as the additional disclosure requirements following from the Norwegian accounting act as of 31 December 2024.The consolidated financial statements and the parent company financial statements are prepared on the historical cost basis, with the exception of financial instruments that are measured at fair value with changes in value through profit or loss.The consolidated financial statements and the parent company financial statements have been prepared applying consistent accounting policies for similar transactions and event.",
"dimensions": {
"concept": "ifrs-full:StatementOfIFRSCompliance",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__17": {
"value": "Basis of preparation The consolidated financial statements and the parent company financial statements of Hofseth BioCare ASA have been prepared in accordance with IFRS\u00ae Accounting Standards as adopted by the EU as of 31 December 2024, as well as the additional disclosure requirements following from the Norwegian accounting act as of 31 December 2024.The consolidated financial statements and the parent company financial statements are prepared on the historical cost basis, with the exception of financial instruments that are measured at fair value with changes in value through profit or loss.The consolidated financial statements and the parent company financial statements have been prepared applying consistent accounting policies for similar transactions and event.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__19": {
"value": "Basis for consolidation(i) SubsidiariesThe consolidated financial statements include Hofseth BioCare ASA and companies controlled by Hofseth BioCare ASA. Companies are determined to be controlled when the Group is exsposed to, or has rights to, variable returns as a result of the involvement from the Group, and the Group is able to influence the returns through its power over the company. All the following criteria must be fulfilled: \u203a power over the company \u203a exposed to, or have rights to, variable returns from its involvement in the company invested in, and \u203a possibility to exercise its power over the company to influence the amount of the returns(ii) Associated companiesAssociated companies are units in which the group has significant influence, but not control over the financial and operational management (normally with an ownership share between 20% and 50%). Significant influence is the power to participate in financial and operational decisions in principle in the company, but where Hofseth BioCare still has no control or joint control. In the case of an ownership interest of less than 20%, in order to be treated as an associated company, it must be clearly demonstrated that significant influence exists, for example through shareholder agreements. The consolidated financial statements include the group\u2019s share of profit from associated companies recognized according to the equity method from the time significant influence is achieved and until such influence ceases. When the group\u2019s share of negative profit exceeds the value of the investment, the carrying amount of the investment decreases to zero and recognition of additional negative profit ceases. The exception is those cases where the group has an obligation to cover negative results.(iii) Joint ventureA joint venture is a type of joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exests only when decisions about the relevant activities require the unanimous consent of the parties sharing control.(iv) Elimination of transactions in the consolidationGroup internal balances and any unrealised gains or losses or revenues and costs related to intra Group transactions, are eliminated in full in the consolidated financial statements.(v) The non-controlling interest in the consolidated financial statements is the non-controlled share of the Group\u2019s equity. In business combinations the non-controlling interest is measured including the non-controlling interest\u2019s share of the acquired entity\u2019s identifyable net assets. The subsidiary\u2019s annual result, together with the individual components recognized in other comprehensive income, is attributable to the parent company and the non-controlling interests. Total comprehensive income is attributed to the share holders of the parent company and to the non-controlling interests even if this results in negative non-controlling interests.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__20-1": {
"value": "(i) SubsidiariesThe consolidated financial statements include Hofseth BioCare ASA and companies controlled by Hofseth BioCare ASA. Companies are determined to be controlled when the Group is exsposed to, or has rights to, variable returns as a result of the involvement from the Group, and the Group is able to influence the returns through its power over the company. All the following criteria must be fulfilled: \u203a power over the company \u203a exposed to, or have rights to, variable returns from its involvement in the company invested in, and possibility to exercise its power over the company to influence the amount of the returnsInvestment in subsidiaries, associated companies and joint venturesInvestments in subsidiaries, associated companies and joint ventures are assessed according to the cost method in the company financial statements. Investments are valued at acquisition cost, unless impairment has been necessary. Write-downs have been made at fair value when impairment is due to reasons that cannot be expected to be temporary. Impairment losses are reversed when the basis for impairment is no longer present.Dividends and other distributions are recognized as income when adopted at the general meeting of the subsidiaries. If dividends exceed the retained earnings after the acquisition, the excess part represents repayment of invested capital, and the dividends are deducted from the value of the investment in the balance sheet.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__22": {
"value": "(ii) Associated companiesAssociated companies are units in which the group has significant influence, but not control over the financial and operational management (normally with an ownership share between 20% and 50%). Significant influence is the power to participate in financial and operational decisions in principle in the company, but where Hofseth BioCare still has no control or joint control. In the case of an ownership interest of less than 20%, in order to be treated as an associated company, it must be clearly demonstrated that significant influence exists, for example through shareholder agreements. The consolidated financial statements include the group\u2019s share of profit from associated companies recognized according to the equity method from the time significant influence is achieved and until such influence ceases. When the group\u2019s share of negative profit exceeds the value of the investment, the carrying amount of the investment decreases to zero and recognition of additional negative profit ceases. The exception is those cases where the group has an obligation to cover negative results.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociates",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__21": {
"value": "(ii) Associated companiesAssociated companies are units in which the group has significant influence, but not control over the financial and operational management (normally with an ownership share between 20% and 50%). Significant influence is the power to participate in financial and operational decisions in principle in the company, but where Hofseth BioCare still has no control or joint control. In the case of an ownership interest of less than 20%, in order to be treated as an associated company, it must be clearly demonstrated that significant influence exists, for example through shareholder agreements. The consolidated financial statements include the group\u2019s share of profit from associated companies recognized according to the equity method from the time significant influence is achieved and until such influence ceases. When the group\u2019s share of negative profit exceeds the value of the investment, the carrying amount of the investment decreases to zero and recognition of additional negative profit ceases. The exception is those cases where the group has an obligation to cover negative results.(iii) Joint ventureA joint venture is a type of joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exests only when decisions about the relevant activities require the unanimous consent of the parties sharing control.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentInAssociatesAndJointVenturesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__23": {
"value": "(iii) Joint ventureA joint venture is a type of joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exests only when decisions about the relevant activities require the unanimous consent of the parties sharing control.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__24": {
"value": "(v) The non-controlling interest in the consolidated financial statements is the non-controlled share of the Group\u2019s equity. In business combinations the non-controlling interest is measured including the non-controlling interest\u2019s share of the acquired entity\u2019s identifyable net assets. The subsidiary\u2019s annual result, together with the individual components recognized in other comprehensive income, is attributable to the parent company and the non-controlling interests. Total comprehensive income is attributed to the share holders of the parent company and to the non-controlling interests even if this results in negative non-controlling interests.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithNoncontrollingInterestsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__25": {
"value": "Functional currency and presentation currencyThe Group\u2019s presentation currency is NOK, which is also the functional currency of all Norwegian companies in the Group. The Companies abroad uses local currency as their functional currency. All amounts are presented in NOK 1 000 unless specifically noted.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__26-1": {
"value": "Use of estimates when preparing the annual financial statementsManagement has to some extent used estimates and assumptions which have affected assets, liabilities, revenues, expenses, and information of potential commitments. Future events may cause changes in the estimates. Estimates and the underlying assumptions are assessed continuously. Changes in accounting estimates are recognized in the period the changes occur. To the extent the changes also affect future periods, the effect is allocated over the current and future periods. See note 2.Note 2 Accounting estimates and management judgement and assumptionsThe preparation of financial statements in accordance with IFRS requires management to make judgments when choosing and applying accounting principles. Further, IFRS requires the management to make estimates based on judgments, and that estimates and assumptions are realistic. All estimates are considered to be the expected value based on the management\u2019s best knowledge.The Group\u2019s most significant accounting estimates and areas of judgment are the following: \u203a Allocation of production costs in manufactruring cost of finished product cost \u203a Transactions with related parties \u203a Recognition of intangible assets \u203a Inventory - obsolescenceAllocation of production costs in manufactruring cost of finished product cost Four types of finished products are produced from a common production process based on the same input factors. The value of the individual finished product is based on the allocation of production costs determined based on the finished product\u2019s relative share of production yield multiplied by the expected sales value. The same model has been used for allocating production costs over several years. The determination of expected sales value as a basis for allocating production costs has significant discretionary assessments and has a significant effect on the calculation of the cost of production of the various finished product products. The group and the parent company are still in a start-up and development phase, but management\u2019s judgment has based on agreed prices in historical sales transactions and expected sales value at the reporting date. See notes 4, 6 and 19.Transactions with related partiesTransactions with related parties constitute a significant part of the Group\u2019s and the parent company\u2019s ordinary operating revenues and costs, and where the determination of arm\u2019s length pricing is largely based on judgment. The transactions also affect liquidity and financial carrying capacity for the Group\u2019s and the parent company\u2019s operations.The most significant transactions with related parties are sale of finished goods, purchase of raw materials (fish trimmings), ongoing rental obligations related to production equipment and factory buildings Midsund and Berk\u00e5k, as well as agreements on short-term, long-term and subordinary loan financing.Hofseth BioCare ASA has a 5 years agreement starting 01.01.2022, and gives the company the exclusive right to buy all the by-products from the production of HofsethSales AS. Judgment has been applied when setting conditions for the purchase of raw materials. See notes 4 and 6.Hofseth BioCare ASA has sold finished goods to related parties in 2023 and 2024. Prices are determined on the basis of current and historical transactions with independent parties in 2023 and 2024. Discretion has been used in determining conditions for the sale of finished goods, see notes 3 and 6.Leases of production equipment, leases of factory facilities at Midsund and Berk\u00e5k, as well as agreements for long-term and subordinated loans. When agreeing financial terms in leases, agreements for long-term loans in 2019 and 2020 a subordinated loan in 2019, historical terms with third parties, achieved by the group and the parent company, have been referred to. Judgement has been applied when setting the financial terms. See notes 6, 12, 13, 16 and 18.Hofseth Biocare ASA sold a patent to HBCI in 2024. The patent was valued at TNOK 47 750, and the company booked a gain of TNOK 8 122 in Q2 2024. Recognition of intangible assetsThe Group has come far in the development phase of establishing production at the targeted level and with the quality that the business model has been based on. The Group invests in research and development activities on an ongoing basis. Uncertainties exist relating to the timing of when the requirements for recognition of intangible assets have been met. The management\u2019s starting point is that development activities are capitalized when there is an identifiable asset or product that is controlled by the company that is expected to result in future economic benefits. Uncertainties also exist relating to the assessment and estimation of the cost price for the intangible assets, and mainly relating to the estimation of cost price for developing intangible assets and product development. Development activities that qualify for capitalization are capitalized both in the Group and parent company. See note 10.InventoriesGoods in stock are valued at the lower of cost and net realisable value. It is used judgment in relation to quality and durability. The Group uses a model in which provision is made for obsolescence gradually if goods in stock approach the expiration of the shelf life. It is set aside TNOK 43,125 for obsolescence, see note 19.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__27": {
"value": "Foreign currencyTransactions in foreign currency are translated at the exchange rates prevailing at the date of the transaction. Monetary items in foreign currency are translated at the exchange rate at the balance sheet date. Currency exchange gains and losses are recognized in the income statement and presented as financial income/financial expense.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__28": {
"value": "Revenue recognition policiesRevenues are primarily generated from manufactured own goods within the following product types: \u203a Salmon oil (OmeGo\u00ae) \u203a Water-soluble protein (ProGo\u00ae) \u203a Calcium (CalGo\u00ae) \u203a Non-soluble protein (PetGo\u2122)Revenue from contracts with customers is recognized when control of goods or services is transferred to the customers with an amount that reflects the consideration that the Group expects to be entitled to in exchange for delivered goods and services. Control is normally transferred to the customer when goods are sent from the warehouse to the customer. To the extent the customers enter into a contract for the purchase of goods, which the customers wish to continue to store at Hofseth BioCares\u2019 warehouse, the consideration is recognized as revenue when control has passed to the purchasing party. The customers have a desire to continue storing on the group\u2019s stock as a result of requirements for moisture, temperature, etc. when storing the goods, especially Calcium and Protein. In such sales, there is an agreement of control transfer to the customers for the actual delivery of the goods. The parent company and the group also earn revenues from the service of storing the goods, which are recognized at a fixed price per month in storage.The Group assesses whether there are obligations in the sales contracts that are separate performance obligations, and for which parts of the transaction price must be allocated or agreed variable payment terms in the contracts. The parent company and the group have offered rights of return when selling from the web-stores to customers in the human market and have factored in an estimated level of returns when calculating revenue. Furthermore, the Group also assesses whether there are significant financing components in the sales contracts (advance payment, extra long credit terms, etc.).",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__29": {
"value": "Trade receivablesA receivable represents the Group\u2019s right to payment of an amount which is unconditional (i.e. the agreed credit time before payment of the consideration falls due). See accounting principles for financial assets\u2019 initial recognition and subsequent measurement. Payment terms in the group\u2019s customer contracts vary from 0 days to 90 days.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__30": {
"value": "SegmentsAn operating segment is a component of the Group that engages in business activities from which it earns revenues and incurs expenses.The Group\u2019s operating results are regularly reviewed by the managing director to monitor the Group\u2019s results and make decisions about resource allocations.As the Group has one common and not separable manufacturing process for its products, management focuses its financial review on revenues and quality generated from the manufacturing process. Management monitors the financial results at Group level and, hence, the Group only has one segment. Information about products is presented in note 3.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__31": {
"value": "Government grantsGovernment grants are recognised at the time it is reasonably assurance that the company complies with the requirements stated to be eligible for the grants and will receive payment. Grants relating to operating expenditures are recognised systematically over the grant period. Grants are recognised against the costs the grant is meant to cover. Grants for investments are recognised systematically over the asset\u2019s useful lives. Grants for investments are recognised as a reduction to the related assets\u2019 carrying amount.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__33-1": {
"value": "Employee benefitsDefined contribution pension planA defined contribution pension plan is an arrangement in which the employer pays fixed constributions to a fund or a pension fund, and in which the parent company and the group has no further legal or constructive obligations to pay additional contributions. The contributions are recognized in the income statement as salary related costs in the period in which the employee renders the service.AFP pension planThe group is affiliated with the AFP scheme, which is a collective pension scheme for the collectively agreed sector in Norway.Accounting-wise, the scheme is considered a defined benefit multi-employer scheme. However, the group is unable to identify its share of the scheme\u2019s underlying financial position and performance with sufficient reliability. Therefore, the scheme is accounted for as a defined contribution scheme. As a result, obligations from the AFP scheme are not recognized on the balance sheet. Premiums to the scheme are expensed as they accrue.Intangible assetsIntangible assets acquired separately are recognised at their cost price. The cost price for intangible assets acquired are recognised at fair value in the Group. Recognised intangible assets are accounted for at cost less any depreciation and impairment write-down.Internally generated intangibe assets, except for recognised development costs, are not recognised, but expensed as incurred.Intangible assets with finite useful life are depreciated over their useful lives and tested for impairment when impairment indicators are present. Depreciation methods and useful lives are assessed annually as a minimum. Changes to depreciation method and/or useful life are accounted for as estimate changes.Fixed assetsFixed assets are measured at cost, less accumulated depreciations and impairment write- downs. Fixed assets are derecognized when sold or disposed of and any gains or losses are recognized in the income statement.Acquisition cost for fixed assets is the cost price and costs directly associated wih getting the asset ready for its intended use.Expenditures incurred after recognition of the fixed asset, such as day-to-day maintenance, are recognized in the income statement as incurred, while expenditures expected to generate future economic benefits are recognized in the carrying amount. Depreciation period, depreciation method and residual values are assessed annually.Fixed assets are carried at cost until manufacturing or development has been completed. Fixed assets under construction are not depreciated until the assets are ready for their intended use.When significant components of a property, plant and equipment are determined to have different useful lives, they are accounted for as separate components. Each component of property, plant and equipment is depreciated on a straight-line basis over its estimated useful life, as this is considered to best represent the consumption of the future economic benefits of the assets. Land is not depreciated. Estimated useful life for the current period and depreciation periods are disclosed in note 11. Depreciation method, useful life and residual values are reassessed at the balance sheet date and adjusted if found necessary. When the carrying amount of a fixed asset or a cash-generating unit is higher than the recoverable amount, the asset is written-down to its recoverable amount. Recoverable amount is the higher of value in use and fair value less costs of disposal.Lease liabilitiesThe company and the group measure the lease liabilities at the present value of the lease payments to be made over the lease term at the commencement date. The lease term is the non-cancellable period of the lease, in addition to periods covered by options to extend or terminate the lease if it is reasonably certain that the group will (will not) exercise the option.The lease payments included in the measurement of the lease liability consist of: \u203a Fixed lease payments (including in substance fixed payments), less any lease incentives receivable \u203a Variable lease payments which are dependant on an index or rate, measured for the first time using the index or rate applicable at the commencement date \u203a Amounts expected to be payable by the company and the group under residual value guarantees \u203a The exercise price for an option to purchase the asset, if it is reasonably certain that the company and the group will exercise this option \u203a Termination fee, if the lease term has been determined on the basis that the company and the group will exercise an option to terminate the leaseThe lease liability is subsequently remeasured by increasing the carrying amount by an accretion amount on the lease liability, and reduce the carrying amount for lease payments made, as well as potential reassessments or changes to the lease agreement, or to reflect adjustments to lease payments as a result of a change in an index or a rate. The company and the group do not include variable lease payments in the lease liability. Variable payments are recognized in the profit or loss as incurred. The company and the group presenter the lease liabilities in separate line items in the statement of financial position.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__32-1": {
"value": "Employee benefitsDefined contribution pension planA defined contribution pension plan is an arrangement in which the employer pays fixed constributions to a fund or a pension fund, and in which the parent company and the group has no further legal or constructive obligations to pay additional contributions. The contributions are recognized in the income statement as salary related costs in the period in which the employee renders the service.AFP pension planThe group is affiliated with the AFP scheme, which is a collective pension scheme for the collectively agreed sector in Norway.Accounting-wise, the scheme is considered a defined benefit multi-employer scheme. However, the group is unable to identify its share of the scheme\u2019s underlying financial position and performance with sufficient reliability. Therefore, the scheme is accounted for as a defined contribution scheme. As a result, obligations from the AFP scheme are not recognized on the balance sheet. Premiums to the scheme are expensed as they accrue.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__38": {
"value": "Financial income and financial expensesFinancial income consists of interest income, dividends, foreign exchange gains and gains from sale of financial instruments. Interest income is recognised when earned, calculated using the effective interest rate method, while dividends are recognised on the date of the general meeting approving the dividends.Financial expenses consist of interest expenses, guarantee commissions, foreign exchange losses and losses from sale of financial instruments. Interest expenses and guarantee commissions are recognized when incurred, calculated using the effective interest rate method.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__37": {
"value": "Financial income and financial expensesFinancial income consists of interest income, dividends, foreign exchange gains and gains from sale of financial instruments. Interest income is recognised when earned, calculated using the effective interest rate method, while dividends are recognised on the date of the general meeting approving the dividends.Financial expenses consist of interest expenses, guarantee commissions, foreign exchange losses and losses from sale of financial instruments. Interest expenses and guarantee commissions are recognized when incurred, calculated using the effective interest rate method.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceCostsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__36": {
"value": "Financial income and financial expensesFinancial income consists of interest income, dividends, foreign exchange gains and gains from sale of financial instruments. Interest income is recognised when earned, calculated using the effective interest rate method, while dividends are recognised on the date of the general meeting approving the dividends.Financial expenses consist of interest expenses, guarantee commissions, foreign exchange losses and losses from sale of financial instruments. Interest expenses and guarantee commissions are recognized when incurred, calculated using the effective interest rate method.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__39": {
"value": "Income taxesIncome tax expenses consist of current taxes payable and changes in deferred taxes. Current taxes payable are taxes payable or tax receivables related to taxable income or loss for the year, based on tax rates substantively enacted at the balance sheet date. Changes in calculated current taxes payable related to prior years are included in the amount.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__40": {
"value": "Deferred tax/deferred tax assets are calculated on all temporary differences between carrying amounts and tax bases for all assets and liabilities on the balance sheet date.Deferred taxes are calculated using the tax rate expected to be applicable at the time of reversal of the temporary differences. Deferred tax assets are recognised to the extent the company is expected to have sufficient taxable income in future periods to utilize the tax benefit.The companies recognize previously unrecognized deferred tax assets to the extent it has become likely that the company may utilize the deferred tax benefit. Likewise, the company will reduce deferred tax assets to the extent the company no longer expects that it will be able to utilise the deferred tax benefit. Deferred tax and deferred tax assets are measured at nominal values. Deferred tax liabilities are presented as provisions/long term liabilities in the balance sheet, while deferred tax assets are presented as intangible assets.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__43-1": {
"value": "Intangible assetsIntangible assets acquired separately are recognised at their cost price. The cost price for intangible assets acquired are recognised at fair value in the Group. Recognised intangible assets are accounted for at cost less any depreciation and impairment write-down.Internally generated intangibe assets, except for recognised development costs, are not recognised, but expensed as incurred.Intangible assets with finite useful life are depreciated over their useful lives and tested for impairment when impairment indicators are present. Depreciation methods and useful lives are assessed annually as a minimum. Changes to depreciation method and/or useful life are accounted for as estimate changes.Patents and licencesAcquisition costs for patents and licences are recognised and depreciated over their estimated useful lives.Development activitiesExpenditures on research are recognised in the income statement as incurred. Expenditures on development activities, including product development (new or improved products) are recognized when all the following criteria are fullfilled: \u203a It is technically possible to complete the asset / product in such a way that the Group may use or sell the asset /product in the future \u203a It is management\u2019s intention to complete the asset / product, as well as to use or sell the asset / product \u203a It is possible to use the asset / sell the product \u203a How the asset / product will generate future revenues can be proven \u203a The Group has sufficient technological and financial ressources available to complete the asset / development of the product \u203a The costs can be reliably measured Recognised costs include cost of material, consultant fees and direct salary costs. Other development costs are recognized in the income statement as incurred. Previously expensed development costs are not subsequently capitalized. Recognised development costs are depreciated on a straight-line basis over the assets / products estimated useful lives.Fixed assetsFixed assets are measured at cost, less accumulated depreciations and impairment write- downs. Fixed assets are derecognized when sold or disposed of and any gains or losses are recognized in the income statement.Acquisition cost for fixed assets is the cost price and costs directly associated wih getting the asset ready for its intended use.Expenditures incurred after recognition of the fixed asset, such as day-to-day maintenance, are recognized in the income statement as incurred, while expenditures expected to generate future economic benefits are recognized in the carrying amount. Depreciation period, depreciation method and residual values are assessed annually.Fixed assets are carried at cost until manufacturing or development has been completed. Fixed assets under construction are not depreciated until the assets are ready for their intended use.When significant components of a property, plant and equipment are determined to have different useful lives, they are accounted for as separate components. Each component of property, plant and equipment is depreciated on a straight-line basis over its estimated useful life, as this is considered to best represent the consumption of the future economic benefits of the assets. Land is not depreciated. Estimated useful life for the current period and depreciation periods are disclosed in note 11. Depreciation method, useful life and residual values are reassessed at the balance sheet date and adjusted if found necessary. When the carrying amount of a fixed asset or a cash-generating unit is higher than the recoverable amount, the asset is written-down to its recoverable amount. Recoverable amount is the higher of value in use and fair value less costs of disposal.Lease liabilitiesThe company and the group measure the lease liabilities at the present value of the lease payments to be made over the lease term at the commencement date. The lease term is the non-cancellable period of the lease, in addition to periods covered by options to extend or terminate the lease if it is reasonably certain that the group will (will not) exercise the option.The lease payments included in the measurement of the lease liability consist of: \u203a Fixed lease payments (including in substance fixed payments), less any lease incentives receivable \u203a Variable lease payments which are dependant on an index or rate, measured for the first time using the index or rate applicable at the commencement date \u203a Amounts expected to be payable by the company and the group under residual value guarantees \u203a The exercise price for an option to purchase the asset, if it is reasonably certain that the company and the group will exercise this option \u203a Termination fee, if the lease term has been determined on the basis that the company and the group will exercise an option to terminate the leaseThe lease liability is subsequently remeasured by increasing the carrying amount by an accretion amount on the lease liability, and reduce the carrying amount for lease payments made, as well as potential reassessments or changes to the lease agreement, or to reflect adjustments to lease payments as a result of a change in an index or a rate. The company and the group do not include variable lease payments in the lease liability. Variable payments are recognized in the profit or loss as incurred. The company and the group presenter the lease liabilities in separate line items in the statement of financial position.Right of use assets The company and the group measures right of use assets at cost, less accumulated depreciations and impairment losses, adjusted for potential new measurements of the lease liability. Cost for the right of use assets comprise: \u203a The amount established at initial recognition of the lease liabiilty All lease payments made at or before the commencement date, less lease incentives received if any \u203a All direct expenditures incurred for the company and the group related to entering into the agreementThe group applies the depreciation provisions in IAS 16 Property, plant and equipment when depreciating the right of use asset, except for the fact that the right of use asset is depreciated from the date of commencement until the end of the lease period or the end of the asset\u2019s useful life, whichever is expected to take place first, unless there is an option to purchase the asset which has been determined to be exercised with reasonable certainty, in which case the right of use asset is depreciated over the expected economic life of the underlying asset.The group applies IAS 36 \u00abImpairment of assets\u00bb in order to determine whether the right of use asset has been impaired and, if this is the case, write it down for impairment.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDepreciationExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__42-1": {
"value": "Intangible assetsIntangible assets acquired separately are recognised at their cost price. The cost price for intangible assets acquired are recognised at fair value in the Group. Recognised intangible assets are accounted for at cost less any depreciation and impairment write-down.Internally generated intangibe assets, except for recognised development costs, are not recognised, but expensed as incurred.Intangible assets with finite useful life are depreciated over their useful lives and tested for impairment when impairment indicators are present. Depreciation methods and useful lives are assessed annually as a minimum. Changes to depreciation method and/or useful life are accounted for as estimate changes.Patents and licencesAcquisition costs for patents and licences are recognised and depreciated over their estimated useful lives.Development activitiesExpenditures on research are recognised in the income statement as incurred. Expenditures on development activities, including product development (new or improved products) are recognized when all the following criteria are fullfilled: \u203a It is technically possible to complete the asset / product in such a way that the Group may use or sell the asset /product in the future \u203a It is management\u2019s intention to complete the asset / product, as well as to use or sell the asset / product \u203a It is possible to use the asset / sell the product \u203a How the asset / product will generate future revenues can be proven \u203a The Group has sufficient technological and financial ressources available to complete the asset / development of the product \u203a The costs can be reliably measured Recognised costs include cost of material, consultant fees and direct salary costs. Other development costs are recognized in the income statement as incurred. Previously expensed development costs are not subsequently capitalized. Recognised development costs are depreciated on a straight-line basis over the assets / products estimated useful lives.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__41-1": {
"value": "Intangible assetsIntangible assets acquired separately are recognised at their cost price. The cost price for intangible assets acquired are recognised at fair value in the Group. Recognised intangible assets are accounted for at cost less any depreciation and impairment write-down.Internally generated intangibe assets, except for recognised development costs, are not recognised, but expensed as incurred.Intangible assets with finite useful life are depreciated over their useful lives and tested for impairment when impairment indicators are present. Depreciation methods and useful lives are assessed annually as a minimum. Changes to depreciation method and/or useful life are accounted for as estimate changes.Patents and licencesAcquisition costs for patents and licences are recognised and depreciated over their estimated useful lives.Development activitiesExpenditures on research are recognised in the income statement as incurred. Expenditures on development activities, including product development (new or improved products) are recognized when all the following criteria are fullfilled: \u203a It is technically possible to complete the asset / product in such a way that the Group may use or sell the asset /product in the future \u203a It is management\u2019s intention to complete the asset / product, as well as to use or sell the asset / product \u203a It is possible to use the asset / sell the product \u203a How the asset / product will generate future revenues can be proven \u203a The Group has sufficient technological and financial ressources available to complete the asset / development of the product \u203a The costs can be reliably measured Recognised costs include cost of material, consultant fees and direct salary costs. Other development costs are recognized in the income statement as incurred. Previously expensed development costs are not subsequently capitalized. Recognised development costs are depreciated on a straight-line basis over the assets / products estimated useful lives.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__50": {
"value": "Development activitiesExpenditures on research are recognised in the income statement as incurred. Expenditures on development activities, including product development (new or improved products) are recognized when all the following criteria are fullfilled: \u203a It is technically possible to complete the asset / product in such a way that the Group may use or sell the asset /product in the future \u203a It is management\u2019s intention to complete the asset / product, as well as to use or sell the asset / product \u203a It is possible to use the asset / sell the product \u203a How the asset / product will generate future revenues can be proven \u203a The Group has sufficient technological and financial ressources available to complete the asset / development of the product \u203a The costs can be reliably measured Recognised costs include cost of material, consultant fees and direct salary costs. Other development costs are recognized in the income statement as incurred. Previously expensed development costs are not subsequently capitalized. Recognised development costs are depreciated on a straight-line basis over the assets / products estimated useful lives.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__52": {
"value": "Fixed assetsFixed assets are measured at cost, less accumulated depreciations and impairment write- downs. Fixed assets are derecognized when sold or disposed of and any gains or losses are recognized in the income statement.Acquisition cost for fixed assets is the cost price and costs directly associated wih getting the asset ready for its intended use.Expenditures incurred after recognition of the fixed asset, such as day-to-day maintenance, are recognized in the income statement as incurred, while expenditures expected to generate future economic benefits are recognized in the carrying amount. Depreciation period, depreciation method and residual values are assessed annually.Fixed assets are carried at cost until manufacturing or development has been completed. Fixed assets under construction are not depreciated until the assets are ready for their intended use.When significant components of a property, plant and equipment are determined to have different useful lives, they are accounted for as separate components. Each component of property, plant and equipment is depreciated on a straight-line basis over its estimated useful life, as this is considered to best represent the consumption of the future economic benefits of the assets. Land is not depreciated. Estimated useful life for the current period and depreciation periods are disclosed in note 11. Depreciation method, useful life and residual values are reassessed at the balance sheet date and adjusted if found necessary. When the carrying amount of a fixed asset or a cash-generating unit is higher than the recoverable amount, the asset is written-down to its recoverable amount. Recoverable amount is the higher of value in use and fair value less costs of disposal.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__55": {
"value": "Investment in subsidiaries, associated companies and joint venturesInvestments in subsidiaries, associated companies and joint ventures are assessed according to the cost method in the company financial statements. Investments are valued at acquisition cost, unless impairment has been necessary. Write-downs have been made at fair value when impairment is due to reasons that cannot be expected to be temporary. Impairment losses are reversed when the basis for impairment is no longer present.Dividends and other distributions are recognized as income when adopted at the general meeting of the subsidiaries. If dividends exceed the retained earnings after the acquisition, the excess part represents repayment of invested capital, and the dividends are deducted from the value of the investment in the balance sheet.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__57-1": {
"value": "LeasesFor contracts constituting or containing a lease, the company and the group separate lease components if the underlying asset may be used either on its own or together with other resources easily available to the company and the group, and the underlying asset is neither dependent nor interrelated on other underlying assets in the contract. The company and the group then account for each single lease component in the contract as one lease contract separately from the non-lease component in the contract. At the time of commencement of a lease contract the company and the group recognize a lease liability and a corresponding right of use asset for all leases, except for the following excemptions elected under the standard: \u203a Short-term leases (lease term of 12 months or less) \u203a Low value assetsFor such leases the company and the group recognize the lease payments as other operating expenses in the profit or loss when incurred.Lease liabilitiesThe company and the group measure the lease liabilities at the present value of the lease payments to be made over the lease term at the commencement date. The lease term is the non-cancellable period of the lease, in addition to periods covered by options to extend or terminate the lease if it is reasonably certain that the group will (will not) exercise the option.The lease payments included in the measurement of the lease liability consist of: \u203a Fixed lease payments (including in substance fixed payments), less any lease incentives receivable \u203a Variable lease payments which are dependant on an index or rate, measured for the first time using the index or rate applicable at the commencement date \u203a Amounts expected to be payable by the company and the group under residual value guarantees \u203a The exercise price for an option to purchase the asset, if it is reasonably certain that the company and the group will exercise this option \u203a Termination fee, if the lease term has been determined on the basis that the company and the group will exercise an option to terminate the leaseThe lease liability is subsequently remeasured by increasing the carrying amount by an accretion amount on the lease liability, and reduce the carrying amount for lease payments made, as well as potential reassessments or changes to the lease agreement, or to reflect adjustments to lease payments as a result of a change in an index or a rate. The company and the group do not include variable lease payments in the lease liability. Variable payments are recognized in the profit or loss as incurred. The company and the group presenter the lease liabilities in separate line items in the statement of financial position.Right of use assets The company and the group measures right of use assets at cost, less accumulated depreciations and impairment losses, adjusted for potential new measurements of the lease liability. Cost for the right of use assets comprise: \u203a The amount established at initial recognition of the lease liabiilty All lease payments made at or before the commencement date, less lease incentives received if any \u203a All direct expenditures incurred for the company and the group related to entering into the agreementThe group applies the depreciation provisions in IAS 16 Property, plant and equipment when depreciating the right of use asset, except for the fact that the right of use asset is depreciated from the date of commencement until the end of the lease period or the end of the asset\u2019s useful life, whichever is expected to take place first, unless there is an option to purchase the asset which has been determined to be exercised with reasonable certainty, in which case the right of use asset is depreciated over the expected economic life of the underlying asset.The group applies IAS 36 \u00abImpairment of assets\u00bb in order to determine whether the right of use asset has been impaired and, if this is the case, write it down for impairment.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__64-1": {
"value": "Impairment of non-financial assetsDepreciable fixed assets and intangible assets are assessed for impairment when impairment indicators are identified. Impairment write-downs for the difference between the carrying amount and the recoverable amount are recognised in the income statement. The recoverable amount for an asset or a cash generating unit is the higher of value in use and fair value less costs of disposal. When assessing value in use, estimated future cash flows are discounted to net present value using a pre-tax market-based discount rate. The discount rate includes the time value of money and asset specific risk. When testing for impairment, assets which are not tested individually are tested at a Group level representing the lowest level of identifiable cash flows which are independent of cash flows from other assets or Groups of assets (cash generating units or CGUs). Impairment write-downs are recognised to the extent the carrying amount of an asset or cash generating unit exceed the estimated recoverable amount. When recognizing impairment write-downs related to cash generating units, any goodwill impairment is recognized first. Any remaining impairment amount is split pro-rata on other assets in the cash generating unit (Group of cash generating units). Impairments are presented in the line item depreciations and impairments.For other assets an assessment as to whether there are indications that the impairment is no longer present or reduced is made on the balance sheet date (reporting date). Impairments are reversed if the estimates in the calculation have favourably changed the recoverable amount. Impairment reversals are limited to the carrying amounts being equal to what it would have been if no impairment had been recognised.Impairment of financial assetsFor accounts receivables and contract assets, the Group uses a simplified approach to calculating expected credit losses (ECL). The Group therefore does not track changes in credit risk, but instead recognizes a loss provision based on expected credit losses over the life of the trade receivable and the contract asset on each reporting date. The Group has established a provision matrix that is based on historical losses, adjusted for future-oriented factors that are specific to the debtors and the economic environment.The Group considers a financial asset to be in default when it is more than 60 days overdue. In some cases, however, the Group may also consider that a financial asset is in default when internal or external information indicates that the Group is unable to receive the outstanding contract amounts in its entirety before taking into account any credit insurance that the Group has. A financial asset is recognized as a loss when there is no reasonable expectation of receiving contractual cash flows.Further information on any impairment of financial assets is provided in notes 20, 21 and 22.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__63": {
"value": "Impairment of non-financial assetsDepreciable fixed assets and intangible assets are assessed for impairment when impairment indicators are identified. Impairment write-downs for the difference between the carrying amount and the recoverable amount are recognised in the income statement. The recoverable amount for an asset or a cash generating unit is the higher of value in use and fair value less costs of disposal. When assessing value in use, estimated future cash flows are discounted to net present value using a pre-tax market-based discount rate. The discount rate includes the time value of money and asset specific risk. When testing for impairment, assets which are not tested individually are tested at a Group level representing the lowest level of identifiable cash flows which are independent of cash flows from other assets or Groups of assets (cash generating units or CGUs). Impairment write-downs are recognised to the extent the carrying amount of an asset or cash generating unit exceed the estimated recoverable amount. When recognizing impairment write-downs related to cash generating units, any goodwill impairment is recognized first. Any remaining impairment amount is split pro-rata on other assets in the cash generating unit (Group of cash generating units). Impairments are presented in the line item depreciations and impairments.For other assets an assessment as to whether there are indications that the impairment is no longer present or reduced is made on the balance sheet date (reporting date). Impairments are reversed if the estimates in the calculation have favourably changed the recoverable amount. Impairment reversals are limited to the carrying amounts being equal to what it would have been if no impairment had been recognised.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__66": {
"value": "Financial assetsFinancial assets are classified at initial recognition and are subsequently measured at amortized cost, at fair value through other comprehensive income (OCI) or at fair value through profit or loss.The classification of financial assets on initial recognition depends on both the characteristics of the financial assets\u2019 contractual cash flows and the Group\u2019s business model for managing these. The Group\u2019s business model for managing financial assets refers to how the Group manages its financial assets to generate cash flows. The business model determines whether cash flows will arise by receiving contractual cash flows, or by selling the financial assets or both.Accounts receivables that do not contain a significant financing component are measured at the transaction price determined in accordance with IFRS 15, see the accounting policies in section on revenue from contracts with customers, and then measured at amortized cost.Other long-term and short-term receivables, as well as cash and cash equivalents, are recognized at fair value on initial recognition and subsequently at amortized cost.Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated at fair value through profit or loss, or financial assets that are required to measure at fair value. Financial assets are classified as held for trading if they are purchased for the purpose of being sold or repurchased within a short period of time. Derivatives are also classified as held for trading.Financial assets at fair value through profit or loss are recognized in the balance sheet at fair value with net changes in fair value recognized in the income statement. The category includes derivative instruments (forward contracts in foreign currency) and long-term equity investments. Dividends on equity investments are recognized as financial income in the income statement when there is a right to payment of dividends. Financial assets are derecognised when the rights to receive cash flows from the assets have expired or the Group has transferred its rights to receive cash flows from the assets.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__65-1": {
"value": "Financial assetsFinancial assets are classified at initial recognition and are subsequently measured at amortized cost, at fair value through other comprehensive income (OCI) or at fair value through profit or loss.The classification of financial assets on initial recognition depends on both the characteristics of the financial assets\u2019 contractual cash flows and the Group\u2019s business model for managing these. The Group\u2019s business model for managing financial assets refers to how the Group manages its financial assets to generate cash flows. The business model determines whether cash flows will arise by receiving contractual cash flows, or by selling the financial assets or both.Accounts receivables that do not contain a significant financing component are measured at the transaction price determined in accordance with IFRS 15, see the accounting policies in section on revenue from contracts with customers, and then measured at amortized cost.Other long-term and short-term receivables, as well as cash and cash equivalents, are recognized at fair value on initial recognition and subsequently at amortized cost.Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated at fair value through profit or loss, or financial assets that are required to measure at fair value. Financial assets are classified as held for trading if they are purchased for the purpose of being sold or repurchased within a short period of time. Derivatives are also classified as held for trading.Financial assets at fair value through profit or loss are recognized in the balance sheet at fair value with net changes in fair value recognized in the income statement. The category includes derivative instruments (forward contracts in foreign currency) and long-term equity investments. Dividends on equity investments are recognized as financial income in the income statement when there is a right to payment of dividends. Financial assets are derecognised when the rights to receive cash flows from the assets have expired or the Group has transferred its rights to receive cash flows from the assets.Impairment of financial assetsFor accounts receivables and contract assets, the Group uses a simplified approach to calculating expected credit losses (ECL). The Group therefore does not track changes in credit risk, but instead recognizes a loss provision based on expected credit losses over the life of the trade receivable and the contract asset on each reporting date. The Group has established a provision matrix that is based on historical losses, adjusted for future-oriented factors that are specific to the debtors and the economic environment.The Group considers a financial asset to be in default when it is more than 60 days overdue. In some cases, however, the Group may also consider that a financial asset is in default when internal or external information indicates that the Group is unable to receive the outstanding contract amounts in its entirety before taking into account any credit insurance that the Group has. A financial asset is recognized as a loss when there is no reasonable expectation of receiving contractual cash flows.Further information on any impairment of financial assets is provided in notes 20, 21 and 22.Cash and short-term depositsCash and short-term desposits in the statement of financial position comprise cash at banks and on hand and short-term higly liquid deposits with a maturity of three months or less, that are held for the purpose of meeting short-term cash commitments and are readily convertible to a known amount of cash and subject to a insignificant risk of change in value.Financial liabilitiesFinancial liabilities are initially recognized as financial liabilities at fair value through profit or loss.Interest-bearing debt and other liabilities are recognized at fair value less transaction costs at the time of establishment. In subsequent periods, loans are recognized at amortized cost using the effective interest rate. For more information see note 16.Financial liabilities at fair value through profit or loss include financial liabilities held for trading purposes and financial liabilities designated at initial recognition at fair value through profit or loss. Financial liabilities are classified as held for trading purposes if they are contractual for the purpose of being sold or repurchased within a short period of time. This category also includes derivative instruments (currency forward contracts). Gains or losses on liabilities held for trading are recognized in the income statement, see note 7.DerivativesThe Group uses financial forward exchange contracts (derivatives) to hedge the Group\u2019s currency risk. The forward exchange contracts are recognized in the balance sheet at fair value at the time the contract is entered into with the credit institutions, and subsequently the portfolio of forward exchange contracts is adjusted continuously at fair value through profit or loss. The forward exchange contracts are capitalized as financial assets when fair value is positive and as financial liabilities when fair value is negative. See notes 7, 15 and 18.The Group does not have forward exchange contracts or other derivatives that are considered hedging instruments in hedging terms as defined in IFRS 9.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__67": {
"value": "Impairment of financial assetsFor accounts receivables and contract assets, the Group uses a simplified approach to calculating expected credit losses (ECL). The Group therefore does not track changes in credit risk, but instead recognizes a loss provision based on expected credit losses over the life of the trade receivable and the contract asset on each reporting date. The Group has established a provision matrix that is based on historical losses, adjusted for future-oriented factors that are specific to the debtors and the economic environment.The Group considers a financial asset to be in default when it is more than 60 days overdue. In some cases, however, the Group may also consider that a financial asset is in default when internal or external information indicates that the Group is unable to receive the outstanding contract amounts in its entirety before taking into account any credit insurance that the Group has. A financial asset is recognized as a loss when there is no reasonable expectation of receiving contractual cash flows.Further information on any impairment of financial assets is provided in notes 20, 21 and 22.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__70": {
"value": "InventoryInventories are measured at the lower of cost and net realisable value. Net realisable value has been estimated as selling price in the ordinary course of business less the estimated costs of completion and the estimated costs for marketing and distribution. Cost is allocated using the FIFO-method and includes expenditures incurred in purchasing the goods, raw material, costs to bring the goods and the raw material to their current condition and location. Owned goods are valued at manufacturing cost and include raw material costs, as well as other variable and fixed production costs that can be allocated based on normal capacity utilization. See note 2 and 19 for more information.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__71": {
"value": "Cash and short-term depositsCash and short-term desposits in the statement of financial position comprise cash at banks and on hand and short-term higly liquid deposits with a maturity of three months or less, that are held for the purpose of meeting short-term cash commitments and are readily convertible to a known amount of cash and subject to a insignificant risk of change in value.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__73": {
"value": "Financial liabilitiesFinancial liabilities are initially recognized as financial liabilities at fair value through profit or loss.Interest-bearing debt and other liabilities are recognized at fair value less transaction costs at the time of establishment. In subsequent periods, loans are recognized at amortized cost using the effective interest rate. For more information see note 16.Financial liabilities at fair value through profit or loss include financial liabilities held for trading purposes and financial liabilities designated at initial recognition at fair value through profit or loss. Financial liabilities are classified as held for trading purposes if they are contractual for the purpose of being sold or repurchased within a short period of time. This category also includes derivative instruments (currency forward contracts). Gains or losses on liabilities held for trading are recognized in the income statement, see note 7.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__76": {
"value": "DerivativesThe Group uses financial forward exchange contracts (derivatives) to hedge the Group\u2019s currency risk. The forward exchange contracts are recognized in the balance sheet at fair value at the time the contract is entered into with the credit institutions, and subsequently the portfolio of forward exchange contracts is adjusted continuously at fair value through profit or loss. The forward exchange contracts are capitalized as financial assets when fair value is positive and as financial liabilities when fair value is negative. See notes 7, 15 and 18.The Group does not have forward exchange contracts or other derivatives that are considered hedging instruments in hedging terms as defined in IFRS 9.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsAndHedgingExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__75": {
"value": "DerivativesThe Group uses financial forward exchange contracts (derivatives) to hedge the Group\u2019s currency risk. The forward exchange contracts are recognized in the balance sheet at fair value at the time the contract is entered into with the credit institutions, and subsequently the portfolio of forward exchange contracts is adjusted continuously at fair value through profit or loss. The forward exchange contracts are capitalized as financial assets when fair value is positive and as financial liabilities when fair value is negative. See notes 7, 15 and 18.The Group does not have forward exchange contracts or other derivatives that are considered hedging instruments in hedging terms as defined in IFRS 9.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__78": {
"value": "ProvisionsA provision is recognised when the company has an obligation (legal or constructive) as a result of a past event, it is likely (more likely than not) that payment will be made as a result of the liability and the amount can be measured reliably. If the effect is significant, the provision is measured at the discounted value of future cash outflows using a pre-tax discount rate reflecting the market\u2019s pricing of the time value of money and, if relevant, the risks specifically related to the liability.A provision for a guarantee is recognised when the under lying products or services are sold. The provision is based on historical information about guarantees and a weighting of potential outcomes against their likelihood of occuring.Provisions for onerous contracts are recognised when the company\u2019s expected revenues from a contract is lower than the unavoidable costs of meeting the obligations under the contract.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__79": {
"value": "Contingent liabilities and contingent assetsContingent liabilities for which it is not likely that the liability will incur are not recognized in the financial statements. Signi ficant contingent liabilities are disclosed, except for contingent liabilities related to which it is remote that payment will have to be made.Contingent assets are not recognised in the financial statements unless they are virtually certain. Othercontingent assets are disclosed if it is likely that an economic benefit will be received by the Group.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__81": {
"value": "Going concern In accordance with the accounting act \u00a7 3-3a we confirm that the condition for continued operations is present and that the annual report have been prepared based on the going concern assumption.The company has a credit facility of 67 million, whereas 19.3 million is available as of the end of the year. Additionally, the board has been authorized by the general meeting held on 10 May 2024 to issue up to 79,016,200 new shares. These authorizations are intended to be utilized in case the parent company requires additional equity and liquidity. As of 31 December 2024, the Company is not in breach with any covenants or loan conditions. Refer to note 16 for more details on the group\u2019s and the parent company\u2019s interest-bearing debt conditions, as well as note 18 for information on liquidity risk and maturity structure of the group\u2019s liabilities. The operations of the Group are subject to uncertainty with respect to its ability to sell products at favourable margins and maintain adequate cash reserves. If additional resources are needed to ensure continuity of operations and support planned activities aimed at generating positive cash flow and profitability, the Board will consider appropriate measures such as obtaining loans or equity. The current outlook indicates a positive trend, and the Board will take necessary steps to sustain this momentum. If the group and the parent company do not achieve planned market measures adequately, new loan facilities or share issues will be established in 2025. Due to the factors described above, there is uncertainty for the Company to continue as a going concern over the next 12 months. Assuming a going concern, the group\u2019s and the parent company\u2019s assets and values are currently present. However, the value of some of the group\u2019s and the parent company\u2019s assets may be lower than their carrying amounts in a potential forced sale related to liquidation. This uncertainty is primarily related to the value of intangible assets, fixed assets, financial assets, and investments, as well as the value of inventories.",
"dimensions": {
"concept": "ifrs-full:DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__80": {
"value": "Going concern In accordance with the accounting act \u00a7 3-3a we confirm that the condition for continued operations is present and that the annual report have been prepared based on the going concern assumption.The company has a credit facility of 67 million, whereas 19.3 million is available as of the end of the year. Additionally, the board has been authorized by the general meeting held on 10 May 2024 to issue up to 79,016,200 new shares. These authorizations are intended to be utilized in case the parent company requires additional equity and liquidity. As of 31 December 2024, the Company is not in breach with any covenants or loan conditions. Refer to note 16 for more details on the group\u2019s and the parent company\u2019s interest-bearing debt conditions, as well as note 18 for information on liquidity risk and maturity structure of the group\u2019s liabilities. The operations of the Group are subject to uncertainty with respect to its ability to sell products at favourable margins and maintain adequate cash reserves. If additional resources are needed to ensure continuity of operations and support planned activities aimed at generating positive cash flow and profitability, the Board will consider appropriate measures such as obtaining loans or equity. The current outlook indicates a positive trend, and the Board will take necessary steps to sustain this momentum. If the group and the parent company do not achieve planned market measures adequately, new loan facilities or share issues will be established in 2025. Due to the factors described above, there is uncertainty for the Company to continue as a going concern over the next 12 months. Assuming a going concern, the group\u2019s and the parent company\u2019s assets and values are currently present. However, the value of some of the group\u2019s and the parent company\u2019s assets may be lower than their carrying amounts in a potential forced sale related to liquidation. This uncertainty is primarily related to the value of intangible assets, fixed assets, financial assets, and investments, as well as the value of inventories.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfGoingConcernExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__83": {
"value": "New accounting standardsIn 2024 new standards and amendments to existing standards have become effective. This is related to the following standards:-Lease liability in a sale leaseback(amendments to IFRS 16)-Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants(amendments to IAS 1)-Supplier Finance Arrangements(Amendments to IAS 7 and IFRS 7)The amendments had no impact on the Group`s consolidated financial statements.The following revised IFRS`s have been issued, but are not yet effective, and in some cases have not been adopted by EU.-Lack of Exchangeability(amendment to IAS 21, The effects of Changes in Foreign Exchange Rates)-Amendments to the Classification and Measurement of Financial Instruments(amendments to IFRS 9, Financial Instruments and IFRS 7, Financial Instruments, Disclosures)-IFRS 18 Presentation and Disclosure in Financial StatementsThe Group is assesing the impact of IFRS 18 - Presentation and Disclosures in Financial Statements, which introduces new presentation and disclosure requriements. The assesment is ongoing, and any necessary adjustments will be made in line with the standard`s effective date and regulatory requriements.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__82": {
"value": "New accounting standardsIn 2024 new standards and amendments to existing standards have become effective. This is related to the following standards:-Lease liability in a sale leaseback(amendments to IFRS 16)-Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants(amendments to IAS 1)-Supplier Finance Arrangements(Amendments to IAS 7 and IFRS 7)The amendments had no impact on the Group`s consolidated financial statements.The following revised IFRS`s have been issued, but are not yet effective, and in some cases have not been adopted by EU.-Lack of Exchangeability(amendment to IAS 21, The effects of Changes in Foreign Exchange Rates)-Amendments to the Classification and Measurement of Financial Instruments(amendments to IFRS 9, Financial Instruments and IFRS 7, Financial Instruments, Disclosures)-IFRS 18 Presentation and Disclosure in Financial StatementsThe Group is assesing the impact of IFRS 18 - Presentation and Disclosures in Financial Statements, which introduces new presentation and disclosure requriements. The assesment is ongoing, and any necessary adjustments will be made in line with the standard`s effective date and regulatory requriements.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__88": {
"value": "Note 3 Segment informationThe processing plants of the parent company are situated in Norway, where the production is according to the standard for human consumption. The Group operates solely in the production of marine ingredients, namely salmon oil (OmeGo\u00ae), hydrolyzed soluble protein (ProGo\u00ae), Calcium/Collagen (CalGo\u00ae or NT-II\u2122), and non- soluble protein (PetGo\u2122), all of which are produced in the Midsund plant.For the production of these products, the raw material is sourced fresh, and stored cold before hydrolysis and separation into product fractions. The unique production process involves the release of oil from the raw material using enzymes, resulting in fresh salmon oil with a long shelf life. OmeGo\u00ae is stored in nitrogen-filled tanks to preserve its quality after the manufacturing process. ProGo\u00ae is a fully hydrolyzed protein and has good solubility in water. The protein production process has been optimized for increased capacity and quality throughout the last years and incremental improvements are made on a continuous basis.CalGo\u00ae or NT-II\u2122 are processed by separating the bones from the raw material, drying and milling the fraction into a powder, stored in small bags or big bags.PetGo\u2122 holds non-soluble proteins, excess oil and small bones fractions, which is separated and dried into a high-quality protein powder, typically for the pet food industry. Although all four products are produced in the same process and from the same raw material supply, the revenue is split by product. The Production Manager manages production by tracking the raw material input and finished goods output of the different products to monitor yields and margins per product.Revenue per product Group ParentRevenue per product 2024 2023 2024 2023By product\u00aeSalmon Oil (OmeGo) 157 976 129 469 157 850 129 730\u00aeSolubleProtein Hydrolysate (ProGo) 59 724 23 901 59 724 23 901\u00aeCalcium (CalGo) 5 431 2 603 5 431 2 603Non-soluble Protein (PetGo\u2122) 33 694 33 254 33 694 33 254Other income 592 2 387 2 209 2 033Sum revenue 257 418 191 614 258 904 191 521Gain on sale of asset 8 122 23 637 8 122 23 637Insurance claim settlement 0 3 260 0 3 260Total revenues 265 539 218 511 267 026 218 418By regionNorway 12 865 9 096 12 069 8 742United Kingdom 16 594 19 890 18 878 20 151France 11 473 40 342 11 473 40 342Belgium 52 445 26 493 52 445 26 493Italia 34 795 3 733 34 795 3 733Germany 15 270 7 743 15 270 7 743Europe excl.NO,UK,FR,BE,IT,GE 13 815 25 048 13 815 25 048Japan 18 485 18 331 18 485 18 331Asia excl.JP 3 797 5 775 3 797 5 775USA 77 878 46 639 77 878 46 639Total revenues 257 418 191 614 258 904 191 521In 2024 goods totaling TNOK 150,068 were sold to three customers, each of which accounted for more than 10 % of total turnover. The sales to each of these customers are TNOK 65,876, TNOK 51,763, and TNOK 32,429, respectively. In 2023, goods totaling TNOK 106,768 were sold to three customers, each of which accounted for more than 10 % of total turnover. The sales to each of these customers are TNOK 40,342, TNOK 39,933, and TNOK 26,493. The company has no contractual assets or liabilities as of 31 December 2024.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__87": {
"value": "Note 3 Segment informationThe processing plants of the parent company are situated in Norway, where the production is according to the standard for human consumption. The Group operates solely in the production of marine ingredients, namely salmon oil (OmeGo\u00ae), hydrolyzed soluble protein (ProGo\u00ae), Calcium/Collagen (CalGo\u00ae or NT-II\u2122), and non- soluble protein (PetGo\u2122), all of which are produced in the Midsund plant.For the production of these products, the raw material is sourced fresh, and stored cold before hydrolysis and separation into product fractions. The unique production process involves the release of oil from the raw material using enzymes, resulting in fresh salmon oil with a long shelf life. OmeGo\u00ae is stored in nitrogen-filled tanks to preserve its quality after the manufacturing process. ProGo\u00ae is a fully hydrolyzed protein and has good solubility in water. The protein production process has been optimized for increased capacity and quality throughout the last years and incremental improvements are made on a continuous basis.CalGo\u00ae or NT-II\u2122 are processed by separating the bones from the raw material, drying and milling the fraction into a powder, stored in small bags or big bags.PetGo\u2122 holds non-soluble proteins, excess oil and small bones fractions, which is separated and dried into a high-quality protein powder, typically for the pet food industry. Although all four products are produced in the same process and from the same raw material supply, the revenue is split by product. The Production Manager manages production by tracking the raw material input and finished goods output of the different products to monitor yields and margins per product.Revenue per product Group ParentRevenue per product 2024 2023 2024 2023By product\u00aeSalmon Oil (OmeGo) 157 976 129 469 157 850 129 730\u00aeSolubleProtein Hydrolysate (ProGo) 59 724 23 901 59 724 23 901\u00aeCalcium (CalGo) 5 431 2 603 5 431 2 603Non-soluble Protein (PetGo\u2122) 33 694 33 254 33 694 33 254Other income 592 2 387 2 209 2 033Sum revenue 257 418 191 614 258 904 191 521Gain on sale of asset 8 122 23 637 8 122 23 637Insurance claim settlement 0 3 260 0 3 260Total revenues 265 539 218 511 267 026 218 418By regionNorway 12 865 9 096 12 069 8 742United Kingdom 16 594 19 890 18 878 20 151France 11 473 40 342 11 473 40 342Belgium 52 445 26 493 52 445 26 493Italia 34 795 3 733 34 795 3 733Germany 15 270 7 743 15 270 7 743Europe excl.NO,UK,FR,BE,IT,GE 13 815 25 048 13 815 25 048Japan 18 485 18 331 18 485 18 331Asia excl.JP 3 797 5 775 3 797 5 775USA 77 878 46 639 77 878 46 639Total revenues 257 418 191 614 258 904 191 521In 2024 goods totaling TNOK 150,068 were sold to three customers, each of which accounted for more than 10 % of total turnover. The sales to each of these customers are TNOK 65,876, TNOK 51,763, and TNOK 32,429, respectively. In 2023, goods totaling TNOK 106,768 were sold to three customers, each of which accounted for more than 10 % of total turnover. The sales to each of these customers are TNOK 40,342, TNOK 39,933, and TNOK 26,493. The company has no contractual assets or liabilities as of 31 December 2024.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__86": {
"value": "Note 3 Segment informationThe processing plants of the parent company are situated in Norway, where the production is according to the standard for human consumption. The Group operates solely in the production of marine ingredients, namely salmon oil (OmeGo\u00ae), hydrolyzed soluble protein (ProGo\u00ae), Calcium/Collagen (CalGo\u00ae or NT-II\u2122), and non- soluble protein (PetGo\u2122), all of which are produced in the Midsund plant.For the production of these products, the raw material is sourced fresh, and stored cold before hydrolysis and separation into product fractions. The unique production process involves the release of oil from the raw material using enzymes, resulting in fresh salmon oil with a long shelf life. OmeGo\u00ae is stored in nitrogen-filled tanks to preserve its quality after the manufacturing process. ProGo\u00ae is a fully hydrolyzed protein and has good solubility in water. The protein production process has been optimized for increased capacity and quality throughout the last years and incremental improvements are made on a continuous basis.CalGo\u00ae or NT-II\u2122 are processed by separating the bones from the raw material, drying and milling the fraction into a powder, stored in small bags or big bags.PetGo\u2122 holds non-soluble proteins, excess oil and small bones fractions, which is separated and dried into a high-quality protein powder, typically for the pet food industry. Although all four products are produced in the same process and from the same raw material supply, the revenue is split by product. The Production Manager manages production by tracking the raw material input and finished goods output of the different products to monitor yields and margins per product.Revenue per product Group ParentRevenue per product 2024 2023 2024 2023By product\u00aeSalmon Oil (OmeGo) 157 976 129 469 157 850 129 730\u00aeSolubleProtein Hydrolysate (ProGo) 59 724 23 901 59 724 23 901\u00aeCalcium (CalGo) 5 431 2 603 5 431 2 603Non-soluble Protein (PetGo\u2122) 33 694 33 254 33 694 33 254Other income 592 2 387 2 209 2 033Sum revenue 257 418 191 614 258 904 191 521Gain on sale of asset 8 122 23 637 8 122 23 637Insurance claim settlement 0 3 260 0 3 260Total revenues 265 539 218 511 267 026 218 418By regionNorway 12 865 9 096 12 069 8 742United Kingdom 16 594 19 890 18 878 20 151France 11 473 40 342 11 473 40 342Belgium 52 445 26 493 52 445 26 493Italia 34 795 3 733 34 795 3 733Germany 15 270 7 743 15 270 7 743Europe excl.NO,UK,FR,BE,IT,GE 13 815 25 048 13 815 25 048Japan 18 485 18 331 18 485 18 331Asia excl.JP 3 797 5 775 3 797 5 775USA 77 878 46 639 77 878 46 639Total revenues 257 418 191 614 258 904 191 521In 2024 goods totaling TNOK 150,068 were sold to three customers, each of which accounted for more than 10 % of total turnover. The sales to each of these customers are TNOK 65,876, TNOK 51,763, and TNOK 32,429, respectively. In 2023, goods totaling TNOK 106,768 were sold to three customers, each of which accounted for more than 10 % of total turnover. The sales to each of these customers are TNOK 40,342, TNOK 39,933, and TNOK 26,493. The company has no contractual assets or liabilities as of 31 December 2024.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfRevenueExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__95": {
"value": "Note 5 Employment costs and expenses for employees and benefits for senior employeesSalariesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Salaries 59 463 47 773 50 150 42 235Social security costs 6 772 6 096 6 348 5 685Pension costs 3 072 3 924 2 666 3 513Other employee benefits 2 401 2 157 2 179 1 901Public grants -1 039 -1 674 -1 039 -1 674Total employee benefit expenses 70 670 58 275 60 304 51 659Average number of FTE\u2019s 67 65 60Remuneration to executive management team 57 GroupManagement team(Amounts in NOK 1 000) 2024 2023Salaries 10 692 9 172Bonus 0 1 229Pension costs 235 230Benefits in kind 73 81Other employee benefits 5 126* 5 924*Total remuneration 16 126 16 635* Includes remuneration of TNOK 5 126 for managing R&D (TNOK 5 924 in 2023). Remuneration for R&D is split in other operating expenses and capitalized development costs in 2024 and 2023 No loans or guarantees are granted to members of the management team, Board of Directors or other elected bodies. Reference is made to the Executive Remuneration Report which will be available on the company\u2019s website before the annual general meeting.Defined contribution pension schemeThe parent company and the group have a statutory obligation to comply with the law on mandatory occupational pensions and have a pension scheme that satisfies the requirements of this Act. Contributions have been expensed in the Group by TNOK 2,986 in 2024 (TNOK 3,420), in the parent company TNOK 2,616 (TNOK 3,009). The group had cost for AFP of TNOK 86 in 2024 (TNOK 504), and TNOK 50 in 2024 (TNOK 504) in the parent company OptionsThe fair value of Jon Olav \u00d8deg\u00e5rd\u2019s options have been calculated at the time of grant, 30 August 2022, and expensed over the vesting period up until 1 November 2022. The fair value of the program has been estimated to TNOK 1,170 in 2022. Fair value of the options has been estimated using the Black-Scholes option pricing model. The options exerciable up until 31 October 2025. Other inputs used in the model are: \u203a Spot price: NOK 3.39 per option \u203a Strike price: NOK 3.63 per option \u203a Volatility: 48.0% \u203a Dividend: 0.0% \u203a Risk-free rate: 3.58%As partial payment for work performed for the company, Tenet Brandlogic Corp. was granted options in the company. The options are expensed over the vesting period in 2021(TNOK 1,462). Total expensed in 2024 is TNOK 0 (TNOK 0 in 2023). No share options were exercied in the agreement, and all 172 000 options has expired per 31.12.2024.Options(Amounts in NOK 1 000) Group 2024 number 2024 WAEP 2023 number 2023 WAEPOutstandig 01.01. 1 172 3.10 1 172 3.10Exerciable 01.01 1 172 3.10 1 172 3.10Granted during the year 0 0 0 0Forfeited during the year 0 0 0 0Exercised during the year 0 0 0 0Expired during the year 172 0.01 0 0Outstandig 31.12. 1 000 3.63 1 172 3.10Exerciable 31.12. 1 000 3.63 1 172 3.10Auditors\u2019s FeeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Audit fees 1 730 1 804 1 575 1 632Other confirmations 67 0 67 0Tax advice 0 0 0 0Other services 44 0 0 0Total 1 840 1 804 1 642 1 632VAT is not included in the amounts above.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__93": {
"value": "Note 5 Employment costs and expenses for employees and benefits for senior employeesSalariesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Salaries 59 463 47 773 50 150 42 235Social security costs 6 772 6 096 6 348 5 685Pension costs 3 072 3 924 2 666 3 513Other employee benefits 2 401 2 157 2 179 1 901Public grants -1 039 -1 674 -1 039 -1 674Total employee benefit expenses 70 670 58 275 60 304 51 659Average number of FTE\u2019s 67 65 60Remuneration to executive management team 57 GroupManagement team(Amounts in NOK 1 000) 2024 2023Salaries 10 692 9 172Bonus 0 1 229Pension costs 235 230Benefits in kind 73 81Other employee benefits 5 126* 5 924*Total remuneration 16 126 16 635* Includes remuneration of TNOK 5 126 for managing R&D (TNOK 5 924 in 2023). Remuneration for R&D is split in other operating expenses and capitalized development costs in 2024 and 2023 No loans or guarantees are granted to members of the management team, Board of Directors or other elected bodies. Reference is made to the Executive Remuneration Report which will be available on the company\u2019s website before the annual general meeting.Defined contribution pension schemeThe parent company and the group have a statutory obligation to comply with the law on mandatory occupational pensions and have a pension scheme that satisfies the requirements of this Act. Contributions have been expensed in the Group by TNOK 2,986 in 2024 (TNOK 3,420), in the parent company TNOK 2,616 (TNOK 3,009). The group had cost for AFP of TNOK 86 in 2024 (TNOK 504), and TNOK 50 in 2024 (TNOK 504) in the parent company",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__94": {
"value": "SalariesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Salaries 59 463 47 773 50 150 42 235Social security costs 6 772 6 096 6 348 5 685Pension costs 3 072 3 924 2 666 3 513Other employee benefits 2 401 2 157 2 179 1 901Public grants -1 039 -1 674 -1 039 -1 674Total employee benefit expenses 70 670 58 275 60 304 51 659Average number of FTE\u2019s 67 65 60Remuneration to executive management team 57 GroupManagement team(Amounts in NOK 1 000) 2024 2023Salaries 10 692 9 172Bonus 0 1 229Pension costs 235 230Benefits in kind 73 81Other employee benefits 5 126* 5 924*Total remuneration 16 126 16 635",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__92": {
"value": "Note 4 Cost of sales and other operating expense Cost of salesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Raw material 80 301 58 356 80 769 59 011Freight 36 360 33 066 35 710 32 590Purchased services 25 771 24 044 24 936 22 374Obsolescence cost 3 479 20 501 3 479 20 501Change in inventory 23 643 14 721 23 643 14 721Total cost of sales 169 553 150 686 168 537 149 196Other operating expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Leases of equipment 3 359 2 342 3 148 2 179Leases of warehouses and factories 2 014 2 151 2 010 2 164Travelling cost 2 606 3 310 2 473 3 226Internal consultant fees 18 851 9 481 22 724 9 481Consultant fees and tax advisory 1 840 2 341 1 642 2 094Lawyers 1 370 2 651 1 370 2 651Consulting 5 586 7 520 6 438 7 315Advertising 15 326 13 486 14 119 12 306R&D and patents 9 323 11 012 9 312 10 998Repair and maintenance 20 258 14 311 19 805 12 749Other operating expenses 10 274 7 889 7 738 7 488Public grants -189 -830 -189 -830Total 90 617 75 665 90 589 71 821The Group recieved public grants of TNOK 1,227 (TNOK 2,255 in 2023), split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. Corresponding numbers was TNOK 1,227 (TNOK 2,255 in 2023) for parent company, split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. See note 5.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfGovernmentGrantsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__91": {
"value": "Note 4 Cost of sales and other operating expense Cost of salesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Raw material 80 301 58 356 80 769 59 011Freight 36 360 33 066 35 710 32 590Purchased services 25 771 24 044 24 936 22 374Obsolescence cost 3 479 20 501 3 479 20 501Change in inventory 23 643 14 721 23 643 14 721Total cost of sales 169 553 150 686 168 537 149 196Other operating expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Leases of equipment 3 359 2 342 3 148 2 179Leases of warehouses and factories 2 014 2 151 2 010 2 164Travelling cost 2 606 3 310 2 473 3 226Internal consultant fees 18 851 9 481 22 724 9 481Consultant fees and tax advisory 1 840 2 341 1 642 2 094Lawyers 1 370 2 651 1 370 2 651Consulting 5 586 7 520 6 438 7 315Advertising 15 326 13 486 14 119 12 306R&D and patents 9 323 11 012 9 312 10 998Repair and maintenance 20 258 14 311 19 805 12 749Other operating expenses 10 274 7 889 7 738 7 488Public grants -189 -830 -189 -830Total 90 617 75 665 90 589 71 821The Group recieved public grants of TNOK 1,227 (TNOK 2,255 in 2023), split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. Corresponding numbers was TNOK 1,227 (TNOK 2,255 in 2023) for parent company, split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. See note 5.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__90": {
"value": "Note 4 Cost of sales and other operating expense Cost of salesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Raw material 80 301 58 356 80 769 59 011Freight 36 360 33 066 35 710 32 590Purchased services 25 771 24 044 24 936 22 374Obsolescence cost 3 479 20 501 3 479 20 501Change in inventory 23 643 14 721 23 643 14 721Total cost of sales 169 553 150 686 168 537 149 196Other operating expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Leases of equipment 3 359 2 342 3 148 2 179Leases of warehouses and factories 2 014 2 151 2 010 2 164Travelling cost 2 606 3 310 2 473 3 226Internal consultant fees 18 851 9 481 22 724 9 481Consultant fees and tax advisory 1 840 2 341 1 642 2 094Lawyers 1 370 2 651 1 370 2 651Consulting 5 586 7 520 6 438 7 315Advertising 15 326 13 486 14 119 12 306R&D and patents 9 323 11 012 9 312 10 998Repair and maintenance 20 258 14 311 19 805 12 749Other operating expenses 10 274 7 889 7 738 7 488Public grants -189 -830 -189 -830Total 90 617 75 665 90 589 71 821The Group recieved public grants of TNOK 1,227 (TNOK 2,255 in 2023), split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. Corresponding numbers was TNOK 1,227 (TNOK 2,255 in 2023) for parent company, split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. See note 5.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__89": {
"value": "Note 4 Cost of sales and other operating expense Cost of salesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Raw material 80 301 58 356 80 769 59 011Freight 36 360 33 066 35 710 32 590Purchased services 25 771 24 044 24 936 22 374Obsolescence cost 3 479 20 501 3 479 20 501Change in inventory 23 643 14 721 23 643 14 721Total cost of sales 169 553 150 686 168 537 149 196Other operating expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Leases of equipment 3 359 2 342 3 148 2 179Leases of warehouses and factories 2 014 2 151 2 010 2 164Travelling cost 2 606 3 310 2 473 3 226Internal consultant fees 18 851 9 481 22 724 9 481Consultant fees and tax advisory 1 840 2 341 1 642 2 094Lawyers 1 370 2 651 1 370 2 651Consulting 5 586 7 520 6 438 7 315Advertising 15 326 13 486 14 119 12 306R&D and patents 9 323 11 012 9 312 10 998Repair and maintenance 20 258 14 311 19 805 12 749Other operating expenses 10 274 7 889 7 738 7 488Public grants -189 -830 -189 -830Total 90 617 75 665 90 589 71 821The Group recieved public grants of TNOK 1,227 (TNOK 2,255 in 2023), split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. Corresponding numbers was TNOK 1,227 (TNOK 2,255 in 2023) for parent company, split by TNOK 189 in other operating expenses and TNOK 1,039 in salaries. See note 5.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCostOfSalesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__96": {
"value": "OptionsThe fair value of Jon Olav \u00d8deg\u00e5rd\u2019s options have been calculated at the time of grant, 30 August 2022, and expensed over the vesting period up until 1 November 2022. The fair value of the program has been estimated to TNOK 1,170 in 2022. Fair value of the options has been estimated using the Black-Scholes option pricing model. The options exerciable up until 31 October 2025. Other inputs used in the model are: \u203a Spot price: NOK 3.39 per option \u203a Strike price: NOK 3.63 per option \u203a Volatility: 48.0% \u203a Dividend: 0.0% \u203a Risk-free rate: 3.58%As partial payment for work performed for the company, Tenet Brandlogic Corp. was granted options in the company. The options are expensed over the vesting period in 2021(TNOK 1,462). Total expensed in 2024 is TNOK 0 (TNOK 0 in 2023). No share options were exercied in the agreement, and all 172 000 options has expired per 31.12.2024.Options(Amounts in NOK 1 000) Group 2024 number 2024 WAEP 2023 number 2023 WAEPOutstandig 01.01. 1 172 3.10 1 172 3.10Exerciable 01.01 1 172 3.10 1 172 3.10Granted during the year 0 0 0 0Forfeited during the year 0 0 0 0Exercised during the year 0 0 0 0Expired during the year 172 0.01 0 0Outstandig 31.12. 1 000 3.63 1 172 3.10Exerciable 31.12. 1 000 3.63 1 172 3.10Auditors\u2019s FeeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Audit fees 1 730 1 804 1 575 1 632Other confirmations 67 0 67 0Tax advice 0 0 0 0Other services 44 0 0 0Total 1 840 1 804 1 642 1 632VAT is not included in the amounts above.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__97": {
"value": "Auditors\u2019s FeeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Audit fees 1 730 1 804 1 575 1 632Other confirmations 67 0 67 0Tax advice 0 0 0 0Other services 44 0 0 0Total 1 840 1 804 1 642 1 632VAT is not included in the amounts above.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__99": {
"value": "Note 6 Related party transactionsThe Group\u2019s related parties include shareholders, board members and the senior management and their related parties. RH Industri AS, Hofseth Property AS, Hofseth International AS, Hofseth Logistics AS, Hofseth AS, Hofseth Sales AS, Hofseth North America, Hofseth Processing AS, \u00c5lesund Kipervikgate 13 AS and Finnvik Eiendom AS are considered to be related parties to Hofseth BioCare ASA. In these companies, board member and shareholder in Hofseth Biocare ASA, Roger Hofseth, has significant influence through ownership interests, leading positions and board memberships. Further is shareholder Yokorei CO. Ltd.considered a related party.All related party transactions have been made in the ordinary course of the business at the arms length principle.The main transactions made in 2023 and 2024: \u203a Purchase of raw materials from Hofseth Sales AS. See further details in the agreement below. \u203a 12 of the company\u2019s (16 in the group) lease agreement for production equipment that are active in 2024 have been entered into with Hofseth AS, Hofseth International AS, Finnvik Eiendom AS and RH Industri AS and subleased to Hofseth BioCare ASA with a mark-up up to 10 % on monthly instalments. \u203a Other minor administration costs are invoiced from Hofseth International AS. \u203a Hofseth North America has purchased goods worth TNOK 1,080 in 2024 (TNOK 39,933 in 2023). \u203a Yokorei Co. Ltd. has purchased goods worth TNOK 126 in 2024 (TNOK 47 in 2023). \u203a The Group rents factory buildings at Midsund and Berk\u00e5k from Hofseth Property AS at a cost of TNOK 12,558 in 2024 (TNOK 12,070 in 2023). The agreement is signed for 15 years, until 2032. \u203a In 2024 a new patent was transferred to HBCI as a contribution in kind, with a gain of TNOK 8 122. See note 22 for further information. The statement of profit and loss and the balance sheet include the following transactions with shareholders and related parties to shareholders: Balance sheet itemsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Right of use assets 91 959 106 574 75 592 88 829Trade receivables 86 3 458 86 3 458Loan from shareholders 0 -144 000 0 -144 000Other receivables 0 0 0 27 787Leasing liabilities -90 112 -99 050 -73 592 -80 734Trade payables -72 510 -41 828 -69 956 -37 485Total -70 576 -174 846 -67 869 -142 145Profit and loss itemsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Sales revenue 1 403 41 391 1 403 41 391Interest income 0 0 2 847 1 341Total income 1 403 41 391 4 250 42 732Cost of sales 58 816 55 651 58 816 55 651Other operating expenses 3 692 8 675 3 692 5 817Financial expenses 7 846 8 507 6 116 6 618Total costs 70 354 72 833 68 624 68 086Raw Material agreementThe company has a 5-year agreement with Hofseth Sales AS on exclusive rights to all by-products from Hofseth Sales`s suppliers starting 01.01.2022. Hofseth Sales AS is a 100 % subsidiary of RH Investments AS, which is closely related to Roger Hofseth.The statement of profit and loss and the balance sheet include the following transactions between parent companies, subsidiaries and associated companies:Balance sheet items Parent Profit and loss items Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Loan from parent to Sold services and goodsHBC Berk\u00e5k AS 45 947 24 283 1 464 0HBC Therapeutics AS 25 0 0 0Hofseth Biocare R\u00f8rvik AS 0 0 0 0Hofseth Biocare UK Limited 2 970 2 733 2 481 2 647Hofseth Biocare Americas Inc. 0 0 65 878 0HBC Immunology Inc(Joint 771 771 0 0venture)Trade receivables from parent Bought servicesHBC Berk\u00e5k AS 0 0 575 220Hofseth Biocare UK Limited 1 074 0 368 607Hofseth Biocare Americas Inc. 6 033 0 13 628 0HBC Immunology Inc(Joint 0 0 474 0venture)HBC Switzerland GmbH 0 -156 40 378Total 56 819 27 631 84 907 3 852Transfered patent from Hofseth Biocare ASA to HBC Immunology Inc. with a gain of TNOK 8 122 in 2024.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfSubordinatedLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__98": {
"value": "Note 6 Related party transactionsThe Group\u2019s related parties include shareholders, board members and the senior management and their related parties. RH Industri AS, Hofseth Property AS, Hofseth International AS, Hofseth Logistics AS, Hofseth AS, Hofseth Sales AS, Hofseth North America, Hofseth Processing AS, \u00c5lesund Kipervikgate 13 AS and Finnvik Eiendom AS are considered to be related parties to Hofseth BioCare ASA. In these companies, board member and shareholder in Hofseth Biocare ASA, Roger Hofseth, has significant influence through ownership interests, leading positions and board memberships. Further is shareholder Yokorei CO. Ltd.considered a related party.All related party transactions have been made in the ordinary course of the business at the arms length principle.The main transactions made in 2023 and 2024: \u203a Purchase of raw materials from Hofseth Sales AS. See further details in the agreement below. \u203a 12 of the company\u2019s (16 in the group) lease agreement for production equipment that are active in 2024 have been entered into with Hofseth AS, Hofseth International AS, Finnvik Eiendom AS and RH Industri AS and subleased to Hofseth BioCare ASA with a mark-up up to 10 % on monthly instalments. \u203a Other minor administration costs are invoiced from Hofseth International AS. \u203a Hofseth North America has purchased goods worth TNOK 1,080 in 2024 (TNOK 39,933 in 2023). \u203a Yokorei Co. Ltd. has purchased goods worth TNOK 126 in 2024 (TNOK 47 in 2023). \u203a The Group rents factory buildings at Midsund and Berk\u00e5k from Hofseth Property AS at a cost of TNOK 12,558 in 2024 (TNOK 12,070 in 2023). The agreement is signed for 15 years, until 2032. \u203a In 2024 a new patent was transferred to HBCI as a contribution in kind, with a gain of TNOK 8 122. See note 22 for further information. The statement of profit and loss and the balance sheet include the following transactions with shareholders and related parties to shareholders: Balance sheet itemsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Right of use assets 91 959 106 574 75 592 88 829Trade receivables 86 3 458 86 3 458Loan from shareholders 0 -144 000 0 -144 000Other receivables 0 0 0 27 787Leasing liabilities -90 112 -99 050 -73 592 -80 734Trade payables -72 510 -41 828 -69 956 -37 485Total -70 576 -174 846 -67 869 -142 145Profit and loss itemsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Sales revenue 1 403 41 391 1 403 41 391Interest income 0 0 2 847 1 341Total income 1 403 41 391 4 250 42 732Cost of sales 58 816 55 651 58 816 55 651Other operating expenses 3 692 8 675 3 692 5 817Financial expenses 7 846 8 507 6 116 6 618Total costs 70 354 72 833 68 624 68 086Raw Material agreementThe company has a 5-year agreement with Hofseth Sales AS on exclusive rights to all by-products from Hofseth Sales`s suppliers starting 01.01.2022. Hofseth Sales AS is a 100 % subsidiary of RH Investments AS, which is closely related to Roger Hofseth.The statement of profit and loss and the balance sheet include the following transactions between parent companies, subsidiaries and associated companies:Balance sheet items Parent Profit and loss items Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Loan from parent to Sold services and goodsHBC Berk\u00e5k AS 45 947 24 283 1 464 0HBC Therapeutics AS 25 0 0 0Hofseth Biocare R\u00f8rvik AS 0 0 0 0Hofseth Biocare UK Limited 2 970 2 733 2 481 2 647Hofseth Biocare Americas Inc. 0 0 65 878 0HBC Immunology Inc(Joint 771 771 0 0venture)Trade receivables from parent Bought servicesHBC Berk\u00e5k AS 0 0 575 220Hofseth Biocare UK Limited 1 074 0 368 607Hofseth Biocare Americas Inc. 6 033 0 13 628 0HBC Immunology Inc(Joint 0 0 474 0venture)HBC Switzerland GmbH 0 -156 40 378Total 56 819 27 631 84 907 3 852Transfered patent from Hofseth Biocare ASA to HBC Immunology Inc. with a gain of TNOK 8 122 in 2024.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__105": {
"value": "Note 7 Financial income and expensesFinancial incomeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest income 790 550 3 612 1 890Foreign exchange gains 8 225 6 047 8 225 6 043Total 9 015 6 597 11 837 7 933Financial expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest expenses 15 685 7 543 13 803 5 506Impairment of shares in associated company 0 0 1 444 3 074Impairment of financial assets 0 0 0 162Foreign exchange losses 6 064 5 750 6 061 5 742Total 21 749 13 293 21 308 14 484",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinanceCostExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__104": {
"value": "Note 7 Financial income and expensesFinancial incomeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest income 790 550 3 612 1 890Foreign exchange gains 8 225 6 047 8 225 6 043Total 9 015 6 597 11 837 7 933Financial expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest expenses 15 685 7 543 13 803 5 506Impairment of shares in associated company 0 0 1 444 3 074Impairment of financial assets 0 0 0 162Foreign exchange losses 6 064 5 750 6 061 5 742Total 21 749 13 293 21 308 14 484",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinanceIncomeExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__103": {
"value": "Note 7 Financial income and expensesFinancial incomeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest income 790 550 3 612 1 890Foreign exchange gains 8 225 6 047 8 225 6 043Total 9 015 6 597 11 837 7 933Financial expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest expenses 15 685 7 543 13 803 5 506Impairment of shares in associated company 0 0 1 444 3 074Impairment of financial assets 0 0 0 162Foreign exchange losses 6 064 5 750 6 061 5 742Total 21 749 13 293 21 308 14 484",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__102": {
"value": "Note 7 Financial income and expensesFinancial incomeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest income 790 550 3 612 1 890Foreign exchange gains 8 225 6 047 8 225 6 043Total 9 015 6 597 11 837 7 933Financial expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest expenses 15 685 7 543 13 803 5 506Impairment of shares in associated company 0 0 1 444 3 074Impairment of financial assets 0 0 0 162Foreign exchange losses 6 064 5 750 6 061 5 742Total 21 749 13 293 21 308 14 484",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInterestExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__101": {
"value": "Note 7 Financial income and expensesFinancial incomeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest income 790 550 3 612 1 890Foreign exchange gains 8 225 6 047 8 225 6 043Total 9 015 6 597 11 837 7 933Financial expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest expenses 15 685 7 543 13 803 5 506Impairment of shares in associated company 0 0 1 444 3 074Impairment of financial assets 0 0 0 162Foreign exchange losses 6 064 5 750 6 061 5 742Total 21 749 13 293 21 308 14 484",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInterestIncomeExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__100": {
"value": "Note 7 Financial income and expensesFinancial incomeGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest income 790 550 3 612 1 890Foreign exchange gains 8 225 6 047 8 225 6 043Total 9 015 6 597 11 837 7 933Financial expensesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Interest expenses 15 685 7 543 13 803 5 506Impairment of shares in associated company 0 0 1 444 3 074Impairment of financial assets 0 0 0 162Foreign exchange losses 6 064 5 750 6 061 5 742Total 21 749 13 293 21 308 14 484",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__107": {
"value": "Note 8 Income taxesIncome taxesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Income tax expense Prior year taxes 0 0 0 0Tax expense 0 0 0 0Calculation of taxable incomeLoss before tax -125 300 -106 684 -97 898 -92 996Permanent differences 7 483 1 230 -1 1 230Change in temporary differences 8 551 32 555 6 392 21 840Taxable result -109 266 -72 899 -91 507 -69 626Temporary differencesFixed assets 1 684 6 839 -2 285 711Loss carry forward -1 216 949 -1 107 683 -1 132 401 -1 041 082Other temporarydifferences -43 768 -40 372 -43 768 -40 372Total -1 259 033 -1 141 216 -1 178 454 -1 080 743Calculated deferred tax asset 22% 276 987 251 068 259 260 237 763Deferred tax assets are not recognised in the balance sheet due to lack of convincing evidence for supporting capital-ization. Reconcilitation of tax expenseGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Loss before tax -125 300 -106 684 -97 898 -92 996Tax 22% 1 646 -23 470 -21 538 -20 459Permanent differences 0 271 0 271Defered tax assest, not recognized 25 920 23 200 21 538 20 189Total tax expense 0 0 0 0",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__106": {
"value": "Note 8 Income taxesIncome taxesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Income tax expense Prior year taxes 0 0 0 0Tax expense 0 0 0 0Calculation of taxable incomeLoss before tax -125 300 -106 684 -97 898 -92 996Permanent differences 7 483 1 230 -1 1 230Change in temporary differences 8 551 32 555 6 392 21 840Taxable result -109 266 -72 899 -91 507 -69 626Temporary differencesFixed assets 1 684 6 839 -2 285 711Loss carry forward -1 216 949 -1 107 683 -1 132 401 -1 041 082Other temporarydifferences -43 768 -40 372 -43 768 -40 372Total -1 259 033 -1 141 216 -1 178 454 -1 080 743Calculated deferred tax asset 22% 276 987 251 068 259 260 237 763Deferred tax assets are not recognised in the balance sheet due to lack of convincing evidence for supporting capital-ization. Reconcilitation of tax expenseGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Loss before tax -125 300 -106 684 -97 898 -92 996Tax 22% 1 646 -23 470 -21 538 -20 459Permanent differences 0 271 0 271Defered tax assest, not recognized 25 920 23 200 21 538 20 189Total tax expense 0 0 0 0",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__108": {
"value": "Note 9 Earnings per shareThe Group\u2019s earnings per share are calculated by dividing the profit for the year attributable to share holders by the weighted average number of shares outstanding during the year.Diluted earnings per share are calculated by dividing the pro fit attributable to the share holders by the weighted average number of shares outstanding during the year. Earnings per shareGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Profit attributable to share holders -125 300 -106 684 -97 898 -92 996Weighted average number of shares outstanding 410 906 395 081 410 906 395 081Earnings per share-ordinary -0.30 -0.27 -0.24 -0.24-diluted -0.30 -0.27 -0.24 -0.24",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__112-1": {
"value": "Note 10 Intangible asset2023 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2023 77 579 6 780 4 714 2 627 91 899Additions 0 325 0 0 325Internally developed 5 543 0 0 0 5 543Disposal 4 486 0 0 0 4 486Cost at 31.12.2023 78 636 7 104 4 914 2 627 93 281Depreciation at 01.01.2023 23 451 1 478 3 754 2 627 31 311Depreciation charge of the year 5 333 1 208 145 0 6 686Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2023 28 784 2 686 3 899 2 627 37 997Net book value at 31.12.2023 49 851 4 418 1 015 0 55 284Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation2024 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2024 78 636 7 104 4 914 2 627 93 281Additions 1 629 0 0 0 1 629Internally developed 0 0 0 0 0Disposal 7 371* 0 0 0 7 371Cost at 31.12.2024 72 894 7 104 4 914 2 627 87 539Depreciation at 01.01.2024 28 784 2 686 3 899 2 627 37 997Depreciation charge of the year 5 660 1 327 124 0 7 112Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2024 34 444 4 013 4 024 2 627 45 108Net book value at 31.12.2024 38 449 3 091 890 0 42 430Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation*Project sold to HBCI, see note 23 for more information.Throughout 2024, HBC R&D has continued its relentless pursuit of innovation by refining its products and processes. Extensive research efforts have further validated the positive health effects of our key ingredients, reinforcing the critical role of development in differentiating HBC\u2019s product portfolio. Core activities, including research, development, and documentation, remain key to our R&D strategy. During the year, investments were made to further research, document and test our trademarked products, including ProGo\u00ae, CollaGo\u00ae, OmeGo\u00ae, CalGo\u00ae and NT-II\u2122, to demonstrate their efficacy and unique attributes for both marketing and sales purposes.In 2024, our R&D activities were integral not only to enhancing product quality but also to increasing production efficiency. By leveraging advanced equipment and managing necessary downtime for maintenance and process optimization, we have continued to push the boundaries in converting raw salmon off-cuts into high-value bioactive ingredients, including implementing new management and goals. Our ongoing research into the ingredients has yielded deeper insights into the biological effects, with some of these health benefits gaining recognition from health authorities both in the US and Europe.To meet environmental and health standards, our development initiatives have focused on innovating more efficient production methods and improving the usability of our products for human consumption. The R&D process at HBC is built on five key pillars: further developing the enzymatic hydrolysis process to maximize the unique health benefits of our ingredients; optimizing the handling of raw materials and finished products across the value chain; advancing technology to yield higher quality product fractions of protein, calcium, and oil; identifying, researching, and documenting the bioactivity of our products; and establishing comprehensive evidence of biosafety, bioavailability, and biological effects through both \u201cin-vitro\u201d and \u201cin-vivo\u201d studies.These continued efforts in 2024 not only enhance our product offerings but also ensure that HBC remains at the forefront of marine nutrition innovation. Total research and development costs for 2024 were TNOK 17,452 (2023 TNOK 20,917). Of this, TNOK 1,629 has been capitalized in 2024 (2023: TNOK 5,543).The Group has registered its trademarks under the international Madrid Protocol. The trademarks are OmeGo\u00ae, ProGo\u00ae, CalGo\u00ae, NT-II\u2122, PetGo\u2122 and Brilliant\u2122.Note 11 Fixed assets2023 Group Parent(Amounts in NOK 1 000) Machinery and equipment Fixtures and fittings Total Machinery and equipment Fixtures and fittings TotalCost at 01.01.2023 188 715 15 581 204 296 178 102 13 431 191 534Additions 8 194 0 8 194 8 187 0 8 187Cost at 31.12.2023 196 909 15 581 212 490 186 289 13 431 199 720Depreciations at 01.01.2023 132 608 11 259 143 868 126 081 11 176 137 258Depreciations for the year 11 608 949 12 557 10 101 936 11 038Depreciations at 31.12.2023 144 219 12 209 156 425 136 183 12 113 148 295Book value 31.12.2023 52 693 3 372 56 065 50 107 1 318 51 425Economic life 5-10 years 3-10 years 5-10 years 3-10 years Method of depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation 2024 Group Parent(Amounts in NOK 1 000) Machinery and equipment Fixtures and fittings Total Machinery and equipment Fixtures and fittings TotalCost at 01.01.2024 196 909 15 581 212 490 186 289 13 431 199 720Additions 1 996 448 2 444 1 963 448 2 411Cost at 31.12.2024 198 905 16 029 214 934 188 252 13 879 202 132Depreciations at 01.01.2024 144 216 12 209 156 425 136 183 12 113 148 295Depreciations for the year 12 887 1 363 14 250 11 384 1 373 12 757Depreciations at 31.12.2024 157 103 13 572 170 675 147 567 13 486 161 052Book value 31.12.2024 41 802 2 458 44 260 40 686 394 41 080Economic life 5-10 years 3-10 years 5-10 years 3-10 years Method of depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation The company has pledged assets as collateral for loans. See more in note 16.Note 12 Leases The company and the group as lessee The company and the group\u2019s right of use assets include manufacturing facilities, machinery and equipment and fixtures and fittings:2023 Group ParentManu fac turing Machinery and Land, manu fac turing Machinery and (Amounts in NOK 1 000)facilitiesequipment Fixtures and fittings Totalfacilitiesequipment Fixtures and fittings TotalCost 01.01.2023 100 594 58 413 2 118 161 125 77 054 52 692 1 585 131 331Additions 7 608 10 834 0 18 442 7 608 10 352 0 17 690Disposals 0 0 0 0 0 0 0 0Costs at 31.12.2023 108 202 69 247 2 118 179 567 84 662 63 044 1 585 149 291Depreciations 01.01.2023 25 672 26 510 577 52 759 19 165 24 377 523 44 065Depreciations for the year 9 267 7 858 45 17 170 7 413 7 006 45 14 464Disposals 0 0 0 0 0 0 0 0Depreciations per 31.12.2023 34 939 34 368 622 69 929 26 578 31 383 568 58 529Carrying amounts 31.12.2023 73 263 34 880 1 496 109 639 58 084 31 661 1 017 90 762Shortest of lease term or 15 years 5 years 3-5 years 15 years 5 years 3-5 years economic lifeDepreciation method Straigt line Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciation depreciation depreciation 2024 Group ParentManu fac turing Machinery and Land, manu fac turing Machinery and (Amounts in NOK 1 000)facilitiesequipment Fixtures and fittings Totalfacilitiesequipment Fixtures and fittings TotalCost 01.01.2024 108 202 69 247 2 118 179 567 84 662 63 044 1 585 149 291Additions 0 2 575 0 2 575 0 2 540 0 2 540Disposals 0 0 0 0 0 0 0 0Costs at 31.12.2024 108 202 71 822 2 118 182 142 84 662 65 584 1 585 151 831Depreciations 01.01.2024 34 939 34 368 622 69 929 26 578 31 383 568 58 529Depreciations for the year 9 223 7 700 1 496 18 420 7 932 7 206 1 017 16 155Disposals 0 0 0 0 0 0 0 0Depreciations per 31.12.2024 44 162 42 068 2 118 88 348 34 510 38 589 1 585 74 684Carrying amounts 31.12.2024 64 040 29 754 0 93 793 50 152 26 995 0 77 147Shortest of lease term or 15 years 5 years 3-5 years 15 years 5 years 3-5 years economic lifeDepreciation method Straigt line Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciation depreciation depreciation Lease liabilities:Group Parent(AmountsinNOK1000) 2024 2023 2024 2023Undiscounted lease liabilities and due dates for paymentsLess than 1 year 19 994 20 402 16 618 16 6832-5 years 72 733 67 989 59 776 56 348More than 5 years 33 628 39 857 26 407 23 383Total undiscounted lease liabilities 31.12 126 355 128 248 102 802 96 414Changes in lease liabilitiesTotal lease liabilities 1.1 107 625 102 815 89 197 82 547New/changed lease liabilitie srecognized in the period 2 575 18 442 2 540 17 960Payment of principal amounts -12 440 -13 632 -10 503 -11 310Payment of interest amounts -8 180 -8 775 - 6 433 -7 000Interest related to the lease liabilities 8 180 8 775 6 433 7 000Total lease liabilities 31.12 97 760 107 625 81 234 89 197Current lease liabilities 31.12 (note16) 11 217 10 794 9 412 8 950Non-current lease liabilities 31.12 (note16) 86 543 96 831 71 822 80 248Cash outflows for lease liabilities -20 582 -22 414 -16 968 -18 230Total cash outflows for leases -24 307 -23 480 -20 478 -20 381The lease agreements do not restrict the parent company\u2019s and the group\u2019s dividend policy or financing opportunities. The parent company and the group do not have significant residual value guarantees in the lease agreements.The parent company and the group\u2019s leases of machinery and equipment include, in addition to lease payments, a requirement to maintain and secure the assets (right of use assets). The terms in the lease agreements varies from 3-5 year, and several of the agreements include an option to extend the lease. At the expiry date of the main term of the lease, the lease og the machinery and equipment may be continued for a lease payment of 1/12 of the lease payments in the main lease period. The company may also request to purchase the equipment.The company and the group\u2019s leases of manufacturing facilities (Midsund og Berk\u00e5k) have lease terms of 15 years, no extension options, and the leases expire 31 March 2032. When entering into an agreement the group assesses whether it is reasonably certain to exercise an option to purchase the assets. The leases of the manufacturing facilities have no options to purchase.Leases of fixtures and fittings in the table above contain no extension or purchase options. The group\u2019s potential future lease payments which have not been included in the lease liabilities relating to purchase options were TNOK 0 as of 31 December 2024.Applied practical expedientsThe company and the group lease warehouses in which both the lessor and the company / group have the right to terminate the agreements on a 3-6 months notice period. For such agreements the company and the group do not recognize lease liabilities and related right of use assets. Such lease payments are expensed when incurred.Lease payments for the abovementioned leases amounted to TNOK 1,711 (TNOK 1,066 in 2023) for fixture and fittings for the Group and TNOK 2,014 (TNOK 2,151 in 2023) for storage, and for the parent company TNOK 1,500 (TNOK 903 in 2023) for fixture and fittings TNOK 2,010(TNOK 2,164 i 2023) for storage (see note 4). Cash flow from these lease obligations is approximately equal to the amount expensed and is included in net cash flow from operating activities.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__111": {
"value": "Note 10 Intangible asset2023 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2023 77 579 6 780 4 714 2 627 91 899Additions 0 325 0 0 325Internally developed 5 543 0 0 0 5 543Disposal 4 486 0 0 0 4 486Cost at 31.12.2023 78 636 7 104 4 914 2 627 93 281Depreciation at 01.01.2023 23 451 1 478 3 754 2 627 31 311Depreciation charge of the year 5 333 1 208 145 0 6 686Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2023 28 784 2 686 3 899 2 627 37 997Net book value at 31.12.2023 49 851 4 418 1 015 0 55 284Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation2024 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2024 78 636 7 104 4 914 2 627 93 281Additions 1 629 0 0 0 1 629Internally developed 0 0 0 0 0Disposal 7 371* 0 0 0 7 371Cost at 31.12.2024 72 894 7 104 4 914 2 627 87 539Depreciation at 01.01.2024 28 784 2 686 3 899 2 627 37 997Depreciation charge of the year 5 660 1 327 124 0 7 112Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2024 34 444 4 013 4 024 2 627 45 108Net book value at 31.12.2024 38 449 3 091 890 0 42 430Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation*Project sold to HBCI, see note 23 for more information.Throughout 2024, HBC R&D has continued its relentless pursuit of innovation by refining its products and processes. Extensive research efforts have further validated the positive health effects of our key ingredients, reinforcing the critical role of development in differentiating HBC\u2019s product portfolio. Core activities, including research, development, and documentation, remain key to our R&D strategy. During the year, investments were made to further research, document and test our trademarked products, including ProGo\u00ae, CollaGo\u00ae, OmeGo\u00ae, CalGo\u00ae and NT-II\u2122, to demonstrate their efficacy and unique attributes for both marketing and sales purposes.In 2024, our R&D activities were integral not only to enhancing product quality but also to increasing production efficiency. By leveraging advanced equipment and managing necessary downtime for maintenance and process optimization, we have continued to push the boundaries in converting raw salmon off-cuts into high-value bioactive ingredients, including implementing new management and goals. Our ongoing research into the ingredients has yielded deeper insights into the biological effects, with some of these health benefits gaining recognition from health authorities both in the US and Europe.To meet environmental and health standards, our development initiatives have focused on innovating more efficient production methods and improving the usability of our products for human consumption. The R&D process at HBC is built on five key pillars: further developing the enzymatic hydrolysis process to maximize the unique health benefits of our ingredients; optimizing the handling of raw materials and finished products across the value chain; advancing technology to yield higher quality product fractions of protein, calcium, and oil; identifying, researching, and documenting the bioactivity of our products; and establishing comprehensive evidence of biosafety, bioavailability, and biological effects through both \u201cin-vitro\u201d and \u201cin-vivo\u201d studies.These continued efforts in 2024 not only enhance our product offerings but also ensure that HBC remains at the forefront of marine nutrition innovation. Total research and development costs for 2024 were TNOK 17,452 (2023 TNOK 20,917). Of this, TNOK 1,629 has been capitalized in 2024 (2023: TNOK 5,543).The Group has registered its trademarks under the international Madrid Protocol. The trademarks are OmeGo\u00ae, ProGo\u00ae, CalGo\u00ae, NT-II\u2122, PetGo\u2122 and Brilliant\u2122.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__110": {
"value": "Note 10 Intangible asset2023 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2023 77 579 6 780 4 714 2 627 91 899Additions 0 325 0 0 325Internally developed 5 543 0 0 0 5 543Disposal 4 486 0 0 0 4 486Cost at 31.12.2023 78 636 7 104 4 914 2 627 93 281Depreciation at 01.01.2023 23 451 1 478 3 754 2 627 31 311Depreciation charge of the year 5 333 1 208 145 0 6 686Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2023 28 784 2 686 3 899 2 627 37 997Net book value at 31.12.2023 49 851 4 418 1 015 0 55 284Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation2024 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2024 78 636 7 104 4 914 2 627 93 281Additions 1 629 0 0 0 1 629Internally developed 0 0 0 0 0Disposal 7 371* 0 0 0 7 371Cost at 31.12.2024 72 894 7 104 4 914 2 627 87 539Depreciation at 01.01.2024 28 784 2 686 3 899 2 627 37 997Depreciation charge of the year 5 660 1 327 124 0 7 112Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2024 34 444 4 013 4 024 2 627 45 108Net book value at 31.12.2024 38 449 3 091 890 0 42 430Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation*Project sold to HBCI, see note 23 for more information.Throughout 2024, HBC R&D has continued its relentless pursuit of innovation by refining its products and processes. Extensive research efforts have further validated the positive health effects of our key ingredients, reinforcing the critical role of development in differentiating HBC\u2019s product portfolio. Core activities, including research, development, and documentation, remain key to our R&D strategy. During the year, investments were made to further research, document and test our trademarked products, including ProGo\u00ae, CollaGo\u00ae, OmeGo\u00ae, CalGo\u00ae and NT-II\u2122, to demonstrate their efficacy and unique attributes for both marketing and sales purposes.In 2024, our R&D activities were integral not only to enhancing product quality but also to increasing production efficiency. By leveraging advanced equipment and managing necessary downtime for maintenance and process optimization, we have continued to push the boundaries in converting raw salmon off-cuts into high-value bioactive ingredients, including implementing new management and goals. Our ongoing research into the ingredients has yielded deeper insights into the biological effects, with some of these health benefits gaining recognition from health authorities both in the US and Europe.To meet environmental and health standards, our development initiatives have focused on innovating more efficient production methods and improving the usability of our products for human consumption. The R&D process at HBC is built on five key pillars: further developing the enzymatic hydrolysis process to maximize the unique health benefits of our ingredients; optimizing the handling of raw materials and finished products across the value chain; advancing technology to yield higher quality product fractions of protein, calcium, and oil; identifying, researching, and documenting the bioactivity of our products; and establishing comprehensive evidence of biosafety, bioavailability, and biological effects through both \u201cin-vitro\u201d and \u201cin-vivo\u201d studies.These continued efforts in 2024 not only enhance our product offerings but also ensure that HBC remains at the forefront of marine nutrition innovation. Total research and development costs for 2024 were TNOK 17,452 (2023 TNOK 20,917). Of this, TNOK 1,629 has been capitalized in 2024 (2023: TNOK 5,543).The Group has registered its trademarks under the international Madrid Protocol. The trademarks are OmeGo\u00ae, ProGo\u00ae, CalGo\u00ae, NT-II\u2122, PetGo\u2122 and Brilliant\u2122.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__109": {
"value": "Note 10 Intangible asset2023 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2023 77 579 6 780 4 714 2 627 91 899Additions 0 325 0 0 325Internally developed 5 543 0 0 0 5 543Disposal 4 486 0 0 0 4 486Cost at 31.12.2023 78 636 7 104 4 914 2 627 93 281Depreciation at 01.01.2023 23 451 1 478 3 754 2 627 31 311Depreciation charge of the year 5 333 1 208 145 0 6 686Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2023 28 784 2 686 3 899 2 627 37 997Net book value at 31.12.2023 49 851 4 418 1 015 0 55 284Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation2024 Group and Parent(Amounts in NOK 1 000) R&D IT-systems Patents Other SumCost at 01.01.2024 78 636 7 104 4 914 2 627 93 281Additions 1 629 0 0 0 1 629Internally developed 0 0 0 0 0Disposal 7 371* 0 0 0 7 371Cost at 31.12.2024 72 894 7 104 4 914 2 627 87 539Depreciation at 01.01.2024 28 784 2 686 3 899 2 627 37 997Depreciation charge of the year 5 660 1 327 124 0 7 112Impairment 0 0 0 0 0Impairment and depreciation at 31.12.2024 34 444 4 013 4 024 2 627 45 108Net book value at 31.12.2024 38 449 3 091 890 0 42 430Economic life 10 years 5-10 years 10 years 5-10 years 5-10 years Method of depreciaton Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciationdepreciation*Project sold to HBCI, see note 23 for more information.Throughout 2024, HBC R&D has continued its relentless pursuit of innovation by refining its products and processes. Extensive research efforts have further validated the positive health effects of our key ingredients, reinforcing the critical role of development in differentiating HBC\u2019s product portfolio. Core activities, including research, development, and documentation, remain key to our R&D strategy. During the year, investments were made to further research, document and test our trademarked products, including ProGo\u00ae, CollaGo\u00ae, OmeGo\u00ae, CalGo\u00ae and NT-II\u2122, to demonstrate their efficacy and unique attributes for both marketing and sales purposes.In 2024, our R&D activities were integral not only to enhancing product quality but also to increasing production efficiency. By leveraging advanced equipment and managing necessary downtime for maintenance and process optimization, we have continued to push the boundaries in converting raw salmon off-cuts into high-value bioactive ingredients, including implementing new management and goals. Our ongoing research into the ingredients has yielded deeper insights into the biological effects, with some of these health benefits gaining recognition from health authorities both in the US and Europe.To meet environmental and health standards, our development initiatives have focused on innovating more efficient production methods and improving the usability of our products for human consumption. The R&D process at HBC is built on five key pillars: further developing the enzymatic hydrolysis process to maximize the unique health benefits of our ingredients; optimizing the handling of raw materials and finished products across the value chain; advancing technology to yield higher quality product fractions of protein, calcium, and oil; identifying, researching, and documenting the bioactivity of our products; and establishing comprehensive evidence of biosafety, bioavailability, and biological effects through both \u201cin-vitro\u201d and \u201cin-vivo\u201d studies.These continued efforts in 2024 not only enhance our product offerings but also ensure that HBC remains at the forefront of marine nutrition innovation. Total research and development costs for 2024 were TNOK 17,452 (2023 TNOK 20,917). Of this, TNOK 1,629 has been capitalized in 2024 (2023: TNOK 5,543).The Group has registered its trademarks under the international Madrid Protocol. The trademarks are OmeGo\u00ae, ProGo\u00ae, CalGo\u00ae, NT-II\u2122, PetGo\u2122 and Brilliant\u2122.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__113": {
"value": "Note 11 Fixed assets2023 Group Parent(Amounts in NOK 1 000) Machinery and equipment Fixtures and fittings Total Machinery and equipment Fixtures and fittings TotalCost at 01.01.2023 188 715 15 581 204 296 178 102 13 431 191 534Additions 8 194 0 8 194 8 187 0 8 187Cost at 31.12.2023 196 909 15 581 212 490 186 289 13 431 199 720Depreciations at 01.01.2023 132 608 11 259 143 868 126 081 11 176 137 258Depreciations for the year 11 608 949 12 557 10 101 936 11 038Depreciations at 31.12.2023 144 219 12 209 156 425 136 183 12 113 148 295Book value 31.12.2023 52 693 3 372 56 065 50 107 1 318 51 425Economic life 5-10 years 3-10 years 5-10 years 3-10 years Method of depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation 2024 Group Parent(Amounts in NOK 1 000) Machinery and equipment Fixtures and fittings Total Machinery and equipment Fixtures and fittings TotalCost at 01.01.2024 196 909 15 581 212 490 186 289 13 431 199 720Additions 1 996 448 2 444 1 963 448 2 411Cost at 31.12.2024 198 905 16 029 214 934 188 252 13 879 202 132Depreciations at 01.01.2024 144 216 12 209 156 425 136 183 12 113 148 295Depreciations for the year 12 887 1 363 14 250 11 384 1 373 12 757Depreciations at 31.12.2024 157 103 13 572 170 675 147 567 13 486 161 052Book value 31.12.2024 41 802 2 458 44 260 40 686 394 41 080Economic life 5-10 years 3-10 years 5-10 years 3-10 years Method of depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation Straigt line depreciation The company has pledged assets as collateral for loans. See more in note 16.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__115": {
"value": "Note 12 Leases The company and the group as lessee The company and the group\u2019s right of use assets include manufacturing facilities, machinery and equipment and fixtures and fittings:2023 Group ParentManu fac turing Machinery and Land, manu fac turing Machinery and (Amounts in NOK 1 000)facilitiesequipment Fixtures and fittings Totalfacilitiesequipment Fixtures and fittings TotalCost 01.01.2023 100 594 58 413 2 118 161 125 77 054 52 692 1 585 131 331Additions 7 608 10 834 0 18 442 7 608 10 352 0 17 690Disposals 0 0 0 0 0 0 0 0Costs at 31.12.2023 108 202 69 247 2 118 179 567 84 662 63 044 1 585 149 291Depreciations 01.01.2023 25 672 26 510 577 52 759 19 165 24 377 523 44 065Depreciations for the year 9 267 7 858 45 17 170 7 413 7 006 45 14 464Disposals 0 0 0 0 0 0 0 0Depreciations per 31.12.2023 34 939 34 368 622 69 929 26 578 31 383 568 58 529Carrying amounts 31.12.2023 73 263 34 880 1 496 109 639 58 084 31 661 1 017 90 762Shortest of lease term or 15 years 5 years 3-5 years 15 years 5 years 3-5 years economic lifeDepreciation method Straigt line Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciation depreciation depreciation 2024 Group ParentManu fac turing Machinery and Land, manu fac turing Machinery and (Amounts in NOK 1 000)facilitiesequipment Fixtures and fittings Totalfacilitiesequipment Fixtures and fittings TotalCost 01.01.2024 108 202 69 247 2 118 179 567 84 662 63 044 1 585 149 291Additions 0 2 575 0 2 575 0 2 540 0 2 540Disposals 0 0 0 0 0 0 0 0Costs at 31.12.2024 108 202 71 822 2 118 182 142 84 662 65 584 1 585 151 831Depreciations 01.01.2024 34 939 34 368 622 69 929 26 578 31 383 568 58 529Depreciations for the year 9 223 7 700 1 496 18 420 7 932 7 206 1 017 16 155Disposals 0 0 0 0 0 0 0 0Depreciations per 31.12.2024 44 162 42 068 2 118 88 348 34 510 38 589 1 585 74 684Carrying amounts 31.12.2024 64 040 29 754 0 93 793 50 152 26 995 0 77 147Shortest of lease term or 15 years 5 years 3-5 years 15 years 5 years 3-5 years economic lifeDepreciation method Straigt line Straigt line Straigt line Straigt line Straigt line Straigt line depreciation depreciation depreciation depreciation depreciation depreciation Lease liabilities:Group Parent(AmountsinNOK1000) 2024 2023 2024 2023Undiscounted lease liabilities and due dates for paymentsLess than 1 year 19 994 20 402 16 618 16 6832-5 years 72 733 67 989 59 776 56 348More than 5 years 33 628 39 857 26 407 23 383Total undiscounted lease liabilities 31.12 126 355 128 248 102 802 96 414Changes in lease liabilitiesTotal lease liabilities 1.1 107 625 102 815 89 197 82 547New/changed lease liabilitie srecognized in the period 2 575 18 442 2 540 17 960Payment of principal amounts -12 440 -13 632 -10 503 -11 310Payment of interest amounts -8 180 -8 775 - 6 433 -7 000Interest related to the lease liabilities 8 180 8 775 6 433 7 000Total lease liabilities 31.12 97 760 107 625 81 234 89 197Current lease liabilities 31.12 (note16) 11 217 10 794 9 412 8 950Non-current lease liabilities 31.12 (note16) 86 543 96 831 71 822 80 248Cash outflows for lease liabilities -20 582 -22 414 -16 968 -18 230Total cash outflows for leases -24 307 -23 480 -20 478 -20 381The lease agreements do not restrict the parent company\u2019s and the group\u2019s dividend policy or financing opportunities. The parent company and the group do not have significant residual value guarantees in the lease agreements.The parent company and the group\u2019s leases of machinery and equipment include, in addition to lease payments, a requirement to maintain and secure the assets (right of use assets). The terms in the lease agreements varies from 3-5 year, and several of the agreements include an option to extend the lease. At the expiry date of the main term of the lease, the lease og the machinery and equipment may be continued for a lease payment of 1/12 of the lease payments in the main lease period. The company may also request to purchase the equipment.The company and the group\u2019s leases of manufacturing facilities (Midsund og Berk\u00e5k) have lease terms of 15 years, no extension options, and the leases expire 31 March 2032. When entering into an agreement the group assesses whether it is reasonably certain to exercise an option to purchase the assets. The leases of the manufacturing facilities have no options to purchase.Leases of fixtures and fittings in the table above contain no extension or purchase options. The group\u2019s potential future lease payments which have not been included in the lease liabilities relating to purchase options were TNOK 0 as of 31 December 2024.Applied practical expedientsThe company and the group lease warehouses in which both the lessor and the company / group have the right to terminate the agreements on a 3-6 months notice period. For such agreements the company and the group do not recognize lease liabilities and related right of use assets. Such lease payments are expensed when incurred.Lease payments for the abovementioned leases amounted to TNOK 1,711 (TNOK 1,066 in 2023) for fixture and fittings for the Group and TNOK 2,014 (TNOK 2,151 in 2023) for storage, and for the parent company TNOK 1,500 (TNOK 903 in 2023) for fixture and fittings TNOK 2,010(TNOK 2,164 i 2023) for storage (see note 4). Cash flow from these lease obligations is approximately equal to the amount expensed and is included in net cash flow from operating activities.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfLeasesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__119-1": {
"value": "Note 13 Changes in liabilities from financial activities Group(Amounts in NOK 1 000) 01.01.2023 Downpayment Withdrawals New leases Adjustments 31.12.2023Short-term interestbearing liabilities (excl. posts below) 540 -540 28 353 0 540 28 893Short-term leasing liabilities 12 855 -13 632 0 0 11 571 10 794Long-term interest-bearing debt (excl. posts below) 812 0 0 0 -540 -27Long-term leasing liabilities 89 960 0 0 18 442 -11 571 96 831Total 104 167 -14 172 28 353 18 442 0 136 790Parent(Amounts in NOK 1 000) 01.01.2023 Downpayment Withdrawals New leases Adjustments 31.12.2023Short-term interest-bearing liabilities (excl. posts below) 0 0 28 353 0 0 28 353Short term leasing liabilities 10 055 -11 310 0 0 10 205 8 950Long-term interest-bearing debt (excl. posts below) 0 0 0 0 0 0Long-term leasing liabilities 72 492 0 0 17 960 -10 205 80 247Total 82 547 -11 310 28 353 17 960 0 117 550Group(Amounts in NOK 1 000) 01.01.2024 Downpayment Withdrawals New leases Adjustments 31.12.2024Short-term interestbearing liabilities (excl. posts below) 28 893 -541 19 397 0 271 48 020Short-term leasing liabilities 10 794 -12 440 0 0 12 863 11 217Long-term interest-bearing debt (excl. posts below) 272 0 25 100 0 -271 25 101Long-term leasing liabilities 96 831 0 0 2 575 -12 863 86 543Total 136 790 -12 981 44 497 2 575 0 170 881Parent(Amounts in NOK 1 000) 01.01.2024 Downpayment Withdrawals New leases Adjustments 31.12.2024Short-term interest-bearing liabilities (excl. posts below) 28 353 0 19 397 0 0 47 750Short-term leasing liabilities 8 950 -10 503 0 0 10 965 9 412Long-term interest-bearing debt (excl. posts below) 0 0 25 100 0 0 25 100Long-term leasing liabilities 80 247 0 0 2 540 -10 965 71 822Total 117 550 -10 503 44 497 2 540 0 154 084Accounts payable are not interest-bearing and normal maturity is from 0 to 60 days. For settlement and terms for accounts payable with related parties, see information in note 6.Note 23 Accounts payable and other short-term liabilitiesAccounts payableGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Accounts payable 21 120 13 560 18 703 11 787Accounts payable related companies 72 510 41 601 69 956 37 249Total 93 629 55 161 88 659 49 037Other short-term liabilitiesGroup Parent(Amounts in NOK 1 000) 2024 2022 2024 2023Public duties payable 5 030 4 903 4 277 4 251Accrued holiday pay 5 960 5 178 5 316 4 566Other accrued costs 4 567 2 948 4 494 2 701Short-term debt to related companies* 0 144 000 0 144 000Total 15 557 157 029 14 087 155 518On 4th of January 2024 the extraordinary general meeting of HBC approved the offsetting of NOK 144 million into preference class B shares. Since there is no contractual obligation to repay the amount, nor principal amount or interests, this is classified as equity. The B-Shares will not hold any voting rights and will carry a preferential right to receive dividends over the Company\u2019s ordinary shares (listed on the Oslo Stock Exchange under ticker code \u201cHBC\u201d) (the \u201cOrdinary Shares\u201d).Following a minimum of five (5) years after the issuance of the B-Shares, Hofseth International can request the B-Shares to be converted into Ordinary Shares. The subscription price shall be NOK 9 per new Ordinary Share. If conversion rights are exercised after seven (7) years, a subscription price ofNOK 12 per new Ordinary Share shall apply. Such conversion into Ordinary Shares will technically be done through a redemption value, equivalent to the Investment Value in addition to the Preferred Amount.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__118-1": {
"value": "Note 13 Changes in liabilities from financial activities Group(Amounts in NOK 1 000) 01.01.2023 Downpayment Withdrawals New leases Adjustments 31.12.2023Short-term interestbearing liabilities (excl. posts below) 540 -540 28 353 0 540 28 893Short-term leasing liabilities 12 855 -13 632 0 0 11 571 10 794Long-term interest-bearing debt (excl. posts below) 812 0 0 0 -540 -27Long-term leasing liabilities 89 960 0 0 18 442 -11 571 96 831Total 104 167 -14 172 28 353 18 442 0 136 790Parent(Amounts in NOK 1 000) 01.01.2023 Downpayment Withdrawals New leases Adjustments 31.12.2023Short-term interest-bearing liabilities (excl. posts below) 0 0 28 353 0 0 28 353Short term leasing liabilities 10 055 -11 310 0 0 10 205 8 950Long-term interest-bearing debt (excl. posts below) 0 0 0 0 0 0Long-term leasing liabilities 72 492 0 0 17 960 -10 205 80 247Total 82 547 -11 310 28 353 17 960 0 117 550Group(Amounts in NOK 1 000) 01.01.2024 Downpayment Withdrawals New leases Adjustments 31.12.2024Short-term interestbearing liabilities (excl. posts below) 28 893 -541 19 397 0 271 48 020Short-term leasing liabilities 10 794 -12 440 0 0 12 863 11 217Long-term interest-bearing debt (excl. posts below) 272 0 25 100 0 -271 25 101Long-term leasing liabilities 96 831 0 0 2 575 -12 863 86 543Total 136 790 -12 981 44 497 2 575 0 170 881Parent(Amounts in NOK 1 000) 01.01.2024 Downpayment Withdrawals New leases Adjustments 31.12.2024Short-term interest-bearing liabilities (excl. posts below) 28 353 0 19 397 0 0 47 750Short-term leasing liabilities 8 950 -10 503 0 0 10 965 9 412Long-term interest-bearing debt (excl. posts below) 0 0 25 100 0 0 25 100Long-term leasing liabilities 80 247 0 0 2 540 -10 965 71 822Total 117 550 -10 503 44 497 2 540 0 154 084Note 23 Accounts payable and other short-term liabilitiesAccounts payableGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Accounts payable 21 120 13 560 18 703 11 787Accounts payable related companies 72 510 41 601 69 956 37 249Total 93 629 55 161 88 659 49 037Accounts payable are not interest-bearing and normal maturity is from 0 to 60 days. For settlement and terms for accounts payable with related parties, see information in note 6. Other short-term liabilitiesGroup Parent(Amounts in NOK 1 000) 2024 2022 2024 2023Public duties payable 5 030 4 903 4 277 4 251Accrued holiday pay 5 960 5 178 5 316 4 566Other accrued costs 4 567 2 948 4 494 2 701Short-term debt to related companies* 0 144 000 0 144 000Total 15 557 157 029 14 087 155 518On 4th of January 2024 the extraordinary general meeting of HBC approved the offsetting of NOK 144 million into preference class B shares. Since there is no contractual obligation to repay the amount, nor principal amount or interests, this is classified as equity. The B-Shares will not hold any voting rights and will carry a preferential right to receive dividends over the Company\u2019s ordinary shares (listed on the Oslo Stock Exchange under ticker code \u201cHBC\u201d) (the \u201cOrdinary Shares\u201d).Following a minimum of five (5) years after the issuance of the B-Shares, Hofseth International can request the B-Shares to be converted into Ordinary Shares. The subscription price shall be NOK 9 per new Ordinary Share. If conversion rights are exercised after seven (7) years, a subscription price ofNOK 12 per new Ordinary Share shall apply. Such conversion into Ordinary Shares will technically be done through a redemption value, equivalent to the Investment Value in addition to the Preferred Amount.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__117-1": {
"value": "Note 13 Changes in liabilities from financial activities Group(Amounts in NOK 1 000) 01.01.2023 Downpayment Withdrawals New leases Adjustments 31.12.2023Short-term interestbearing liabilities (excl. posts below) 540 -540 28 353 0 540 28 893Short-term leasing liabilities 12 855 -13 632 0 0 11 571 10 794Long-term interest-bearing debt (excl. posts below) 812 0 0 0 -540 -27Long-term leasing liabilities 89 960 0 0 18 442 -11 571 96 831Total 104 167 -14 172 28 353 18 442 0 136 790Parent(Amounts in NOK 1 000) 01.01.2023 Downpayment Withdrawals New leases Adjustments 31.12.2023Short-term interest-bearing liabilities (excl. posts below) 0 0 28 353 0 0 28 353Short term leasing liabilities 10 055 -11 310 0 0 10 205 8 950Long-term interest-bearing debt (excl. posts below) 0 0 0 0 0 0Long-term leasing liabilities 72 492 0 0 17 960 -10 205 80 247Total 82 547 -11 310 28 353 17 960 0 117 550Group(Amounts in NOK 1 000) 01.01.2024 Downpayment Withdrawals New leases Adjustments 31.12.2024Short-term interestbearing liabilities (excl. posts below) 28 893 -541 19 397 0 271 48 020Short-term leasing liabilities 10 794 -12 440 0 0 12 863 11 217Long-term interest-bearing debt (excl. posts below) 272 0 25 100 0 -271 25 101Long-term leasing liabilities 96 831 0 0 2 575 -12 863 86 543Total 136 790 -12 981 44 497 2 575 0 170 881Parent(Amounts in NOK 1 000) 01.01.2024 Downpayment Withdrawals New leases Adjustments 31.12.2024Short-term interest-bearing liabilities (excl. posts below) 28 353 0 19 397 0 0 47 750Short-term leasing liabilities 8 950 -10 503 0 0 10 965 9 412Long-term interest-bearing debt (excl. posts below) 0 0 25 100 0 0 25 100Long-term leasing liabilities 80 247 0 0 2 540 -10 965 71 822Total 117 550 -10 503 44 497 2 540 0 154 084Note 23 Accounts payable and other short-term liabilitiesAccounts payableGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Accounts payable 21 120 13 560 18 703 11 787Accounts payable related companies 72 510 41 601 69 956 37 249Total 93 629 55 161 88 659 49 037Accounts payable are not interest-bearing and normal maturity is from 0 to 60 days. For settlement and terms for accounts payable with related parties, see information in note 6. Other short-term liabilitiesGroup Parent(Amounts in NOK 1 000) 2024 2022 2024 2023Public duties payable 5 030 4 903 4 277 4 251Accrued holiday pay 5 960 5 178 5 316 4 566Other accrued costs 4 567 2 948 4 494 2 701Short-term debt to related companies* 0 144 000 0 144 000Total 15 557 157 029 14 087 155 518On 4th of January 2024 the extraordinary general meeting of HBC approved the offsetting of NOK 144 million into preference class B shares. Since there is no contractual obligation to repay the amount, nor principal amount or interests, this is classified as equity. The B-Shares will not hold any voting rights and will carry a preferential right to receive dividends over the Company\u2019s ordinary shares (listed on the Oslo Stock Exchange under ticker code \u201cHBC\u201d) (the \u201cOrdinary Shares\u201d).Following a minimum of five (5) years after the issuance of the B-Shares, Hofseth International can request the B-Shares to be converted into Ordinary Shares. The subscription price shall be NOK 9 per new Ordinary Share. If conversion rights are exercised after seven (7) years, a subscription price ofNOK 12 per new Ordinary Share shall apply. Such conversion into Ordinary Shares will technically be done through a redemption value, equivalent to the Investment Value in addition to the Preferred Amount.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__121-1": {
"value": "Note 14 Fair value measurement The following tables provide fair value measurement hierarchy of the group\u2019s financial liabilities. The fair value of financial assets is not disclosed as the fair value is approximately book value.Liabilities measured at fair value, Group(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market pries (Level 2) Non-observed input (Level 3)Liabilities in which fair value is stated in note 18:Interest-bearing loansInterest-bearing loans floating interest rate 31.12.23 811 0 0 811Interest-bearing loans fixed interest rate 31.12.23 0 0 0 0Liabilities measured at fair value, parent company(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market prices (Level 2) Non-observed input (Level 3)Liabilities in which fair value is stated in note 18:Interest-bearing loansInterest-bearing loans floating interest rate 31.12.23 0 0 0 0Interest-bearing loans fixed interest rate 31.12.23 0 0 0 0Interest-bearing loans floating interest rate from subsidiaries 31.12.23 0 0 0 0Liabilities measured at fair value, Group(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market prices (Level 2) Non-observed input (Level 3)Liabilities of which the fair value has been provided in note 18:Interes-bearing loanInterest-bearing loan floating interest rates 31.12.24 271 0 0 271Interest-bearing loan fixed interest rates 31.12.24 0 0 0 0Liabilities measured at fair value, parent company(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market prices (Level 2) Non-observed input (Level 3)Liabilities of which the fair value has been provided in note 18:Interes-bearing loanInterest-bearing loan floating interest rates 31.12.24 0 0 0 0Interest-bearing loan fixed interest rates 31.12.24 0 0 0 0Interest-bearing loan from subsidiary floating interest rates 31.12.24 0 0 0 0Note 15 Financial assetsFinancial assetsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Amortized cost receivables:Accounts receivable 18 853 14 849 18 716 14 094Other current receivable 771 771 49 712 27 787Total financial assets 19 624 15 620 68 429 41 881Total current financial assets 19 624 15 620 68 429 41 881Total non-current financial assets 0 0 0 0IFRS 9 requires the Group\u2019s to recognize a provision for expected credit losses for all debt instruments that are not held at fair value through profit or loss, and for contract assets. The company and the group have a high degree of collateral for credit insurance on all accounts receivables and collaterals on other receivables and loans and, hence, no significant provisions have been made in relation to these, see note 20.Note 16 Interest-bearing debt and borrowingsNon-current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2026- 0 271 0 0Loan 10.00% 2026- 25 100 0 25 100 0Lease liability 6.86% 2026- 86 543 96 831 71 822 80 248Total 111 643 97 102 96 922 80 248Current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2025 271 540 0 0Credit facility 7.73% 2025 47 750 28 353 47 750 28 353Lease liability 6.86% 2025 11 217 10 794 9 412 8 950Total 59 238 39 687 57 162 37 303Sum interest 170 881 136 789 154 084 117 550bearingdebtThe parent company has a credit facility in bank with a credit limit of TNOK 67,000. As of 31 December 2024 the company have used TNOK 47,750 of this credit (TNOK 28,353 as of 31 December 2023)In addition to the above, the parent company had a current interest- bearing liabilities towards the subsidiary HBC Berk\u00e5k AS amounting to TNOK 45,947 as of 31 December 2024 (TNOK 24,283 as of 31 December 2023). The interest rate had been agreed to NIBOR + 3 %. CollateralsCredit facility in parent company is secured in trade receivable and inventory. (Amounts in NOK 1 000) 2024 2023Fixed assets 41 080 51 425Trade receivable 18 716 14 094Inventory 55 203 81 439Total 114 999 146 959The Group insures significant receivables against credit risk. The insurance is limited to a maximum of TNOK 18,700 and a coverage rate of 90%. Financial covenantsCredit facility Sparebank1 Nordm\u00f8re As of 30 June and 31 December each year, the company will have a liquidity reserve of at least NOK 10 million in the form of cash and unused drawing rights in operating credit facility. The book value of equity in Hofseth BioCare ASA shall at all times amount to at least 25% of the book value of the company\u2019s assets. The company was not in breach with covenants per 31.12.2024, but due to increased loans in 2025 the equity ratio will drop and there is a risk that the company will be in breach with covenants within the next twelve months.Note 17 Financial assets and liabilities by category Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Financial assets at amortized cost:Long-term financial lending and deposit 0 0 0 0Accounts receivable 18 853 14 849 18 716 14 094Bank deposits 25 577 23 890 23 232 22 751Other financial loans (see note 15) 771 771 49 712 27 787Total financial assets amortized cost 45 201 39 511 91 660 64 632Total financial assets 45 201 39 511 91 660 64 632Fair value is equal to carrying amount.Financial liabilities at amortized cost:Interest-bearing short-term debt 48 020 0 47 750 0Accounts payable 93 629 55 161 88 659 49 037Interest-bearing short-term debt subsidiaries 0 0 0 0Other short-term debt (note 23) 15 557 157 029 14 087 155 518Non-current interest-bearing debt 25 100 271 25 100 0Non-current leasing obligations 86 543 96 831 71 822 80 248Total financial liabilities amortized cost 268 849 309 292 247 417 248 802Level 3, parent2024 2023(Amounts in NOK 1 000) Booked value Fair value Booked value Fair valueCurrent interest-bearing liabilities 57 162 57 162 37 303 37 303Non-current interest-bearing liabilities 96 922 100 548 80 248 80 248Level 3, groupCurrent interest-bearing liabilities 59 238 59 538 39 687 39 687Non-current interest-bearing liabilities 111 643 115 270 97 102 97 102Presentation of fair value measurements by level in the fair value hierarchy:Level 1: Quoted prices in active markets for identical assets or liabilitiesLevel 2: Valuation based on other observable factors either directly (price) or indirectly (derived from price) than the quoted price (used in level 1) for the asset or liabilityLevel 3: Valuation based on factors not obtained from observable market data (unobservable conditions)The fair value of interest-bearing current and long-term fixed rate debt (level 3) is calculated by comparing the Group and parent company\u2019s conditions with market terms for debt with similar maturity and credit risk.The company has no other financial instruments measured at fair value, except for forward exchange contracts. The carrying value of cash and cash equivalents, short-term receivables, and short-term payables approximates fair value as these instruments have short maturities, and \u00abordinary\u00bb conditions.Note 18 Financial risk managementFinancial riskThrough its activities, the Group is exposed to various types of financial risks: market risk, credit risk and liquidity risk. Management monitors these risks continuously and establishes guidelines for their management. The Group\u2019s overall risk management program focuses on the unpredictability of the financial markets and seeks to minimize potential adverse effects on the Group\u2019s financial results. The Group may use financial derivatives to hedge against certain risks. The company has loans from credit institutions and financial leasing arrangements with the purpose of obtaining capital for investments in the Groups operations. In addition, the company has financial instruments such as accounts receivable and accounts payable, etc., which are directly related to the daily operational activities. Interest rate riskSince the company and the group have no significant interest-bearing assets, the exposure to interest rate risk is through their financing activities. The company\u2019s and the group\u2019s interest rate risk is related to non-current interest-bearing loans, current interest-bearing loans and lease liabilities. Loans with floating interest rates lead to interest rate risk for the company\u2019s and the Group\u2019s cash flow. See note 17 for the book value and fair value of the financing activities and note 16 for interest rate terms relating to interest-bearing financing obligations as of 31 december 2024. For the company\u2019s and the Group\u2019s loan portfolios that have floating interest rates, this means that the company is affected by changes in the interest rate level. The loans are recognized at amortized cost. The following table shows the Group\u2019s sensitivity to interest rate fluctuations. The calculation includes all interest-bearing instruments and financial interest rate derivatives to the extent that they are present.Effect on interest rate Effect on profit \u2013 before tax Interest rate group \u2013 sensitivity year\u2013 basis-point(Amounts in NOK 1 000)2023 +100 -1 368-100 1 3682024 +100 -1 458-100 1 458The following table shows the parent company\u2019s sensitivity to interest rate fluctuations. The calculation includes all interest- bearing instruments and financial interest rate derivatives to the extent that they are present.Interest rate parent company\u2013 sensitivity Effect on interest rate Effect on profit \u2013 before tax year\u2013 basis-point(Amounts in NOK 1 000)2023 +100 -1 176-100 1 1762024 +100 -1 290-100 1 290Average interest rates on financial instruments were as follows:Average interest rate in % 2024 2023Unsecured debt 10.00 n/aCredit line 7.73 7.99Secured debt 6.70 6.73Lease liabilities 6.86 5.45Foreign exchange risk The parent company and the group have a foreign exchange loan in CHF and a large part of their operating income in foreign currency and, to a lesser extent, the purchase of input factors in foreign currency, and are therefore exposed to currency risk. Management has monitored movements in the foreign exchange market and has assessed hedging strategies in 2024 based on the parent company\u2019s and the group\u2019s contractual and predictable income streams. The parent company and the group therefore entered into forward exchange contracts both in 2023 and in 2024 in order to secure the Group\u2019s budgeted future sales in foreign currency (Euro and USD), but have not used hedge accounting. The Group and the parent company had none such forwards per 31.12.2024. The parent company and the group had the following positions per 31 December 2023:Date Amount Rate15.02.24 EUR 300,000 11.91225.04.24 EUR 300,000 11.92213.06.24 EUR 300,000 11.92622.08.24 EUR 300,000 11.928 The below table demonstrates the sensitivity of possible changes in EUR, USD, CHF and GBP when all other variables are constant. The effect on the parent company\u2019s and the Group\u2019s profit before tax is due to changes in the fair value of monetary assets and liabilities, including forward exchange contracts. If the company had used hedge accounting, a currency change would also have resulted in changes to the OCI. The company does not use hedge accounting.Change in currency Change in NOK Effect on profit before tax Effect on balanceto foreign (Amounts in NOK 1 000)currency EUR USD GBP USD EUR CHF2023 +10% 9 722 6 414 1 941 n/a 1 355 n/a -10 % -9 722 -6 4142024 -1 941 n/a -1 355 n/a+10% 13 019 10 670 1 547 102 839 -2 510 -10% -13 019 -10 670 -1 547 -102 -839 2 510Credit riskThe parent company and the Group are exposed to credit risk primarily related to accounts receivable, non-current financial loans, current financial loans, as well as other financial activities including cash and cash equivalents (bank deposits).The Group limits its exposure to credit risk through a credit rating of its customers before credit is given. The Group has credit insurance for all its significant accounts receivable through Coface Norway (see 20 for further information on credit exposure and maturity analyzes on accounts receivable).The maximum risk exposure of trade receivables for the group as of 31 December 2024 is TNOK 18,853 (TNOK 14,849 as of 31 December 2023), and for parent company TNOK 18,716 (TNOK 14,094 as of 31 December 2023). The risk of loss on accounts receivable is considered low and there has been no need to provide for losses. See note 20 for further information.Loan to subsidary of TNOK 45,947 (TNOK 27,787 in 2023), where credit risk is considered low. (see note 15, 17 and 20 for further information on financial loans and other current receivables).Credit risk for cash and cash equivalents, including bank deposits, is managed by the Group\u2019s management. The Group\u2019s surplus liquidity is invested by bank deposits with a financial counterparty with low credit risk. The Group has no investments in excess liquidity in debt or equity instruments.The Group has not provided any guarantees for third-party debt.Liquidity riskLiquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group\u2019s approach to liquidity management is to ensure, to the extent possible, that it will always have sufficient liquidity to meet its liabilities when due, both under normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group\u2019s reputation. Cash flows are regularly monitored by the finance department to ensure that the parent company has sufficient cash to meet operational commitments, and at any time to maintain sufficient flexibility in the form of credit facilities so that it does not violate limits or covenants for any of the loans. The parent company and the Group aims to have sufficient cash, cash equivalents or credit opportunities in the medium term to cover interest and principal payments in the short term. Please also refer to note 1 section Going concern.As of 31 December 2024 the group had MNOK 25,6 in cash, of which MNOK 3,0 were restricted cash. As of 31 December 2023 the group had MNOK 23,9 in cash, of which MNOK 3,0 were restricted cash. The group expects to have a stable production level with stable quality which satisfies the requirements for human quality. The activities to increase sales to existing customers, as well as the expectation of increased sales of oil, water-soluble protein, non-soluble protein and calcium could result in significant improvement in the company\u2019s cash flows. Expected cash flows are subject to uncertainties related to achieved sales prices and volume. Risk factors should be considered in conjunction with the risk factors described in note 2 accounting estimates.The table below shows the maturity profile of the Group\u2019s financial liabilities, both interest and installments, based on contractual undiscounted payments, classified according to maturity structure, that is, taken into account contracts with fixed maturity dates. When the counterparty can make an election of when an amount is to be paid, the liability is included in the basis covering the earliest date on which the entity can be required to pay. Financial liabilities that may be required to be paid on demand are included in the \u00abwithin 1-3 months\u00bbGroup2023(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2025 2026 2027 2028 > 5 years TotalInterest bearing debt to financial institutions 0 298 0 289 280 0 0 0 0 866Credit line 28 353 0 0 0 0 0 0 0 0 28 353Lease libilities 5 311 5 171 4 996 4 924 18 828 17 876 17 128 14 157 39 857 128 247Trade payables 50 160 0 0 0 0 0 0 0 0 50 160Other current liabilities 7 851 5 178 0 0 0 0 0 0 0 13 029Total 86 675 10 646 4 996 5 213 19 107 17 876 17 128 14 157 39 857 220 655Group2024(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2026 2027 2028 2029 > 5 years TotalInterest bearing debt to financial institutions 0 280 0 0 0 0 0 0 0 280Loan and subordinated loan 0 0 2 713 0 2 510 27 610 0 0 0 32 833Credit line 47 750 0 0 0 0 0 0 0 0 47 750Lease liabilities 5 165 5 106 5 042 4 681 19 714 19 272 18 997 14 750 33 628 126 355Trade payables 93 629 0 0 0 0 0 0 0 0 93 629Other current liabilities 9 597 5 960 0 0 0 0 0 0 0 15 557Total 156 141 11 345 7 755 4 681 22 224 46 882 18 997 14 750 33 628 316 403Parent2023(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2025 2026 2027 2028 > 5 years TotalCredit line 28 353 0 0 0 0 0 0 0 0 28 353Lease libilities 4 342 4 200 4 103 4 038 15 747 15 008 14 264 11 329 23 383 96 414Trade payables 49 001 0 0 0 0 0 0 0 0 49 001Other current liabilities 6 952 4 566 0 0 0 0 0 0 0 11 518Total 83 648 8 766 4 103 4 038 15 747 15 008 14 264 11 329 23 383 185 285Parent2024(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2026 2027 2028 2029 > 5 years TotalLoan and subordinated loan 0 0 2 713 0 2 510 27 610 0 0 0 32 833Credit line 47 750 0 0 0 0 0 0 0 0 47 750Lease libilities 4 219 4 156 4 154 4 089 16 210 15 845 15 440 12 281 26 407 102 802Trade payables 88 659 0 0 0 0 0 0 0 0 88 659Other current liabilities 8 771 5 316 0 0 0 0 0 0 0 14 087Total 149 399 9 472 6 867 4 089 18 721 43 455 15 440 12 281 26 407 286 131The group and the parent company signed in December 2023 a increased credit facility for up until TNOK 67,000 with SpareBank 1 Nordm\u00f8re for working capital need related to future sales contracts. In addition to the available cash and cash equivalents as of 31 December 2024, this secures the group and the company sufficient liquidity for 2025.See note 16 on interest-bearing debt for further information.In the future, the management and the board will continue to prioritize the work on an appropriate and long-term financing of Hofseth BioCare ASA.Capital structure and equityThe group and the parent company\u2019s objectives with respect to capital management is to ensure the continuation as a going concern, to provide returns to shareholders and other stakeholders, and to maintain an optimal capital structure to reduce capital costs. By ensuring sound ratios between equity and debt the group and the parent company will support its operations, thus maximizing the value of its shares.The parent company manages its capital structure and makes necessary changes to it on the basis of an ongoing assessment of the financial conditions under which the business is run, and the prospects seen in the short and medium term, including any adjustment of dividend shares, buyback of own shares, reduction of share capital or issuance of new shares. There has been no change in the policy in this area in 2024. The Group completed a convertion of debt to equity 4 January 2024, and strengthened the equity with TNOK 144,000. The Group\u2019s equity ratio was 17.9 % as of 31 December 2024 and (10.5 % as of 31 December 2023). The parent company\u2019s equity ratio was 31.9 % as of 31 December 2024 (18.8 % as of 31 December 2023).Note 20 Trade receivables and other current receivablesTrade receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2022Trade receivables USA 6 190 3 458 6 190 3 458Trade receivables Belgium 6 166 1 757 6 166 1 757Trade receivables Italia 2 140 707 2 140 707Trade receivables France 555 4 170 555 4 170Trade receivables other 3 802 4 756 3 665 4 002Sum trade receivables 18 853 14 849 18 716 14 094Trade receivables related parties 7 106 3 458 7 106 3 458Provision for expected credit losses 0 0 0 0Accounts receivable are not interest-bearing receivables and general terms and conditions for paymentare from 7 to 120 days. All significant accounts receivables are credit secured by Coface Norway, limited to a maximum of MNOK 11.5 and with a coverage rate of 90 %. Historical credit losses for customers over the past five years are approximately TNOK 499. Aging of trade receivables - Group(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 854 17 695 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 849 13 287 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0Aging of trade receivables - Parent(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 716 17 557 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 094 12 532 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0The Group has established a model in which the Group calculates provisions for credit losses by multiplying the expected credit losses by the proportion of non-credit-secured accounts receivable. The Group uses an increasing factor for expected credit losses according to maturity analyzes above. When analyzing future information about the Group\u2019s customers and markets, no future challenges are listed today which indicate that there will be a significant credit loss in the future (see and note 18 on credit risk). The Group and the parent company have TNOK 0 in provisions for losses on accounts receivable both in 2024 and 2023. Other current receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Prepayments 4 587 2 551 4 371 2 585VAT receivable 4 519 3 292 3 859 2 906Intercompany Group 0 0 49 712 27 016Benefit funds 1 227 2 255 1 227 2 255Other 1 384 1 623 715 1 497Total 11 716 9 721 59 885 36 259Note 21 Cash and cash equivalentsDeposits with a credit institution totaled TNOK 25,577 as of 31 December 2024 and TNOK 23,890 as of 31 December 2023 and the Group earns interest income according to agreed floating interest rate terms.At 31 December 2024, restricted funds for the Group amounted to TNOK 3,013 which derives from the employees\u2019 tax deductions. As of 31 December 2023, this amounted to TNOK 3,019.Note 23 Accounts payable and other short-term liabilitiesAccounts payableGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Accounts payable 21 120 13 560 18 703 11 787Accounts payable related companies 72 510 41 601 69 956 37 249Total 93 629 55 161 88 659 49 037Accounts payable are not interest-bearing and normal maturity is from 0 to 60 days. For settlement and terms for accounts payable with related parties, see information in note 6. Other short-term liabilitiesGroup Parent(Amounts in NOK 1 000) 2024 2022 2024 2023Public duties payable 5 030 4 903 4 277 4 251Accrued holiday pay 5 960 5 178 5 316 4 566Other accrued costs 4 567 2 948 4 494 2 701Short-term debt to related companies* 0 144 000 0 144 000Total 15 557 157 029 14 087 155 518On 4th of January 2024 the extraordinary general meeting of HBC approved the offsetting of NOK 144 million into preference class B shares. Since there is no contractual obligation to repay the amount, nor principal amount or interests, this is classified as equity. The B-Shares will not hold any voting rights and will carry a preferential right to receive dividends over the Company\u2019s ordinary shares (listed on the Oslo Stock Exchange under ticker code \u201cHBC\u201d) (the \u201cOrdinary Shares\u201d).Following a minimum of five (5) years after the issuance of the B-Shares, Hofseth International can request the B-Shares to be converted into Ordinary Shares. The subscription price shall be NOK 9 per new Ordinary Share. If conversion rights are exercised after seven (7) years, a subscription price ofNOK 12 per new Ordinary Share shall apply. Such conversion into Ordinary Shares will technically be done through a redemption value, equivalent to the Investment Value in addition to the Preferred Amount.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__120": {
"value": "Note 14 Fair value measurement The following tables provide fair value measurement hierarchy of the group\u2019s financial liabilities. The fair value of financial assets is not disclosed as the fair value is approximately book value.Liabilities measured at fair value, Group(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market pries (Level 2) Non-observed input (Level 3)Liabilities in which fair value is stated in note 18:Interest-bearing loansInterest-bearing loans floating interest rate 31.12.23 811 0 0 811Interest-bearing loans fixed interest rate 31.12.23 0 0 0 0Liabilities measured at fair value, parent company(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market prices (Level 2) Non-observed input (Level 3)Liabilities in which fair value is stated in note 18:Interest-bearing loansInterest-bearing loans floating interest rate 31.12.23 0 0 0 0Interest-bearing loans fixed interest rate 31.12.23 0 0 0 0Interest-bearing loans floating interest rate from subsidiaries 31.12.23 0 0 0 0Liabilities measured at fair value, Group(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market prices (Level 2) Non-observed input (Level 3)Liabilities of which the fair value has been provided in note 18:Interes-bearing loanInterest-bearing loan floating interest rates 31.12.24 271 0 0 271Interest-bearing loan fixed interest rates 31.12.24 0 0 0 0Liabilities measured at fair value, parent company(Amounts in NOK 1 000) Date of measurement Amount Active markets (Level 1) Observed market prices (Level 2) Non-observed input (Level 3)Liabilities of which the fair value has been provided in note 18:Interes-bearing loanInterest-bearing loan floating interest rates 31.12.24 0 0 0 0Interest-bearing loan fixed interest rates 31.12.24 0 0 0 0Interest-bearing loan from subsidiary floating interest rates 31.12.24 0 0 0 0",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__124-1": {
"value": "Note 15 Financial assetsFinancial assetsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Amortized cost receivables:Accounts receivable 18 853 14 849 18 716 14 094Other current receivable 771 771 49 712 27 787Total financial assets 19 624 15 620 68 429 41 881Total current financial assets 19 624 15 620 68 429 41 881Total non-current financial assets 0 0 0 0IFRS 9 requires the Group\u2019s to recognize a provision for expected credit losses for all debt instruments that are not held at fair value through profit or loss, and for contract assets. The company and the group have a high degree of collateral for credit insurance on all accounts receivables and collaterals on other receivables and loans and, hence, no significant provisions have been made in relation to these, see note 20.Note 20 Trade receivables and other current receivablesTrade receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2022Trade receivables USA 6 190 3 458 6 190 3 458Trade receivables Belgium 6 166 1 757 6 166 1 757Trade receivables Italia 2 140 707 2 140 707Trade receivables France 555 4 170 555 4 170Trade receivables other 3 802 4 756 3 665 4 002Sum trade receivables 18 853 14 849 18 716 14 094Trade receivables related parties 7 106 3 458 7 106 3 458Provision for expected credit losses 0 0 0 0Accounts receivable are not interest-bearing receivables and general terms and conditions for paymentare from 7 to 120 days. All significant accounts receivables are credit secured by Coface Norway, limited to a maximum of MNOK 11.5 and with a coverage rate of 90 %. Historical credit losses for customers over the past five years are approximately TNOK 499. Aging of trade receivables - Group(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 854 17 695 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 849 13 287 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0Aging of trade receivables - Parent(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 716 17 557 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 094 12 532 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0The Group has established a model in which the Group calculates provisions for credit losses by multiplying the expected credit losses by the proportion of non-credit-secured accounts receivable. The Group uses an increasing factor for expected credit losses according to maturity analyzes above. When analyzing future information about the Group\u2019s customers and markets, no future challenges are listed today which indicate that there will be a significant credit loss in the future (see and note 18 on credit risk). The Group and the parent company have TNOK 0 in provisions for losses on accounts receivable both in 2024 and 2023. Other current receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Prepayments 4 587 2 551 4 371 2 585VAT receivable 4 519 3 292 3 859 2 906Intercompany Group 0 0 49 712 27 016Benefit funds 1 227 2 255 1 227 2 255Other 1 384 1 623 715 1 497Total 11 716 9 721 59 885 36 259",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__123": {
"value": "Note 15 Financial assetsFinancial assetsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Amortized cost receivables:Accounts receivable 18 853 14 849 18 716 14 094Other current receivable 771 771 49 712 27 787Total financial assets 19 624 15 620 68 429 41 881Total current financial assets 19 624 15 620 68 429 41 881Total non-current financial assets 0 0 0 0IFRS 9 requires the Group\u2019s to recognize a provision for expected credit losses for all debt instruments that are not held at fair value through profit or loss, and for contract assets. The company and the group have a high degree of collateral for credit insurance on all accounts receivables and collaterals on other receivables and loans and, hence, no significant provisions have been made in relation to these, see note 20.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__122-1": {
"value": "Note 15 Financial assetsFinancial assetsGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Amortized cost receivables:Accounts receivable 18 853 14 849 18 716 14 094Other current receivable 771 771 49 712 27 787Total financial assets 19 624 15 620 68 429 41 881Total current financial assets 19 624 15 620 68 429 41 881Total non-current financial assets 0 0 0 0IFRS 9 requires the Group\u2019s to recognize a provision for expected credit losses for all debt instruments that are not held at fair value through profit or loss, and for contract assets. The company and the group have a high degree of collateral for credit insurance on all accounts receivables and collaterals on other receivables and loans and, hence, no significant provisions have been made in relation to these, see note 20.Note 20 Trade receivables and other current receivablesTrade receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2022Trade receivables USA 6 190 3 458 6 190 3 458Trade receivables Belgium 6 166 1 757 6 166 1 757Trade receivables Italia 2 140 707 2 140 707Trade receivables France 555 4 170 555 4 170Trade receivables other 3 802 4 756 3 665 4 002Sum trade receivables 18 853 14 849 18 716 14 094Trade receivables related parties 7 106 3 458 7 106 3 458Provision for expected credit losses 0 0 0 0Accounts receivable are not interest-bearing receivables and general terms and conditions for paymentare from 7 to 120 days. All significant accounts receivables are credit secured by Coface Norway, limited to a maximum of MNOK 11.5 and with a coverage rate of 90 %. Historical credit losses for customers over the past five years are approximately TNOK 499. Aging of trade receivables - Group(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 854 17 695 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 849 13 287 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0Aging of trade receivables - Parent(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 716 17 557 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 094 12 532 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0The Group has established a model in which the Group calculates provisions for credit losses by multiplying the expected credit losses by the proportion of non-credit-secured accounts receivable. The Group uses an increasing factor for expected credit losses according to maturity analyzes above. When analyzing future information about the Group\u2019s customers and markets, no future challenges are listed today which indicate that there will be a significant credit loss in the future (see and note 18 on credit risk). The Group and the parent company have TNOK 0 in provisions for losses on accounts receivable both in 2024 and 2023. Other current receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Prepayments 4 587 2 551 4 371 2 585VAT receivable 4 519 3 292 3 859 2 906Intercompany Group 0 0 49 712 27 016Benefit funds 1 227 2 255 1 227 2 255Other 1 384 1 623 715 1 497Total 11 716 9 721 59 885 36 259",
"dimensions": {
"concept": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__128": {
"value": "Note 16 Interest-bearing debt and borrowingsNon-current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2026- 0 271 0 0Loan 10.00% 2026- 25 100 0 25 100 0Lease liability 6.86% 2026- 86 543 96 831 71 822 80 248Total 111 643 97 102 96 922 80 248Current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2025 271 540 0 0Credit facility 7.73% 2025 47 750 28 353 47 750 28 353Lease liability 6.86% 2025 11 217 10 794 9 412 8 950Total 59 238 39 687 57 162 37 303Sum interest 170 881 136 789 154 084 117 550bearingdebtThe parent company has a credit facility in bank with a credit limit of TNOK 67,000. As of 31 December 2024 the company have used TNOK 47,750 of this credit (TNOK 28,353 as of 31 December 2023)In addition to the above, the parent company had a current interest- bearing liabilities towards the subsidiary HBC Berk\u00e5k AS amounting to TNOK 45,947 as of 31 December 2024 (TNOK 24,283 as of 31 December 2023). The interest rate had been agreed to NIBOR + 3 %. CollateralsCredit facility in parent company is secured in trade receivable and inventory. (Amounts in NOK 1 000) 2024 2023Fixed assets 41 080 51 425Trade receivable 18 716 14 094Inventory 55 203 81 439Total 114 999 146 959The Group insures significant receivables against credit risk. The insurance is limited to a maximum of TNOK 18,700 and a coverage rate of 90%. Financial covenantsCredit facility Sparebank1 Nordm\u00f8re As of 30 June and 31 December each year, the company will have a liquidity reserve of at least NOK 10 million in the form of cash and unused drawing rights in operating credit facility. The book value of equity in Hofseth BioCare ASA shall at all times amount to at least 25% of the book value of the company\u2019s assets. The company was not in breach with covenants per 31.12.2024, but due to increased loans in 2025 the equity ratio will drop and there is a risk that the company will be in breach with covenants within the next twelve months.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCollateralExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__127": {
"value": "Note 16 Interest-bearing debt and borrowingsNon-current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2026- 0 271 0 0Loan 10.00% 2026- 25 100 0 25 100 0Lease liability 6.86% 2026- 86 543 96 831 71 822 80 248Total 111 643 97 102 96 922 80 248Current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2025 271 540 0 0Credit facility 7.73% 2025 47 750 28 353 47 750 28 353Lease liability 6.86% 2025 11 217 10 794 9 412 8 950Total 59 238 39 687 57 162 37 303Sum interest 170 881 136 789 154 084 117 550bearingdebtThe parent company has a credit facility in bank with a credit limit of TNOK 67,000. As of 31 December 2024 the company have used TNOK 47,750 of this credit (TNOK 28,353 as of 31 December 2023)In addition to the above, the parent company had a current interest- bearing liabilities towards the subsidiary HBC Berk\u00e5k AS amounting to TNOK 45,947 as of 31 December 2024 (TNOK 24,283 as of 31 December 2023). The interest rate had been agreed to NIBOR + 3 %. CollateralsCredit facility in parent company is secured in trade receivable and inventory. (Amounts in NOK 1 000) 2024 2023Fixed assets 41 080 51 425Trade receivable 18 716 14 094Inventory 55 203 81 439Total 114 999 146 959The Group insures significant receivables against credit risk. The insurance is limited to a maximum of TNOK 18,700 and a coverage rate of 90%. Financial covenantsCredit facility Sparebank1 Nordm\u00f8re As of 30 June and 31 December each year, the company will have a liquidity reserve of at least NOK 10 million in the form of cash and unused drawing rights in operating credit facility. The book value of equity in Hofseth BioCare ASA shall at all times amount to at least 25% of the book value of the company\u2019s assets. The company was not in breach with covenants per 31.12.2024, but due to increased loans in 2025 the equity ratio will drop and there is a risk that the company will be in breach with covenants within the next twelve months.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__126": {
"value": "Note 16 Interest-bearing debt and borrowingsNon-current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2026- 0 271 0 0Loan 10.00% 2026- 25 100 0 25 100 0Lease liability 6.86% 2026- 86 543 96 831 71 822 80 248Total 111 643 97 102 96 922 80 248Current debtGroup ParentEffective (Amounts in NOK 1 000)interest rate Maturity 2024 2023 2024 2023Rennebu Municipality 6.70% 2025 271 540 0 0Credit facility 7.73% 2025 47 750 28 353 47 750 28 353Lease liability 6.86% 2025 11 217 10 794 9 412 8 950Total 59 238 39 687 57 162 37 303Sum interest 170 881 136 789 154 084 117 550bearingdebtThe parent company has a credit facility in bank with a credit limit of TNOK 67,000. As of 31 December 2024 the company have used TNOK 47,750 of this credit (TNOK 28,353 as of 31 December 2023)In addition to the above, the parent company had a current interest- bearing liabilities towards the subsidiary HBC Berk\u00e5k AS amounting to TNOK 45,947 as of 31 December 2024 (TNOK 24,283 as of 31 December 2023). The interest rate had been agreed to NIBOR + 3 %. CollateralsCredit facility in parent company is secured in trade receivable and inventory. (Amounts in NOK 1 000) 2024 2023Fixed assets 41 080 51 425Trade receivable 18 716 14 094Inventory 55 203 81 439Total 114 999 146 959The Group insures significant receivables against credit risk. The insurance is limited to a maximum of TNOK 18,700 and a coverage rate of 90%. Financial covenantsCredit facility Sparebank1 Nordm\u00f8re As of 30 June and 31 December each year, the company will have a liquidity reserve of at least NOK 10 million in the form of cash and unused drawing rights in operating credit facility. The book value of equity in Hofseth BioCare ASA shall at all times amount to at least 25% of the book value of the company\u2019s assets. The company was not in breach with covenants per 31.12.2024, but due to increased loans in 2025 the equity ratio will drop and there is a risk that the company will be in breach with covenants within the next twelve months.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfBorrowingsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__130": {
"value": "Note 17 Financial assets and liabilities by category Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Financial assets at amortized cost:Long-term financial lending and deposit 0 0 0 0Accounts receivable 18 853 14 849 18 716 14 094Bank deposits 25 577 23 890 23 232 22 751Other financial loans (see note 15) 771 771 49 712 27 787Total financial assets amortized cost 45 201 39 511 91 660 64 632Total financial assets 45 201 39 511 91 660 64 632Fair value is equal to carrying amount.Financial liabilities at amortized cost:Interest-bearing short-term debt 48 020 0 47 750 0Accounts payable 93 629 55 161 88 659 49 037Interest-bearing short-term debt subsidiaries 0 0 0 0Other short-term debt (note 23) 15 557 157 029 14 087 155 518Non-current interest-bearing debt 25 100 271 25 100 0Non-current leasing obligations 86 543 96 831 71 822 80 248Total financial liabilities amortized cost 268 849 309 292 247 417 248 802Level 3, parent2024 2023(Amounts in NOK 1 000) Booked value Fair value Booked value Fair valueCurrent interest-bearing liabilities 57 162 57 162 37 303 37 303Non-current interest-bearing liabilities 96 922 100 548 80 248 80 248Level 3, groupCurrent interest-bearing liabilities 59 238 59 538 39 687 39 687Non-current interest-bearing liabilities 111 643 115 270 97 102 97 102Presentation of fair value measurements by level in the fair value hierarchy:Level 1: Quoted prices in active markets for identical assets or liabilitiesLevel 2: Valuation based on other observable factors either directly (price) or indirectly (derived from price) than the quoted price (used in level 1) for the asset or liabilityLevel 3: Valuation based on factors not obtained from observable market data (unobservable conditions)The fair value of interest-bearing current and long-term fixed rate debt (level 3) is calculated by comparing the Group and parent company\u2019s conditions with market terms for debt with similar maturity and credit risk.The company has no other financial instruments measured at fair value, except for forward exchange contracts. The carrying value of cash and cash equivalents, short-term receivables, and short-term payables approximates fair value as these instruments have short maturities, and \u00abordinary\u00bb conditions.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__132": {
"value": "Note 18 Financial risk managementFinancial riskThrough its activities, the Group is exposed to various types of financial risks: market risk, credit risk and liquidity risk. Management monitors these risks continuously and establishes guidelines for their management. The Group\u2019s overall risk management program focuses on the unpredictability of the financial markets and seeks to minimize potential adverse effects on the Group\u2019s financial results. The Group may use financial derivatives to hedge against certain risks. The company has loans from credit institutions and financial leasing arrangements with the purpose of obtaining capital for investments in the Groups operations. In addition, the company has financial instruments such as accounts receivable and accounts payable, etc., which are directly related to the daily operational activities. Interest rate riskSince the company and the group have no significant interest-bearing assets, the exposure to interest rate risk is through their financing activities. The company\u2019s and the group\u2019s interest rate risk is related to non-current interest-bearing loans, current interest-bearing loans and lease liabilities. Loans with floating interest rates lead to interest rate risk for the company\u2019s and the Group\u2019s cash flow. See note 17 for the book value and fair value of the financing activities and note 16 for interest rate terms relating to interest-bearing financing obligations as of 31 december 2024. For the company\u2019s and the Group\u2019s loan portfolios that have floating interest rates, this means that the company is affected by changes in the interest rate level. The loans are recognized at amortized cost. The following table shows the Group\u2019s sensitivity to interest rate fluctuations. The calculation includes all interest-bearing instruments and financial interest rate derivatives to the extent that they are present.Effect on interest rate Effect on profit \u2013 before tax Interest rate group \u2013 sensitivity year\u2013 basis-point(Amounts in NOK 1 000)2023 +100 -1 368-100 1 3682024 +100 -1 458-100 1 458The following table shows the parent company\u2019s sensitivity to interest rate fluctuations. The calculation includes all interest- bearing instruments and financial interest rate derivatives to the extent that they are present.Interest rate parent company\u2013 sensitivity Effect on interest rate Effect on profit \u2013 before tax year\u2013 basis-point(Amounts in NOK 1 000)2023 +100 -1 176-100 1 1762024 +100 -1 290-100 1 290Average interest rates on financial instruments were as follows:Average interest rate in % 2024 2023Unsecured debt 10.00 n/aCredit line 7.73 7.99Secured debt 6.70 6.73Lease liabilities 6.86 5.45Foreign exchange risk The parent company and the group have a foreign exchange loan in CHF and a large part of their operating income in foreign currency and, to a lesser extent, the purchase of input factors in foreign currency, and are therefore exposed to currency risk. Management has monitored movements in the foreign exchange market and has assessed hedging strategies in 2024 based on the parent company\u2019s and the group\u2019s contractual and predictable income streams. The parent company and the group therefore entered into forward exchange contracts both in 2023 and in 2024 in order to secure the Group\u2019s budgeted future sales in foreign currency (Euro and USD), but have not used hedge accounting. The Group and the parent company had none such forwards per 31.12.2024. The parent company and the group had the following positions per 31 December 2023:Date Amount Rate15.02.24 EUR 300,000 11.91225.04.24 EUR 300,000 11.92213.06.24 EUR 300,000 11.92622.08.24 EUR 300,000 11.928 The below table demonstrates the sensitivity of possible changes in EUR, USD, CHF and GBP when all other variables are constant. The effect on the parent company\u2019s and the Group\u2019s profit before tax is due to changes in the fair value of monetary assets and liabilities, including forward exchange contracts. If the company had used hedge accounting, a currency change would also have resulted in changes to the OCI. The company does not use hedge accounting.Change in currency Change in NOK Effect on profit before tax Effect on balanceto foreign (Amounts in NOK 1 000)currency EUR USD GBP USD EUR CHF2023 +10% 9 722 6 414 1 941 n/a 1 355 n/a -10 % -9 722 -6 4142024 -1 941 n/a -1 355 n/a+10% 13 019 10 670 1 547 102 839 -2 510 -10% -13 019 -10 670 -1 547 -102 -839 2 510Credit riskThe parent company and the Group are exposed to credit risk primarily related to accounts receivable, non-current financial loans, current financial loans, as well as other financial activities including cash and cash equivalents (bank deposits).The Group limits its exposure to credit risk through a credit rating of its customers before credit is given. The Group has credit insurance for all its significant accounts receivable through Coface Norway (see 20 for further information on credit exposure and maturity analyzes on accounts receivable).The maximum risk exposure of trade receivables for the group as of 31 December 2024 is TNOK 18,853 (TNOK 14,849 as of 31 December 2023), and for parent company TNOK 18,716 (TNOK 14,094 as of 31 December 2023). The risk of loss on accounts receivable is considered low and there has been no need to provide for losses. See note 20 for further information.Loan to subsidary of TNOK 45,947 (TNOK 27,787 in 2023), where credit risk is considered low. (see note 15, 17 and 20 for further information on financial loans and other current receivables).Credit risk for cash and cash equivalents, including bank deposits, is managed by the Group\u2019s management. The Group\u2019s surplus liquidity is invested by bank deposits with a financial counterparty with low credit risk. The Group has no investments in excess liquidity in debt or equity instruments.The Group has not provided any guarantees for third-party debt.Liquidity riskLiquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group\u2019s approach to liquidity management is to ensure, to the extent possible, that it will always have sufficient liquidity to meet its liabilities when due, both under normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group\u2019s reputation. Cash flows are regularly monitored by the finance department to ensure that the parent company has sufficient cash to meet operational commitments, and at any time to maintain sufficient flexibility in the form of credit facilities so that it does not violate limits or covenants for any of the loans. The parent company and the Group aims to have sufficient cash, cash equivalents or credit opportunities in the medium term to cover interest and principal payments in the short term. Please also refer to note 1 section Going concern.As of 31 December 2024 the group had MNOK 25,6 in cash, of which MNOK 3,0 were restricted cash. As of 31 December 2023 the group had MNOK 23,9 in cash, of which MNOK 3,0 were restricted cash. The group expects to have a stable production level with stable quality which satisfies the requirements for human quality. The activities to increase sales to existing customers, as well as the expectation of increased sales of oil, water-soluble protein, non-soluble protein and calcium could result in significant improvement in the company\u2019s cash flows. Expected cash flows are subject to uncertainties related to achieved sales prices and volume. Risk factors should be considered in conjunction with the risk factors described in note 2 accounting estimates.The table below shows the maturity profile of the Group\u2019s financial liabilities, both interest and installments, based on contractual undiscounted payments, classified according to maturity structure, that is, taken into account contracts with fixed maturity dates. When the counterparty can make an election of when an amount is to be paid, the liability is included in the basis covering the earliest date on which the entity can be required to pay. Financial liabilities that may be required to be paid on demand are included in the \u00abwithin 1-3 months\u00bbGroup2023(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2025 2026 2027 2028 > 5 years TotalInterest bearing debt to financial institutions 0 298 0 289 280 0 0 0 0 866Credit line 28 353 0 0 0 0 0 0 0 0 28 353Lease libilities 5 311 5 171 4 996 4 924 18 828 17 876 17 128 14 157 39 857 128 247Trade payables 50 160 0 0 0 0 0 0 0 0 50 160Other current liabilities 7 851 5 178 0 0 0 0 0 0 0 13 029Total 86 675 10 646 4 996 5 213 19 107 17 876 17 128 14 157 39 857 220 655Group2024(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2026 2027 2028 2029 > 5 years TotalInterest bearing debt to financial institutions 0 280 0 0 0 0 0 0 0 280Loan and subordinated loan 0 0 2 713 0 2 510 27 610 0 0 0 32 833Credit line 47 750 0 0 0 0 0 0 0 0 47 750Lease liabilities 5 165 5 106 5 042 4 681 19 714 19 272 18 997 14 750 33 628 126 355Trade payables 93 629 0 0 0 0 0 0 0 0 93 629Other current liabilities 9 597 5 960 0 0 0 0 0 0 0 15 557Total 156 141 11 345 7 755 4 681 22 224 46 882 18 997 14 750 33 628 316 403Parent2023(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2025 2026 2027 2028 > 5 years TotalCredit line 28 353 0 0 0 0 0 0 0 0 28 353Lease libilities 4 342 4 200 4 103 4 038 15 747 15 008 14 264 11 329 23 383 96 414Trade payables 49 001 0 0 0 0 0 0 0 0 49 001Other current liabilities 6 952 4 566 0 0 0 0 0 0 0 11 518Total 83 648 8 766 4 103 4 038 15 747 15 008 14 264 11 329 23 383 185 285Parent2024(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2026 2027 2028 2029 > 5 years TotalLoan and subordinated loan 0 0 2 713 0 2 510 27 610 0 0 0 32 833Credit line 47 750 0 0 0 0 0 0 0 0 47 750Lease libilities 4 219 4 156 4 154 4 089 16 210 15 845 15 440 12 281 26 407 102 802Trade payables 88 659 0 0 0 0 0 0 0 0 88 659Other current liabilities 8 771 5 316 0 0 0 0 0 0 0 14 087Total 149 399 9 472 6 867 4 089 18 721 43 455 15 440 12 281 26 407 286 131The group and the parent company signed in December 2023 a increased credit facility for up until TNOK 67,000 with SpareBank 1 Nordm\u00f8re for working capital need related to future sales contracts. In addition to the available cash and cash equivalents as of 31 December 2024, this secures the group and the company sufficient liquidity for 2025.See note 16 on interest-bearing debt for further information.In the future, the management and the board will continue to prioritize the work on an appropriate and long-term financing of Hofseth BioCare ASA.Capital structure and equityThe group and the parent company\u2019s objectives with respect to capital management is to ensure the continuation as a going concern, to provide returns to shareholders and other stakeholders, and to maintain an optimal capital structure to reduce capital costs. By ensuring sound ratios between equity and debt the group and the parent company will support its operations, thus maximizing the value of its shares.The parent company manages its capital structure and makes necessary changes to it on the basis of an ongoing assessment of the financial conditions under which the business is run, and the prospects seen in the short and medium term, including any adjustment of dividend shares, buyback of own shares, reduction of share capital or issuance of new shares. There has been no change in the policy in this area in 2024. The Group completed a convertion of debt to equity 4 January 2024, and strengthened the equity with TNOK 144,000. The Group\u2019s equity ratio was 17.9 % as of 31 December 2024 and (10.5 % as of 31 December 2023). The parent company\u2019s equity ratio was 31.9 % as of 31 December 2024 (18.8 % as of 31 December 2023).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__133": {
"value": "Financial riskThrough its activities, the Group is exposed to various types of financial risks: market risk, credit risk and liquidity risk. Management monitors these risks continuously and establishes guidelines for their management. The Group\u2019s overall risk management program focuses on the unpredictability of the financial markets and seeks to minimize potential adverse effects on the Group\u2019s financial results. The Group may use financial derivatives to hedge against certain risks. The company has loans from credit institutions and financial leasing arrangements with the purpose of obtaining capital for investments in the Groups operations. In addition, the company has financial instruments such as accounts receivable and accounts payable, etc., which are directly related to the daily operational activities. Interest rate riskSince the company and the group have no significant interest-bearing assets, the exposure to interest rate risk is through their financing activities. The company\u2019s and the group\u2019s interest rate risk is related to non-current interest-bearing loans, current interest-bearing loans and lease liabilities. Loans with floating interest rates lead to interest rate risk for the company\u2019s and the Group\u2019s cash flow. See note 17 for the book value and fair value of the financing activities and note 16 for interest rate terms relating to interest-bearing financing obligations as of 31 december 2024. For the company\u2019s and the Group\u2019s loan portfolios that have floating interest rates, this means that the company is affected by changes in the interest rate level. The loans are recognized at amortized cost. The following table shows the Group\u2019s sensitivity to interest rate fluctuations. The calculation includes all interest-bearing instruments and financial interest rate derivatives to the extent that they are present.Effect on interest rate Effect on profit \u2013 before tax Interest rate group \u2013 sensitivity year\u2013 basis-point(Amounts in NOK 1 000)2023 +100 -1 368-100 1 3682024 +100 -1 458-100 1 458The following table shows the parent company\u2019s sensitivity to interest rate fluctuations. The calculation includes all interest- bearing instruments and financial interest rate derivatives to the extent that they are present.Interest rate parent company\u2013 sensitivity Effect on interest rate Effect on profit \u2013 before tax year\u2013 basis-point(Amounts in NOK 1 000)2023 +100 -1 176-100 1 1762024 +100 -1 290-100 1 290Average interest rates on financial instruments were as follows:Average interest rate in % 2024 2023Unsecured debt 10.00 n/aCredit line 7.73 7.99Secured debt 6.70 6.73Lease liabilities 6.86 5.45Foreign exchange risk The parent company and the group have a foreign exchange loan in CHF and a large part of their operating income in foreign currency and, to a lesser extent, the purchase of input factors in foreign currency, and are therefore exposed to currency risk. Management has monitored movements in the foreign exchange market and has assessed hedging strategies in 2024 based on the parent company\u2019s and the group\u2019s contractual and predictable income streams. The parent company and the group therefore entered into forward exchange contracts both in 2023 and in 2024 in order to secure the Group\u2019s budgeted future sales in foreign currency (Euro and USD), but have not used hedge accounting. The Group and the parent company had none such forwards per 31.12.2024. The parent company and the group had the following positions per 31 December 2023:Date Amount Rate15.02.24 EUR 300,000 11.91225.04.24 EUR 300,000 11.92213.06.24 EUR 300,000 11.92622.08.24 EUR 300,000 11.928 The below table demonstrates the sensitivity of possible changes in EUR, USD, CHF and GBP when all other variables are constant. The effect on the parent company\u2019s and the Group\u2019s profit before tax is due to changes in the fair value of monetary assets and liabilities, including forward exchange contracts. If the company had used hedge accounting, a currency change would also have resulted in changes to the OCI. The company does not use hedge accounting.Change in currency Change in NOK Effect on profit before tax Effect on balanceto foreign (Amounts in NOK 1 000)currency EUR USD GBP USD EUR CHF2023 +10% 9 722 6 414 1 941 n/a 1 355 n/a -10 % -9 722 -6 4142024 -1 941 n/a -1 355 n/a+10% 13 019 10 670 1 547 102 839 -2 510 -10% -13 019 -10 670 -1 547 -102 -839 2 510",
"dimensions": {
"concept": "ifrs-full:DisclosureOfMarketRiskExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__134": {
"value": "Foreign exchange risk The parent company and the group have a foreign exchange loan in CHF and a large part of their operating income in foreign currency and, to a lesser extent, the purchase of input factors in foreign currency, and are therefore exposed to currency risk. Management has monitored movements in the foreign exchange market and has assessed hedging strategies in 2024 based on the parent company\u2019s and the group\u2019s contractual and predictable income streams. The parent company and the group therefore entered into forward exchange contracts both in 2023 and in 2024 in order to secure the Group\u2019s budgeted future sales in foreign currency (Euro and USD), but have not used hedge accounting. The Group and the parent company had none such forwards per 31.12.2024. The parent company and the group had the following positions per 31 December 2023:Date Amount Rate15.02.24 EUR 300,000 11.91225.04.24 EUR 300,000 11.92213.06.24 EUR 300,000 11.92622.08.24 EUR 300,000 11.928 The below table demonstrates the sensitivity of possible changes in EUR, USD, CHF and GBP when all other variables are constant. The effect on the parent company\u2019s and the Group\u2019s profit before tax is due to changes in the fair value of monetary assets and liabilities, including forward exchange contracts. If the company had used hedge accounting, a currency change would also have resulted in changes to the OCI. The company does not use hedge accounting.Change in currency Change in NOK Effect on profit before tax Effect on balanceto foreign (Amounts in NOK 1 000)currency EUR USD GBP USD EUR CHF2023 +10% 9 722 6 414 1 941 n/a 1 355 n/a -10 % -9 722 -6 4142024 -1 941 n/a -1 355 n/a+10% 13 019 10 670 1 547 102 839 -2 510 -10% -13 019 -10 670 -1 547 -102 -839 2 510",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__135": {
"value": "Credit riskThe parent company and the Group are exposed to credit risk primarily related to accounts receivable, non-current financial loans, current financial loans, as well as other financial activities including cash and cash equivalents (bank deposits).The Group limits its exposure to credit risk through a credit rating of its customers before credit is given. The Group has credit insurance for all its significant accounts receivable through Coface Norway (see 20 for further information on credit exposure and maturity analyzes on accounts receivable).The maximum risk exposure of trade receivables for the group as of 31 December 2024 is TNOK 18,853 (TNOK 14,849 as of 31 December 2023), and for parent company TNOK 18,716 (TNOK 14,094 as of 31 December 2023). The risk of loss on accounts receivable is considered low and there has been no need to provide for losses. See note 20 for further information.Loan to subsidary of TNOK 45,947 (TNOK 27,787 in 2023), where credit risk is considered low. (see note 15, 17 and 20 for further information on financial loans and other current receivables).Credit risk for cash and cash equivalents, including bank deposits, is managed by the Group\u2019s management. The Group\u2019s surplus liquidity is invested by bank deposits with a financial counterparty with low credit risk. The Group has no investments in excess liquidity in debt or equity instruments.The Group has not provided any guarantees for third-party debt.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCreditRiskExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__136": {
"value": "Liquidity riskLiquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group\u2019s approach to liquidity management is to ensure, to the extent possible, that it will always have sufficient liquidity to meet its liabilities when due, both under normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group\u2019s reputation. Cash flows are regularly monitored by the finance department to ensure that the parent company has sufficient cash to meet operational commitments, and at any time to maintain sufficient flexibility in the form of credit facilities so that it does not violate limits or covenants for any of the loans. The parent company and the Group aims to have sufficient cash, cash equivalents or credit opportunities in the medium term to cover interest and principal payments in the short term. Please also refer to note 1 section Going concern.As of 31 December 2024 the group had MNOK 25,6 in cash, of which MNOK 3,0 were restricted cash. As of 31 December 2023 the group had MNOK 23,9 in cash, of which MNOK 3,0 were restricted cash. The group expects to have a stable production level with stable quality which satisfies the requirements for human quality. The activities to increase sales to existing customers, as well as the expectation of increased sales of oil, water-soluble protein, non-soluble protein and calcium could result in significant improvement in the company\u2019s cash flows. Expected cash flows are subject to uncertainties related to achieved sales prices and volume. Risk factors should be considered in conjunction with the risk factors described in note 2 accounting estimates.The table below shows the maturity profile of the Group\u2019s financial liabilities, both interest and installments, based on contractual undiscounted payments, classified according to maturity structure, that is, taken into account contracts with fixed maturity dates. When the counterparty can make an election of when an amount is to be paid, the liability is included in the basis covering the earliest date on which the entity can be required to pay. Financial liabilities that may be required to be paid on demand are included in the \u00abwithin 1-3 months\u00bbGroup2023(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2025 2026 2027 2028 > 5 years TotalInterest bearing debt to financial institutions 0 298 0 289 280 0 0 0 0 866Credit line 28 353 0 0 0 0 0 0 0 0 28 353Lease libilities 5 311 5 171 4 996 4 924 18 828 17 876 17 128 14 157 39 857 128 247Trade payables 50 160 0 0 0 0 0 0 0 0 50 160Other current liabilities 7 851 5 178 0 0 0 0 0 0 0 13 029Total 86 675 10 646 4 996 5 213 19 107 17 876 17 128 14 157 39 857 220 655Group2024(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2026 2027 2028 2029 > 5 years TotalInterest bearing debt to financial institutions 0 280 0 0 0 0 0 0 0 280Loan and subordinated loan 0 0 2 713 0 2 510 27 610 0 0 0 32 833Credit line 47 750 0 0 0 0 0 0 0 0 47 750Lease liabilities 5 165 5 106 5 042 4 681 19 714 19 272 18 997 14 750 33 628 126 355Trade payables 93 629 0 0 0 0 0 0 0 0 93 629Other current liabilities 9 597 5 960 0 0 0 0 0 0 0 15 557Total 156 141 11 345 7 755 4 681 22 224 46 882 18 997 14 750 33 628 316 403Parent2023(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2025 2026 2027 2028 > 5 years TotalCredit line 28 353 0 0 0 0 0 0 0 0 28 353Lease libilities 4 342 4 200 4 103 4 038 15 747 15 008 14 264 11 329 23 383 96 414Trade payables 49 001 0 0 0 0 0 0 0 0 49 001Other current liabilities 6 952 4 566 0 0 0 0 0 0 0 11 518Total 83 648 8 766 4 103 4 038 15 747 15 008 14 264 11 329 23 383 185 285Parent2024(Amounts in NOK 1 000) 1-3 months 4-6 months 7-9 months 10-12 months 2026 2027 2028 2029 > 5 years TotalLoan and subordinated loan 0 0 2 713 0 2 510 27 610 0 0 0 32 833Credit line 47 750 0 0 0 0 0 0 0 0 47 750Lease libilities 4 219 4 156 4 154 4 089 16 210 15 845 15 440 12 281 26 407 102 802Trade payables 88 659 0 0 0 0 0 0 0 0 88 659Other current liabilities 8 771 5 316 0 0 0 0 0 0 0 14 087Total 149 399 9 472 6 867 4 089 18 721 43 455 15 440 12 281 26 407 286 131The group and the parent company signed in December 2023 a increased credit facility for up until TNOK 67,000 with SpareBank 1 Nordm\u00f8re for working capital need related to future sales contracts. In addition to the available cash and cash equivalents as of 31 December 2024, this secures the group and the company sufficient liquidity for 2025.See note 16 on interest-bearing debt for further information.In the future, the management and the board will continue to prioritize the work on an appropriate and long-term financing of Hofseth BioCare ASA.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfLiquidityRiskExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__137": {
"value": "Capital structure and equityThe group and the parent company\u2019s objectives with respect to capital management is to ensure the continuation as a going concern, to provide returns to shareholders and other stakeholders, and to maintain an optimal capital structure to reduce capital costs. By ensuring sound ratios between equity and debt the group and the parent company will support its operations, thus maximizing the value of its shares.The parent company manages its capital structure and makes necessary changes to it on the basis of an ongoing assessment of the financial conditions under which the business is run, and the prospects seen in the short and medium term, including any adjustment of dividend shares, buyback of own shares, reduction of share capital or issuance of new shares. There has been no change in the policy in this area in 2024. The Group completed a convertion of debt to equity 4 January 2024, and strengthened the equity with TNOK 144,000. The Group\u2019s equity ratio was 17.9 % as of 31 December 2024 and (10.5 % as of 31 December 2023). The parent company\u2019s equity ratio was 31.9 % as of 31 December 2024 (18.8 % as of 31 December 2023).",
"dimensions": {
"concept": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__139": {
"value": "Note 19 InventoryInventoryGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Salmon oil 12 506 10 645 12 506 10 645Soulible protein 9 262 29 735 9 262 29 735Calcium 11 220 15 499 11 220 15 499Non-soluble protein and other 1 417 1 913 1 417 1 913Consumer products 7 511 10 488 7 025 9 817Total finished goods 41 916 68 280 41 430 67 610Packaging and auxiliary materials 14 000 14 262 13 773 13 829Total inventory 55 917 82 542 55 203 81 439Provision for obsolescence of TNOK 43,125 as of 31 December 2024 compared to TNOK 39,646 as of 31 December 2023. Profit effect change in obsolescence provisions is included in cost of goods with TNOK 3,479 in 2024 (TNOK 20,501 in 2023). See notes 2, 3 and 4 for more information.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInventoriesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__144": {
"value": "Note 20 Trade receivables and other current receivablesTrade receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2022Trade receivables USA 6 190 3 458 6 190 3 458Trade receivables Belgium 6 166 1 757 6 166 1 757Trade receivables Italia 2 140 707 2 140 707Trade receivables France 555 4 170 555 4 170Trade receivables other 3 802 4 756 3 665 4 002Sum trade receivables 18 853 14 849 18 716 14 094Trade receivables related parties 7 106 3 458 7 106 3 458Provision for expected credit losses 0 0 0 0Accounts receivable are not interest-bearing receivables and general terms and conditions for paymentare from 7 to 120 days. All significant accounts receivables are credit secured by Coface Norway, limited to a maximum of MNOK 11.5 and with a coverage rate of 90 %. Historical credit losses for customers over the past five years are approximately TNOK 499. Aging of trade receivables - Group(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 854 17 695 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 849 13 287 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0Aging of trade receivables - Parent(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 716 17 557 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 094 12 532 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0The Group has established a model in which the Group calculates provisions for credit losses by multiplying the expected credit losses by the proportion of non-credit-secured accounts receivable. The Group uses an increasing factor for expected credit losses according to maturity analyzes above. When analyzing future information about the Group\u2019s customers and markets, no future challenges are listed today which indicate that there will be a significant credit loss in the future (see and note 18 on credit risk). The Group and the parent company have TNOK 0 in provisions for losses on accounts receivable both in 2024 and 2023. Other current receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Prepayments 4 587 2 551 4 371 2 585VAT receivable 4 519 3 292 3 859 2 906Intercompany Group 0 0 49 712 27 016Benefit funds 1 227 2 255 1 227 2 255Other 1 384 1 623 715 1 497Total 11 716 9 721 59 885 36 259",
"dimensions": {
"concept": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__143": {
"value": "Note 20 Trade receivables and other current receivablesTrade receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2022Trade receivables USA 6 190 3 458 6 190 3 458Trade receivables Belgium 6 166 1 757 6 166 1 757Trade receivables Italia 2 140 707 2 140 707Trade receivables France 555 4 170 555 4 170Trade receivables other 3 802 4 756 3 665 4 002Sum trade receivables 18 853 14 849 18 716 14 094Trade receivables related parties 7 106 3 458 7 106 3 458Provision for expected credit losses 0 0 0 0Accounts receivable are not interest-bearing receivables and general terms and conditions for paymentare from 7 to 120 days. All significant accounts receivables are credit secured by Coface Norway, limited to a maximum of MNOK 11.5 and with a coverage rate of 90 %. Historical credit losses for customers over the past five years are approximately TNOK 499. Aging of trade receivables - Group(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 854 17 695 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 849 13 287 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0Aging of trade receivables - Parent(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 716 17 557 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 094 12 532 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0The Group has established a model in which the Group calculates provisions for credit losses by multiplying the expected credit losses by the proportion of non-credit-secured accounts receivable. The Group uses an increasing factor for expected credit losses according to maturity analyzes above. When analyzing future information about the Group\u2019s customers and markets, no future challenges are listed today which indicate that there will be a significant credit loss in the future (see and note 18 on credit risk). The Group and the parent company have TNOK 0 in provisions for losses on accounts receivable both in 2024 and 2023. Other current receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Prepayments 4 587 2 551 4 371 2 585VAT receivable 4 519 3 292 3 859 2 906Intercompany Group 0 0 49 712 27 016Benefit funds 1 227 2 255 1 227 2 255Other 1 384 1 623 715 1 497Total 11 716 9 721 59 885 36 259",
"dimensions": {
"concept": "ifrs-full:DisclosureOfAllowanceForCreditLossesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__142": {
"value": "Note 20 Trade receivables and other current receivablesTrade receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2022Trade receivables USA 6 190 3 458 6 190 3 458Trade receivables Belgium 6 166 1 757 6 166 1 757Trade receivables Italia 2 140 707 2 140 707Trade receivables France 555 4 170 555 4 170Trade receivables other 3 802 4 756 3 665 4 002Sum trade receivables 18 853 14 849 18 716 14 094Trade receivables related parties 7 106 3 458 7 106 3 458Provision for expected credit losses 0 0 0 0Accounts receivable are not interest-bearing receivables and general terms and conditions for paymentare from 7 to 120 days. All significant accounts receivables are credit secured by Coface Norway, limited to a maximum of MNOK 11.5 and with a coverage rate of 90 %. Historical credit losses for customers over the past five years are approximately TNOK 499. Aging of trade receivables - Group(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 854 17 695 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 849 13 287 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0Aging of trade receivables - Parent(Amounts in NOK 1 000) Total Not due <30d 30-60d 60-90d >90d2024Accounts receivables 18 716 17 557 1 078 0 0 81Credit-secured share 10 350 10 317 0 27 0 5Expected loss 0 0 0 0 0 02023Accounts receivables 14 094 12 532 692 345 32 492Credit-secured share 10 260 8 746 692 316 31 475Expected credit loss 0 0 0 0 0 0The Group has established a model in which the Group calculates provisions for credit losses by multiplying the expected credit losses by the proportion of non-credit-secured accounts receivable. The Group uses an increasing factor for expected credit losses according to maturity analyzes above. When analyzing future information about the Group\u2019s customers and markets, no future challenges are listed today which indicate that there will be a significant credit loss in the future (see and note 18 on credit risk). The Group and the parent company have TNOK 0 in provisions for losses on accounts receivable both in 2024 and 2023. Other current receivablesGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Prepayments 4 587 2 551 4 371 2 585VAT receivable 4 519 3 292 3 859 2 906Intercompany Group 0 0 49 712 27 016Benefit funds 1 227 2 255 1 227 2 255Other 1 384 1 623 715 1 497Total 11 716 9 721 59 885 36 259",
"dimensions": {
"concept": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__146": {
"value": "Note 21 Cash and cash equivalentsDeposits with a credit institution totaled TNOK 25,577 as of 31 December 2024 and TNOK 23,890 as of 31 December 2023 and the Group earns interest income according to agreed floating interest rate terms.At 31 December 2024, restricted funds for the Group amounted to TNOK 3,013 which derives from the employees\u2019 tax deductions. As of 31 December 2023, this amounted to TNOK 3,019.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__152": {
"value": "Note 22 Equity investmentsSubsidiaries Country Head office Share capital Ownership Voting share Earnings 2024 Equity 31.12.2024HBC Berk\u00e5k AS Norway Rennebu 100 100% 100% -20 907 10 546HBC Therapeutics AS Norway \u00c5lesund 2 000 100% 100% -52 -341HBC Switzerland GmbH Switzerland Z\u00fcrich CFH20 100% 100% -26 16Hofseth BioCare R\u00f8rvik AS Norway R\u00f8rvik 100 51% 51% -4 -1 421Hofseth Biocare Americas Holdings Inc. USA Mendham, NJ 0 100% 100% 588 588Hofseth Biocare UK Ltd. UK Brentford 0 100% 100% -231 -2 356Company Country Head office Share capital Ownership Voting shareHBC Immunology Inc. USA Delaware 0 71% 50%Atlantic Delights Ltd. Hong Kong Hong Kong HKD 6 163 34% 34%Atlantic Delights ltdThe parent company and the group acquired 34 % of Atlantic Delights Ltd., Hong Kong on 27 August 2020, through a share issue with a nominal value of TNOK 6,517 in the company. Estimated surplus value related to customer base amounts to TNOK 3,395 calculated at the time of acquisition and which is depreciated on a straight-line basis over 5 years. Profit share from the company in the ownership period is included after tax expense and amortization of surplus value.HBC Immunology Inc.During Q2 2023 HBC established HBCI. HBC transfered one patent, and a licence free non-exclusive right to apply data from another of HBC`s patent. Hofseth Biocare ASA\u2019s contribution in kind of intangible assets was accounted as a partial gain, since the ownership after the transaction was 75%. 25% gain on the transaction of TNOK 23,488 is classified as other income. The Group has as at 31 December 2023 71% interest in HBCI, a joint venture that aims to develop a co-treatment for use in treatment of prostate cancer. Since HBC only votes for 50% of the shares, and one other party votes for the remaining 50%, the interest is accounted for under the equity method in the consolidated financial statements. During Q3 and Q4 the ownership percentage has been diluted from 75% to 71% ownership as a result of external capital increases in HBCI. The dilution effect is accounted for under share of profit and loss. Summarised financial information of the joint venture, based on its IFRS financial statements, and reconciliation with the carrying amount of the investment in the consolidated financial statements are set out below:In 2024, a new patent from HBC was transferred to HBCI as a contribution in kind. The patent was valued at TNOK 47 750(TUSD4,500), including the other joint venture partners contribution (25%), and the gain booked in HBC was TNOK 8 122. The gain was accounted for as partial gain, due to that HBC own 71% after the transaction.Investment in associated company Atlantic Delights LtdGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 3 443 5 559 3 443 6 517Access 0 0 0 0Amitization added value -679 -679 0 0Profit share after tax -765 -1 438 0 0Impairment shares 0 0 -1 444* -3 074Net asset 31.12. 1 999 3 443 1 999 3 443* Shares are written down to fair valueInvestment in joint venture HBC Immunology Inc.Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 34 247 0 29 589 0Access 15 493 29 589 15 493 29 589Dillution effect -329 5 789 0 0Profit share after tax -5 711 -1 130 0 0Net asset 31.12. 43 700 34 247 45 082 29 589Financial information in associated company and joint ventureAtlantic Delights Ltd. HBC Immunology Inc.(Amounts in NOK 1 000) 2024 2023 2024 2023Current assets 2 551 3 358 5 117 8 801Fixed assets 66 65 192 780 127 500Current liabilities 1 554 1 468 0 0Non-current liabilities 11 002 9 595 1 134 1 020Operating revenue 1 620 1 700 475 0Total earnings -2 251 -4 228 -5 393 -1 602",
"dimensions": {
"concept": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__151": {
"value": "Note 22 Equity investmentsSubsidiaries Country Head office Share capital Ownership Voting share Earnings 2024 Equity 31.12.2024HBC Berk\u00e5k AS Norway Rennebu 100 100% 100% -20 907 10 546HBC Therapeutics AS Norway \u00c5lesund 2 000 100% 100% -52 -341HBC Switzerland GmbH Switzerland Z\u00fcrich CFH20 100% 100% -26 16Hofseth BioCare R\u00f8rvik AS Norway R\u00f8rvik 100 51% 51% -4 -1 421Hofseth Biocare Americas Holdings Inc. USA Mendham, NJ 0 100% 100% 588 588Hofseth Biocare UK Ltd. UK Brentford 0 100% 100% -231 -2 356Company Country Head office Share capital Ownership Voting shareHBC Immunology Inc. USA Delaware 0 71% 50%Atlantic Delights Ltd. Hong Kong Hong Kong HKD 6 163 34% 34%Atlantic Delights ltdThe parent company and the group acquired 34 % of Atlantic Delights Ltd., Hong Kong on 27 August 2020, through a share issue with a nominal value of TNOK 6,517 in the company. Estimated surplus value related to customer base amounts to TNOK 3,395 calculated at the time of acquisition and which is depreciated on a straight-line basis over 5 years. Profit share from the company in the ownership period is included after tax expense and amortization of surplus value.HBC Immunology Inc.During Q2 2023 HBC established HBCI. HBC transfered one patent, and a licence free non-exclusive right to apply data from another of HBC`s patent. Hofseth Biocare ASA\u2019s contribution in kind of intangible assets was accounted as a partial gain, since the ownership after the transaction was 75%. 25% gain on the transaction of TNOK 23,488 is classified as other income. The Group has as at 31 December 2023 71% interest in HBCI, a joint venture that aims to develop a co-treatment for use in treatment of prostate cancer. Since HBC only votes for 50% of the shares, and one other party votes for the remaining 50%, the interest is accounted for under the equity method in the consolidated financial statements. During Q3 and Q4 the ownership percentage has been diluted from 75% to 71% ownership as a result of external capital increases in HBCI. The dilution effect is accounted for under share of profit and loss. Summarised financial information of the joint venture, based on its IFRS financial statements, and reconciliation with the carrying amount of the investment in the consolidated financial statements are set out below:In 2024, a new patent from HBC was transferred to HBCI as a contribution in kind. The patent was valued at TNOK 47 750(TUSD4,500), including the other joint venture partners contribution (25%), and the gain booked in HBC was TNOK 8 122. The gain was accounted for as partial gain, due to that HBC own 71% after the transaction.Investment in associated company Atlantic Delights LtdGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 3 443 5 559 3 443 6 517Access 0 0 0 0Amitization added value -679 -679 0 0Profit share after tax -765 -1 438 0 0Impairment shares 0 0 -1 444* -3 074Net asset 31.12. 1 999 3 443 1 999 3 443* Shares are written down to fair valueInvestment in joint venture HBC Immunology Inc.Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 34 247 0 29 589 0Access 15 493 29 589 15 493 29 589Dillution effect -329 5 789 0 0Profit share after tax -5 711 -1 130 0 0Net asset 31.12. 43 700 34 247 45 082 29 589Financial information in associated company and joint ventureAtlantic Delights Ltd. HBC Immunology Inc.(Amounts in NOK 1 000) 2024 2023 2024 2023Current assets 2 551 3 358 5 117 8 801Fixed assets 66 65 192 780 127 500Current liabilities 1 554 1 468 0 0Non-current liabilities 11 002 9 595 1 134 1 020Operating revenue 1 620 1 700 475 0Total earnings -2 251 -4 228 -5 393 -1 602",
"dimensions": {
"concept": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__150": {
"value": "Note 22 Equity investmentsSubsidiaries Country Head office Share capital Ownership Voting share Earnings 2024 Equity 31.12.2024HBC Berk\u00e5k AS Norway Rennebu 100 100% 100% -20 907 10 546HBC Therapeutics AS Norway \u00c5lesund 2 000 100% 100% -52 -341HBC Switzerland GmbH Switzerland Z\u00fcrich CFH20 100% 100% -26 16Hofseth BioCare R\u00f8rvik AS Norway R\u00f8rvik 100 51% 51% -4 -1 421Hofseth Biocare Americas Holdings Inc. USA Mendham, NJ 0 100% 100% 588 588Hofseth Biocare UK Ltd. UK Brentford 0 100% 100% -231 -2 356Company Country Head office Share capital Ownership Voting shareHBC Immunology Inc. USA Delaware 0 71% 50%Atlantic Delights Ltd. Hong Kong Hong Kong HKD 6 163 34% 34%Atlantic Delights ltdThe parent company and the group acquired 34 % of Atlantic Delights Ltd., Hong Kong on 27 August 2020, through a share issue with a nominal value of TNOK 6,517 in the company. Estimated surplus value related to customer base amounts to TNOK 3,395 calculated at the time of acquisition and which is depreciated on a straight-line basis over 5 years. Profit share from the company in the ownership period is included after tax expense and amortization of surplus value.HBC Immunology Inc.During Q2 2023 HBC established HBCI. HBC transfered one patent, and a licence free non-exclusive right to apply data from another of HBC`s patent. Hofseth Biocare ASA\u2019s contribution in kind of intangible assets was accounted as a partial gain, since the ownership after the transaction was 75%. 25% gain on the transaction of TNOK 23,488 is classified as other income. The Group has as at 31 December 2023 71% interest in HBCI, a joint venture that aims to develop a co-treatment for use in treatment of prostate cancer. Since HBC only votes for 50% of the shares, and one other party votes for the remaining 50%, the interest is accounted for under the equity method in the consolidated financial statements. During Q3 and Q4 the ownership percentage has been diluted from 75% to 71% ownership as a result of external capital increases in HBCI. The dilution effect is accounted for under share of profit and loss. Summarised financial information of the joint venture, based on its IFRS financial statements, and reconciliation with the carrying amount of the investment in the consolidated financial statements are set out below:In 2024, a new patent from HBC was transferred to HBCI as a contribution in kind. The patent was valued at TNOK 47 750(TUSD4,500), including the other joint venture partners contribution (25%), and the gain booked in HBC was TNOK 8 122. The gain was accounted for as partial gain, due to that HBC own 71% after the transaction.Investment in associated company Atlantic Delights LtdGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 3 443 5 559 3 443 6 517Access 0 0 0 0Amitization added value -679 -679 0 0Profit share after tax -765 -1 438 0 0Impairment shares 0 0 -1 444* -3 074Net asset 31.12. 1 999 3 443 1 999 3 443* Shares are written down to fair valueInvestment in joint venture HBC Immunology Inc.Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 34 247 0 29 589 0Access 15 493 29 589 15 493 29 589Dillution effect -329 5 789 0 0Profit share after tax -5 711 -1 130 0 0Net asset 31.12. 43 700 34 247 45 082 29 589Financial information in associated company and joint ventureAtlantic Delights Ltd. HBC Immunology Inc.(Amounts in NOK 1 000) 2024 2023 2024 2023Current assets 2 551 3 358 5 117 8 801Fixed assets 66 65 192 780 127 500Current liabilities 1 554 1 468 0 0Non-current liabilities 11 002 9 595 1 134 1 020Operating revenue 1 620 1 700 475 0Total earnings -2 251 -4 228 -5 393 -1 602",
"dimensions": {
"concept": "ifrs-full:DisclosureOfJointVenturesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__149": {
"value": "Note 22 Equity investmentsSubsidiaries Country Head office Share capital Ownership Voting share Earnings 2024 Equity 31.12.2024HBC Berk\u00e5k AS Norway Rennebu 100 100% 100% -20 907 10 546HBC Therapeutics AS Norway \u00c5lesund 2 000 100% 100% -52 -341HBC Switzerland GmbH Switzerland Z\u00fcrich CFH20 100% 100% -26 16Hofseth BioCare R\u00f8rvik AS Norway R\u00f8rvik 100 51% 51% -4 -1 421Hofseth Biocare Americas Holdings Inc. USA Mendham, NJ 0 100% 100% 588 588Hofseth Biocare UK Ltd. UK Brentford 0 100% 100% -231 -2 356Company Country Head office Share capital Ownership Voting shareHBC Immunology Inc. USA Delaware 0 71% 50%Atlantic Delights Ltd. Hong Kong Hong Kong HKD 6 163 34% 34%Atlantic Delights ltdThe parent company and the group acquired 34 % of Atlantic Delights Ltd., Hong Kong on 27 August 2020, through a share issue with a nominal value of TNOK 6,517 in the company. Estimated surplus value related to customer base amounts to TNOK 3,395 calculated at the time of acquisition and which is depreciated on a straight-line basis over 5 years. Profit share from the company in the ownership period is included after tax expense and amortization of surplus value.HBC Immunology Inc.During Q2 2023 HBC established HBCI. HBC transfered one patent, and a licence free non-exclusive right to apply data from another of HBC`s patent. Hofseth Biocare ASA\u2019s contribution in kind of intangible assets was accounted as a partial gain, since the ownership after the transaction was 75%. 25% gain on the transaction of TNOK 23,488 is classified as other income. The Group has as at 31 December 2023 71% interest in HBCI, a joint venture that aims to develop a co-treatment for use in treatment of prostate cancer. Since HBC only votes for 50% of the shares, and one other party votes for the remaining 50%, the interest is accounted for under the equity method in the consolidated financial statements. During Q3 and Q4 the ownership percentage has been diluted from 75% to 71% ownership as a result of external capital increases in HBCI. The dilution effect is accounted for under share of profit and loss. Summarised financial information of the joint venture, based on its IFRS financial statements, and reconciliation with the carrying amount of the investment in the consolidated financial statements are set out below:In 2024, a new patent from HBC was transferred to HBCI as a contribution in kind. The patent was valued at TNOK 47 750(TUSD4,500), including the other joint venture partners contribution (25%), and the gain booked in HBC was TNOK 8 122. The gain was accounted for as partial gain, due to that HBC own 71% after the transaction.Investment in associated company Atlantic Delights LtdGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 3 443 5 559 3 443 6 517Access 0 0 0 0Amitization added value -679 -679 0 0Profit share after tax -765 -1 438 0 0Impairment shares 0 0 -1 444* -3 074Net asset 31.12. 1 999 3 443 1 999 3 443* Shares are written down to fair valueInvestment in joint venture HBC Immunology Inc.Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 34 247 0 29 589 0Access 15 493 29 589 15 493 29 589Dillution effect -329 5 789 0 0Profit share after tax -5 711 -1 130 0 0Net asset 31.12. 43 700 34 247 45 082 29 589Financial information in associated company and joint ventureAtlantic Delights Ltd. HBC Immunology Inc.(Amounts in NOK 1 000) 2024 2023 2024 2023Current assets 2 551 3 358 5 117 8 801Fixed assets 66 65 192 780 127 500Current liabilities 1 554 1 468 0 0Non-current liabilities 11 002 9 595 1 134 1 020Operating revenue 1 620 1 700 475 0Total earnings -2 251 -4 228 -5 393 -1 602",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__148": {
"value": "Note 22 Equity investmentsSubsidiaries Country Head office Share capital Ownership Voting share Earnings 2024 Equity 31.12.2024HBC Berk\u00e5k AS Norway Rennebu 100 100% 100% -20 907 10 546HBC Therapeutics AS Norway \u00c5lesund 2 000 100% 100% -52 -341HBC Switzerland GmbH Switzerland Z\u00fcrich CFH20 100% 100% -26 16Hofseth BioCare R\u00f8rvik AS Norway R\u00f8rvik 100 51% 51% -4 -1 421Hofseth Biocare Americas Holdings Inc. USA Mendham, NJ 0 100% 100% 588 588Hofseth Biocare UK Ltd. UK Brentford 0 100% 100% -231 -2 356Company Country Head office Share capital Ownership Voting shareHBC Immunology Inc. USA Delaware 0 71% 50%Atlantic Delights Ltd. Hong Kong Hong Kong HKD 6 163 34% 34%Atlantic Delights ltdThe parent company and the group acquired 34 % of Atlantic Delights Ltd., Hong Kong on 27 August 2020, through a share issue with a nominal value of TNOK 6,517 in the company. Estimated surplus value related to customer base amounts to TNOK 3,395 calculated at the time of acquisition and which is depreciated on a straight-line basis over 5 years. Profit share from the company in the ownership period is included after tax expense and amortization of surplus value.HBC Immunology Inc.During Q2 2023 HBC established HBCI. HBC transfered one patent, and a licence free non-exclusive right to apply data from another of HBC`s patent. Hofseth Biocare ASA\u2019s contribution in kind of intangible assets was accounted as a partial gain, since the ownership after the transaction was 75%. 25% gain on the transaction of TNOK 23,488 is classified as other income. The Group has as at 31 December 2023 71% interest in HBCI, a joint venture that aims to develop a co-treatment for use in treatment of prostate cancer. Since HBC only votes for 50% of the shares, and one other party votes for the remaining 50%, the interest is accounted for under the equity method in the consolidated financial statements. During Q3 and Q4 the ownership percentage has been diluted from 75% to 71% ownership as a result of external capital increases in HBCI. The dilution effect is accounted for under share of profit and loss. Summarised financial information of the joint venture, based on its IFRS financial statements, and reconciliation with the carrying amount of the investment in the consolidated financial statements are set out below:In 2024, a new patent from HBC was transferred to HBCI as a contribution in kind. The patent was valued at TNOK 47 750(TUSD4,500), including the other joint venture partners contribution (25%), and the gain booked in HBC was TNOK 8 122. The gain was accounted for as partial gain, due to that HBC own 71% after the transaction.Investment in associated company Atlantic Delights LtdGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 3 443 5 559 3 443 6 517Access 0 0 0 0Amitization added value -679 -679 0 0Profit share after tax -765 -1 438 0 0Impairment shares 0 0 -1 444* -3 074Net asset 31.12. 1 999 3 443 1 999 3 443* Shares are written down to fair valueInvestment in joint venture HBC Immunology Inc.Group Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Net asset 1.1. 34 247 0 29 589 0Access 15 493 29 589 15 493 29 589Dillution effect -329 5 789 0 0Profit share after tax -5 711 -1 130 0 0Net asset 31.12. 43 700 34 247 45 082 29 589Financial information in associated company and joint ventureAtlantic Delights Ltd. HBC Immunology Inc.(Amounts in NOK 1 000) 2024 2023 2024 2023Current assets 2 551 3 358 5 117 8 801Fixed assets 66 65 192 780 127 500Current liabilities 1 554 1 468 0 0Non-current liabilities 11 002 9 595 1 134 1 020Operating revenue 1 620 1 700 475 0Total earnings -2 251 -4 228 -5 393 -1 602",
"dimensions": {
"concept": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__154": {
"value": "Note 23 Accounts payable and other short-term liabilitiesAccounts payableGroup Parent(Amounts in NOK 1 000) 2024 2023 2024 2023Accounts payable 21 120 13 560 18 703 11 787Accounts payable related companies 72 510 41 601 69 956 37 249Total 93 629 55 161 88 659 49 037Accounts payable are not interest-bearing and normal maturity is from 0 to 60 days. For settlement and terms for accounts payable with related parties, see information in note 6. Other short-term liabilitiesGroup Parent(Amounts in NOK 1 000) 2024 2022 2024 2023Public duties payable 5 030 4 903 4 277 4 251Accrued holiday pay 5 960 5 178 5 316 4 566Other accrued costs 4 567 2 948 4 494 2 701Short-term debt to related companies* 0 144 000 0 144 000Total 15 557 157 029 14 087 155 518On 4th of January 2024 the extraordinary general meeting of HBC approved the offsetting of NOK 144 million into preference class B shares. Since there is no contractual obligation to repay the amount, nor principal amount or interests, this is classified as equity. The B-Shares will not hold any voting rights and will carry a preferential right to receive dividends over the Company\u2019s ordinary shares (listed on the Oslo Stock Exchange under ticker code \u201cHBC\u201d) (the \u201cOrdinary Shares\u201d).Following a minimum of five (5) years after the issuance of the B-Shares, Hofseth International can request the B-Shares to be converted into Ordinary Shares. The subscription price shall be NOK 9 per new Ordinary Share. If conversion rights are exercised after seven (7) years, a subscription price ofNOK 12 per new Ordinary Share shall apply. Such conversion into Ordinary Shares will technically be done through a redemption value, equivalent to the Investment Value in addition to the Preferred Amount.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__160": {
"value": "Note 24 Share capital, shareholders and dividendsAs of 31 December 2024, Hofseth BioCare ASA had NOK 411,081,030 in share capital, divided into 395,081,030 A-shares, and 16 000 000 B-shares, each with a nominal value of NOK 0.01. All shares are fully paid.B-shares has no voting rights. B-Shares carry a preferential rights to dividens over the Companys A-shares. The 20 largest shareholders of Hofseth BioCare ASA as of 31 December 2024 are:Largest shareholders # A shares # B shares % shareSIX SIS AG 91 475 100 23.15RH INDUSTRI AS 69 300 190 17.54HOFSETH INTERNATIONAL AS 59 611 772 16 000 000* 15.09YOKOREI CO. LTD 40 951 333 10.37GOLDMAN SACHS INTERNATIONAL 22 450 000 5.68BRILLIANT INVEST AS 11 000 000 2.78UBS SWITZERLAND AG 10 978 069 2.78GOLDMAN SACHS & CO. LLC 9 251 830 2.34CITIBANK, N.A. 8 015 022 2.03JPMORGAN CHASE BANK, N.A., LONDON 4 606 816 1.17BOMI FRAMROZE HOLDING AS 3 453 370 0.87LGT BANK AG 3 248 329 0.82SAXO BANK A/S 3 190 979 0.81BNP PARIBAS 2 827 628 0.72CLEARSTREAM BANKING S.A. 2 322 933 0.59VERDIPAPIRFONDET DNB SMB 2 317 100 0.59\u00d8DEG\u00c5RD PROSJEKT AS 2 174 039 0.55INTERACTIVE BROKERS LLC 2 135 280 0.54SINKABERG AS 1 764 107 0.45CITIBANK, N.A. 1 627 423 0.41In total, the 20 largest shareholders 352 701 320 16 000 000 89.27Total others 42 379 710 0 10.73Total number of shareholders 395 081 030 16 000 000 100.00 *No voting rights Total no. of shareholders: 1,520 Shares owned by CEO and the Board 2024 20231)Jon Olav \u00d8deg\u00e5rd3 084 039 3 084 0391)Roger Hofseth129 098 628 128 863 421Christoph Baldegger 2 547 853 800 0001)Crawford Currie750 000 750 000Total 135 480 520 133 497 4601) Includes shares owned by related companies and persons.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__159": {
"value": "Note 24 Share capital, shareholders and dividendsAs of 31 December 2024, Hofseth BioCare ASA had NOK 411,081,030 in share capital, divided into 395,081,030 A-shares, and 16 000 000 B-shares, each with a nominal value of NOK 0.01. All shares are fully paid.B-shares has no voting rights. B-Shares carry a preferential rights to dividens over the Companys A-shares. The 20 largest shareholders of Hofseth BioCare ASA as of 31 December 2024 are:Largest shareholders # A shares # B shares % shareSIX SIS AG 91 475 100 23.15RH INDUSTRI AS 69 300 190 17.54HOFSETH INTERNATIONAL AS 59 611 772 16 000 000* 15.09YOKOREI CO. LTD 40 951 333 10.37GOLDMAN SACHS INTERNATIONAL 22 450 000 5.68BRILLIANT INVEST AS 11 000 000 2.78UBS SWITZERLAND AG 10 978 069 2.78GOLDMAN SACHS & CO. LLC 9 251 830 2.34CITIBANK, N.A. 8 015 022 2.03JPMORGAN CHASE BANK, N.A., LONDON 4 606 816 1.17BOMI FRAMROZE HOLDING AS 3 453 370 0.87LGT BANK AG 3 248 329 0.82SAXO BANK A/S 3 190 979 0.81BNP PARIBAS 2 827 628 0.72CLEARSTREAM BANKING S.A. 2 322 933 0.59VERDIPAPIRFONDET DNB SMB 2 317 100 0.59\u00d8DEG\u00c5RD PROSJEKT AS 2 174 039 0.55INTERACTIVE BROKERS LLC 2 135 280 0.54SINKABERG AS 1 764 107 0.45CITIBANK, N.A. 1 627 423 0.41In total, the 20 largest shareholders 352 701 320 16 000 000 89.27Total others 42 379 710 0 10.73Total number of shareholders 395 081 030 16 000 000 100.00 *No voting rights Total no. of shareholders: 1,520 Shares owned by CEO and the Board 2024 20231)Jon Olav \u00d8deg\u00e5rd3 084 039 3 084 0391)Roger Hofseth129 098 628 128 863 421Christoph Baldegger 2 547 853 800 0001)Crawford Currie750 000 750 000Total 135 480 520 133 497 4601) Includes shares owned by related companies and persons.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
},
"f1__s8__6__161": {
"value": "Note 25 Subsequent eventsOn 21 February 2025, HBC partnered with Symrise to expand its manufacturing and market reach. Symrise has provided a \u20ac5 million loan to fund HBC\u2019s second enzymatic hydrolysis plant in Berk\u00e5k, tripling production capacity. HBC also signed an exclusive distribution agreement for OmeGo\u00ae, ProGo\u00ae, and NT-II\u2122 with Symrise\u2019s global key accounts. With an additional NOK 60 million loan from Sparebank 1 Nordm\u00f8re, the project has started, and construction is set to begin after approvals in Q2 2025, with production expected before Q3 2027. On 10 March 2025, HBC engaged Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds of maximum CHF 8 million and a tenor of three years, to secure growth and working capital for the Group. The bonds are targeted towards investors in Switzerland and Liechtenstein. HBC may also contact investors in Norway directly. For going concern, please refer to note 1.",
"dimensions": {
"concept": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
"language": "en",
"entity": "scheme:5967007LIEEXZXGGEO44",
"period": "2024-01-01T00:00:00/2025-01-01T00:00:00"
}
}
}
}